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Abstract 
 
Cyclin-Dependent Kinases (CDKs) play a fundamental role in eukaryotic cell cycle 
progression, particularly at cell cycle checkpoints, and are therefore important 
targets for anticancer drug discovery. Activation of CDK2 in complex with Cyclin A 
regulates entry into S phase of the eukaryotic cell cycle. CDK7, a dual-function 
enzyme, acts both as a CDK-Activating Kinase (CAK) and as a component of the 
general transcription factor TFIIH. However, experiments with MAT1-knockdown 
mice have shown that cell cycle arrest by CAK inhibition would not be detrimental for 
transcriptional activity in non-dividing cells, as CDK9 in complex with Cyclin T can 
perform transcriptional duties in the absence of TFIIH.  
 
Previous studies have resulted in the identification of NU6102 (1, IC50 µM = 0.005 
(CDK2), 4.4 (CDK7)) as a potent and selective CDK2 inhibitor, and NU6247 (2, IC50 
µM = 0.12 (CDK2), 0.23 (CDK7)) as an equipotent CDK2/7 inhibitor. It was shown 
that the sulfonamide group of 1 confers potency and selectivity for CDK2, whereas 
the pendant piperazinyl substituent of 2 diminishes CDK2 actvity whilst improving 
activity versus CDK7. 
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AccordinglyAs part of the work described in the present thesis, sulfonamide 3 (IC50 
µM = 0.012 (CDK2), 0.67 (CDK7)) was synthesised and found to be is a potent 
CDK2 inhibitor, but with some CDK7-inhibitory activity (IC50 µM = 0.012 (CDK2), 0.67 
(CDK7)). Further elaboration of the side-chain function has enabled the development 
of structure-activity relationships (SARs), and the identification of purines (e.g. 4, IC50 
µM = 2.6 (CDK2), 0.56 (CDK7)) exhibiting some selectivity for CDK7, albeit with a 
loss of potency. 
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Subsequent SAR studies conducted on 2 have enabled the following observations to 
be made: firstly, the purine 6-cyclohexylmethoxy substituent is necessary for activity, 
with the corresponding 6-unsubstituted purine (5, IC50 µM = 46.9 (CDK2), 20.8 
(CDK7)) exhibiting a 100-fold loss of potency against both CDK2 and CDK7. A 
terminal basic group (e.g. piperazinyl in 2) is required for activity, as replacement by 
a cyclohexyl substituent results in loss of activity against both kinases (6, 11% 
inhibition at 10 µM (CDK2), 13% inhibition at 100 µM (CDK7)). 
                       
The sulfone linker is not a prerequisite for CDK7 activity, with the simple 
alkylpiperazine derivative (7, IC50 µM = 0.48 (CDK2), 0.51 (CDK7)) exhibiting 
comparable potency and selectivity. Finally, there appears to be some opportunity 
for expansion into the gatekeeper pocket of CDK7 by introducing small substituents 
at the purine C-8 position, with the potential for selectivity over CDK2 (8, 47% 
inhibition at 100 µM (CDK2), IC50 = 5 µM (CDK7)). 
 
                  
Isolation and biological evaluation of the vinyl sulfone 9, an intermediate in the 
synthesis of 2, indicated a time-dependent inhibition of CDK2, suggesting that 9 is an 
irreversible inhibitor of CDK2. This would be the first reported irreversible inhibitor of 
a cyclin-dependent kinase, and therefore the activity of the compound against CDK2 
was investigated using protein crystallography and site-directed mutagenesis 
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techniques. From these studies, encouraging evidence has emerged that 9 acts as 
an irreversible inhibitor of CDK2, covalently binding to a lysine residue within the 
ATP-binding pocket. 
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Chapter 1 - Kinases and Cancer 
 
 
1.1 Cancer: definition and hallmarks 
 
The term “cancer” is used to describe a disease in which loss of regulation in cellular 
processes results in uncontrolled proliferation of cells and, subsequently, in the 
generation of a malignant tumour. Cancer cells have defects in regulatory circuits 
that govern normal proliferation and homeostasis. 1 
To date, more than 100 types of cancer have been described, subtypes of which can 
arise within certain specific organs. Hanahan and Weinberg 1 have suggested that 
this wide variety of cancer phenomenology is a manifestation of six essential 
alterations in cell physiology:  
 
• Self-sufficiency in growth signals 
Normal cell proliferation depends upon correct communication with the 
external environment through the exchange of signalling molecules (growth 
factors). Tumour cells are do not divide according to external growth factor 
signalling. Acquired genetic mutations result in the cell bypassing growth 
factor pathways, which leads to unregulated growth, either by internal 
production of growth factors or by responding to levels of external signals 
usually not sufficient to induce proliferation in normal cells. 
 
• Insensitivity to anti-growth signals 
In normal tissue, the stability of the cell population (homeostasis) is 
maintained by a number of signals and processes inhibiting cell proliferation 
and differentiation (e.g. contact with neighbouring cells inhibits cell growth). 
Cancer cells survive and replicate by not responding to anti-growth signals, as 
acquired mutations interfere with, or allow, the cell to bypass the inhibitory 
pathways.  
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• Evasion of apoptosis  
In normal tissues, the stability of the cell population is maintained through a 
process of programmed cell death, or apoptosis. In response to DNA damage, 
or any other sign of abnormality within a cell, sensors monitoring the cellular 
environment regulate the action of apoptotic effectors, resulting in cell death. 
Loss of apoptotic regulators through mutation leads to evasion of apoptosis in 
cancer cells. This mechanism is thought to be a critical survival factor for the 
majority of tumours. 
 
• Limitless replicative potential 
After every round of DNA replication, chromosomal ends (telomeres) are 
shortened. This constitutes an effective method by which normal cells are 
able to ‘keep count’ of their doublings, and results in the cell entering 
senescence after a finite number of replications. Tumour cell populations 
acquire unlimited replicative potential by maintenance of telomere length, 
either by overexpressing telomerase or by recombination processes, 
effectively gaining “immortality”. 
 
• Angiogenesis 
In normal tissues, continued cell function is dependent on the availability of 
oxygen and nutrients through the capillary beds. The vascular architecture is 
more or less constant in adults, and angiogenesis, the ability to induce the 
growth of new blood vessels, is transitory and carefully regulated. Cancer 
cells have acquired the capability to override angiogenesis inhibitors and 
activate the angiogenetic switch to supply the resources necessary for tumour 
survival and expansion. 
 
• Tissue invasion and metastasis 
Normal cells maintain their location in the body and generally do not migrate. 
Cancer cells spread from the primary tumour site through the body to colonise 
distant tissues to form metastases. Up to 90% of cancer deaths are due to 
metastatic disease. Several classes of proteins involved in the tethering of 
cells to their surrounding tissues are altered in cancer cells. Cell-cell adhesion  
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and cell-to-environment interactions are subverted so that the metastatic cell 
acquires the ability to colonise distant territories where nutrients and space 
are more abundant. 
 
These six capabilities that a cancerous cell acquires are found to be common in 
most, if not all, types of tumours. 
In a recent revisitation of their earlier 2000 work, 2 Hanahan and Weinberg expanded 
upon these six established characteristics and recognised two additional emerging 
hallmarks of cancer, as well as two enabling characteristics that allow a cell to 
become physiologically altered in this manner. 
 
• The first emerging hallmark is the reprogramming of the cell’s energy 
metabolism. 
Chronic and uncontrolled cell proliferation in cancer involves not only 
deregulated control of cell proliferation but also corresponding adjustments of 
energy metabolism in order to fuel cell growth and division. Cancer cells can 
reprogram their glucose metabolism, and therefore their energy production, by 
limiting their energy metabolism largely to glycolysis. This has been shown to 
be associated with activated oncogenes and mutated tumour suppressor 
genes, resulting in the onset of malignancy. 
 
• The second emerging hallmark is the evasion of immune destruction. 
Normal cells and tissue are constantly monitored by the immune system, and 
this immune surveillance is responsible for recognising and eliminating a vast 
proportion of incipient cancer cells and nascent tumours. Solid tumours that 
do reach a malignant stage have either managed to avoid detection by the 
immune system, or to limit the extent of the immunological response, thereby 
evading eradication. 
 
Acquisition of the above eight fundamental hallmarks of cancer (two of which are in 
the course of being validated and therefore remain deemed “emerging”) appears to 
be enabled by two fundamental characteristics of cancerous cells: 
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• The first enabling characteristic is the instability of the genome. 
The ability of the genome maintenance system to detect and correct defects 
in the DNA ensures that mutation rates remain low during each cell 
generation. In the course of acquiring the mutant genes needed to initiate 
tumorigenesis, cancer cells are able to increase the rate of mutation through 
increased sensitivity to mutagenic agents, a breakdown in ordinary DNA 
repair pathways, or both.  
 
• The second enabling characteristic is tumour-promoting inflammation. 
Virtually every neoplastic lesion contains immune cells present at densities 
ranging from subtle infiltration to gross inflammation. Such tumour-associated 
inflammatory response has the effect of enhancing tumorigenesis and 
progression, contributing to multiple hallmark capabilities by supplying growth 
factors, survival factors, angiogenic factors etc. Additionally, inflammatory 
cells can release reactive chemical species, such as oxygen radicals, that are 
actively mutagenic and contribute the genetic evolution towards a heightened 
state of malignancy. 
 
 Despite the apparent simplicity of this description, cancer is an extremely complex 
disease and, as such, has so far presented an immense challenge to the 
development of effective treatments. After the human genome was elucidated, 3 
genomics has offered an additional tool aiding the comprehension of cancer from a 
molecular point of view. Oncogenes (genes whose activation cause cancer) and 
tumour suppressor genes (genes whose inactivation cause cancer) were 
discovered and found to be mutated in tumours, although depending on the specific 
type of tumour, mutations can occur at different stages of its development. Cancer 
genomics contributes to defining molecular targets for tumour specific effects and 
constitutes an important tool for the design of new molecular therapies. 4 5 Relevant 
studies have focused on the tumour suppressor genes p53 and retinoblastoma (Rb), 
which are found mutated in over a half of all cancers cases, as they play key roles in 
inhibiting carcinogenesis. The most common mutations within these cancer-related 
genes are found within the protein kinase domain. 6 
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Protein kinases play a leading role in the control of cellular biology and in signal 
transduction pathways, and it is therefore of little surprise that they would be 
universally recognised as targets of primary interest for anticancer drug discovery. 
 
1.2 Protein Kinases 
 
Ever since the discovery more than 50 years ago that reversible phosphorylation 
regulates the activity of glycogen phosphorylase, 7 there has been intense interest in 
the role of protein phosphorylation in regulating protein function. 
The protein kinase family is the largest functional family of enzymes encoded by the 
human genome. 8 The completion of the human genome sequence has allowed the 
identification of 518 kinases, constituting approximately 1.7% of all human genes. 8 
To compare related kinases in human organisms and to gain insights into kinase 
function and evolution, all kinases are divided into nine broad groups, comprising 
134 families and 196 subfamilies, classified with regard to the sequence alignment of 
their catalytic domains which all relate to the same superfamily containing a 
eukaryotic protein kinase (ePK) domain. A family of 13 atypical protein kinases (aPK) 
were also identified. 
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Figure 1 
Phylogenetic tree representing the main protein kinase families 8 
 
The reaction of ATP, which contains a somewhat activated linkage between the β- 
and γ-phosphate groups, with an alcohol or phenol will produce very little phosphate 
ester, as the reaction is kinetically very slow and also rather disfavoured in an 
aqueous medium, where the water itself is a competing nucleophile. Therefore, for 
the reaction to be useful, it must be catalysed. 9 Protein kinases are ATP-dependent 
phosphotransferases that deliver a single phosphate group from the γ position of 
ATP to a hydroxyl group of a tyrosine, serine or threonine residue belonging to a 
specific protein substrate. 10 
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Figure 2 
The protein phosphorylation cycle 
 
 
The phosphoryl transfer reaction is facilitated by the presence of a divalent metal ion 
(usually Mg++) which assists in the ATP binding, and the phosphorylation reaction 
taking place in the active site of the protein kinase is a complex process which 
involves structural changes. Protein phosphatases remove the phosphate, thereby 
creating a “molecular switch”, 11 which enables the control and mediation of most of 
the signal transduction processes in eukaryotic cells. Protein kinases also control 
many other cellular processes, including transcription, cell cycle progression, 
cytoskeletal rearrangement and cell movement, apoptosis and differentiation. 
Metabolic activities involving carbohydrate and lipid metabolism, neurotransmitter 
biosynthesis and organelle trafficking are also organised by the combined action of 
kinases and phosphatases. 7 12 Phosphorylation is one of the most important post-
translational modifications that a protein can undergo, and it has a profound impact 
at both the molecular and the cellular level. 
 
Sequence comparisons of members of the protein kinase family reveal that theyir 
catalytic domains, normally ranging from  200-250 amino acids, often share  a 
conserved region of approximately 200-250 amino acids sequences alternating 
 regions of high and low conservation
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Figure 3 
Crystal structure of a typical protein kinase (AMPK 
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Nearly all protein kinases thus far characterised with regard to substrate specificity 
fall within one of two broad classes, serine/threonine-specific and tyrosine-
specific. There is a third and less common class, called the dual-function kinases, 
which phosphorylate all three amino acids. 
Although classified so broadly, protein kinases have an extremely high specificity 
towards their chosen substrate. The specificity is primarily due to the variations in the 
local sequence of amino acids either side of the phosphorylation site. These highly 
characteristic amino acidic residues provide significant interactions between the 
enzyme and the substrate, thereby directing the phosphoryl transfer. Additional 
assistance may also be provided by interactions of the substrate with functionalities 
remote from the active site. Many examples exist of long-distance recognition 
assessed even at a 40 Å distance from the phosphorylation site, 10 demonstrating 
that although protein kinases share a highly conserved ATP-binding site, they are 
absolutely specific to the substrate assigned to them. 
This specific reversible phosphorylation of protein substrates in the cell is among the 
most important post-translational modifications to occur, and it is the principal 
method by which cellular control and adaptation is achieved. Today, it is difficult to 
discuss any biochemical event in the living cell that is not affected directly or 
indirectly by protein phosphorylation. Protein activation leads to the amplification of 
cellular signalling (Figure 4) and aids the regulation of virtually all cellular processes 
such as metabolism, growth and proliferation. 15 Protein kinases therefore play a 
crucial role in signal transduction pathways. 
 Figure 4 
Schematic representation of a signal transduction pathway.
 
 
1.3 Kinase inhibitors as anticancer agents
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inhibitors were intended to be ATP-competitive increased the degree of uncertainty 
regarding this therapeutic approach. 16 However, the marketing of imatinib (3), 
gefitinib (4), sorafenib (5), erlotinib (6), sunitinib (7) and lapatinib (8) in the last 
decade has dispelled these concerns, and established the value and efficacy of 
kinase inhibitors as anticancer agents. 
 
 
 
Imatinib (3, Glivec/ST1571) received Food and Drug Administration (FDA) * approval 
in 2001. It was developed by Novartis in one of the first successful examples of a 
rational drug design approach. Imatinib is the first member of a new class of agents 
that are intended to specifically inhibit a certain enzyme that is characteristic of a  
* The Food and Drug Administration (FDA or USFDA), an agency of the United States Department of Health and Human 
Services, is responsible for the regulation and supervision of food  safety, tobacco products, dietary supplements, prescription 
and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, 
electromagnetic radiation emitting devices (ERED), veterinary products and cosmetics. 
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particular cancer cell (Bcr-Abl tyrosine kinase), rather than non-specifically inhibiting 
and killing all rapidly dividing cells, and served as a model for other targeted therapy 
modalities. This drug is mainly used in the treatment of chronic myeloid leukaemia 
(CML), but its applications were extended to the treatment of gastrointestinal stromal 
tumours (GISTs), after the observation that 3 also inhibited the c-Kit receptor 
tyrosine kinase. This observation emphasises that complete kinase selectivity is not 
necessarily a crucial factor for the clinical success of protein kinase inhibitors. 17 
 
Sunitinib (7, Sutent/SU11248) is a multi-targeted receptor tyrosine kinase (RTK) 
inhibitor, which was approved in 2006 for the treatment of renal cell carcinoma 
(RCC) and Imatinib-resistant GISTs. It was the first anticancer drug simultaneously 
approved for two different indications, and has now become the standard treatment 
for both of these cancers. 18 
 
Gefitinib (4, Iressa/ZD1839), Erlotinib (6, Tarceva/OSI-774) and Lapatinib (8, 
Tykerb/GW572016) are small molecule kinase inhibitors based upon the 4-
anilinoquinazoline scaffold. Gefitinib was the first drug to selectively target the 
epidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed 
and occasionally mutated in various forms of cancer. 19 Gefitinib was approved in 
2004 for the treatment of advanced non-small cell lung cancer (NSCLC). However, 
later studies revealed that efficacy seems to rely on the dependence of the cancer 
upon particular molecular abnormalities. 20 21 
 
Sorafenib (5, Nexavar/BAY43-9006) targets the Raf/Mek/Erk signalling pathway. Raf 
and Mek are members of the mitogen-activated protein (MAP) kinase family, while 
Erk is an extracellular signal-regulated kinase. The drug was originally identified as 
an ATP-competitive inhibitor of b-Raf and approved for the treatment of RCC in 
2005. Subsequent studies revealed its activity against platelet-derived growth factor 
(PDGF), VEGF and c-Kit kinases, which play a role in both tumour angiogenesis and 
tumour cell proliferation. These investigations resulted in approval of Sorafenib for 
the treatment of hepatocellular carcinoma (HC), which is the most common form of 
liver cancer. Sorafenib thus represents an example of a multiple kinase inhibitor. 22 
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1.4 ATP-competitive inhibition of protein kinases 
 
Kinase inhibition can be approached in several possible ways. Firstly, it is possible to 
interfere with the factors that regulate the translation of a kinase; secondly, substrate 
binding may be inhibited by targeting the substrate specific binding site; thirdly, the 
activity of a kinase may be ablated by interfering with the factors that regulate its 
activation. The fourth approach is, of course, to target the ATP-binding site of the 
kinase. ATP-competitive inhibition is the mechanism by which the vast majority of 
kinase inhibitors prepared to date are thought to function. 16 
 
Although ATP-competitive kinase inhibitors exhibit a wide spectrum of chemical 
diversity, for the most part they all interact with the kinase in a broadly similar 
fashion, via key hydrogen bonding interactions with the hinge region of the ATP-
binding domain. 23 24 Determination of the crystal structure of ATP-kinase complexes 
reveals two important hydrogen bond interactions between ATP and the backbone 
amino acid residues of the active site cleft. Thus, N1 of the adenine acts as a 
hydrogen-bond acceptor from an amide proton of the protein backbone, whilst the 6-
amino group donates a hydrogen bond to the oxygen of a backbone carbonyl group. 
This doublet of hydrogen bonds anchors the adenine to the hinge region, allowing 
the ribose to point towards and interact with a highly hydrophobic region of the ATP-
binding domain. 25 26 
 
Structural studies on protein kinases in complex with ATP have further revealed that 
there are regions within, or close to, the binding cleft that ATP does not fully occupy, 
such as the gatekeeper and specificity pocket (Figure 5). 27 The gatekeeper region 
is a lipophilic pocket located furthest away from the entrance to the ATP-binding 
cleft, in the direction of N7 and C6 of the adenine. The size of the pocket is 
determined by the bulk of the amino acid sidechains surrounding this region. The 
specificity pocket is a cleft that opens to solvent, characterised by lipophilic surfaces 
above and below the adenine heterocycle surface and providing for additional 
interactions with potential inhibitors. The name arises from the poor homology 
observed among the different families of protein kinases, and this cavity has been 
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exploited to introduce water-solubilising groups on inhibitors, as it faces the exterior 
of the ATP-domain and does not hinder binding of the inhibitor to the kinase. 28 
 
 
 
 
Figure 5 
Schematic representation of the regions into which the ATP-binding site of most kinases is usually 
divided. 27  
 
 
These pockets are usually poorly occupied by ATP, and show structural diversity 
between members of the kinase family, thereby providing opportunities for the 
design of selective ATP-competitive inhibitors. 28 
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Chapter 2 – Cyclin-Dependent Kinases (CDKs) 
 
2.1 The cell cycle 
 
The cell is the structural and functional unit of all living organisms, containing all 
components necessary for the continuation and expression of life. The continued 
integrity of every life form relies on the ability of its component cells to transfer faithfully 
their genetic material. Cells proliferate through a complex process, known as the cell 
cycle, which consists of a series of checkpoints and regulatory mechanisms to 
ensure that the DNA is correctly replicated and equally distributed between the two 
daughter cells (Figure 6). 29 
The cell cycle is divided into four phases: S phase (DNA replication), M phase 
(mitosis) and two gap phases (G1 and G2) that separate the M and S phases. The 
sequence G1-S-G2 is sometimes collectively referred to as interphase.  
 
 
 
Figure 6 
The cell cycle. 30 
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The M phase is itself composed of two tightly coupled processes: mitosis, where the 
cell's chromosomes are divided between the two daughter cells (Figure 7), and 
cytokinesis, where the cell's cytoplasm physically divides. 
 
 
 
 
Figure 7 
The progression of mitosis through four phases. 31 
 
 
The cell cycle is a very delicate process occurring in an extremely complex 
environment. The gap phases are necessary for the cell to correctly decipher and 
interpret the vast array of information and signalling that regulate the mechanisms of 
DNA repair and replication, and the preparation for cell division. 32 
During G1 phase, for instance, growth factors (mitogens) must be available for the 
cell to correctly enter S phase. If that is not the case, at the restriction point 33 (R in 
Figure 6) the cell enters a phase called G0 and is described as being quiescent. 
Despite being termed ‘the quiescent phase’, G0 is an active phase in that cellular 
functions and cell growth occur. Cell growth (the increase in cell size and protein 
mass) is a term that is frequently confused with cell proliferation. However, in certain 
biological systems – such as oocytes, neurons and muscle cells, where cell growth 
might exist without cell division, and in fertilised eggs, where cell division might occur 
without cell growth – these processes function in an independent, or even 
complementary, fashion. In most cells, cell division without concurrent cell growth 
would generate smaller daughter cells, which would affect their viability. 34 Once 
mitogens become available, the cell can pass the restriction point and correctly 
complete the cell cycle. It is to be noted that the restriction point constitutes a critical 
stage for the cell: once it has made the decision to progress past this stage, it is 
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irreversibly committed to entering DNA synthesis and completing the cycle. Cells that 
have entered the G0 phase permanently, due to age, extensive DNA damage or 
other irreversible problems are said to be senescent. Some cell types in mature 
organisms, such as parenchymal cells of the liver and kidney, enter the G0 phase 
semi-permanently and can only be induced to begin dividing again under very 
specific circumstances; 35 other types, such as epithelial cells, continue to divide 
throughout an organism’s life and are never known to enter the G0 phase at all. 
 
Although the various stages of interphase are not usually morphologically 
distinguishable, each phase of the cell cycle has a distinct set of specialised 
biochemical processes that prepare the cell for initiation of the cell division. The term 
post-mitotic is sometimes used to refer to both quiescent and senescent cells. 
Nonproliferative cells in multicellular eukaryotes generally enter the quiescent G0 
state from G1 and may remain quiescent for long periods of time, possibly indefinitely 
(as is often the case for neurons). This is very common for cells that are fully 
differentiated. Cellular senescence is a state that occurs in response to DNA 
damage or degradation that would make a cell’s progeny non-viable; it is often a 
biochemical alternative to programmed cell death (apoptosis).36 
 
2.2 The Cyclin-Dependent Kinases (CDKs) 
 
The cell cycle is a unidirectional process, where progression from one phase to the 
next can be initiated only after passage through specific control mechanisms –
checkpoints. Each separate transition cannot take place without verifying the correct 
completion of the previous one, the two often being linked via regulatory loops. 33 37 
Cancer cells often show alterations in the signal transduction pathways that lead to 
proliferation in response to external signals. Indeed, many growth factors and their 
receptors, as well as their membrane, cytoplasmic and nuclear downstream effectors 
have been identified as oncogenes or tumour-suppressor genes. Other genes 
mutated in cancer include those that inactivate apoptotic pathways, induce genomic 
instability and promote angiogenesis. Tumour-associated mutations in many of these 
molecules result in the alteration of the basic regulatory mechanisms that control the 
mammalian cell cycle. 34 
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Instrumental to the regulation of these checkpoints are the cyclin-dependent kinases 
(CDKs), which facilitate critical cell cycle transitions. CDK inhibitors are therefore 
recognised to have potential therapeutic effect in the treatment of proliferative 
diseases. 38 39  
 
The cyclin-dependent kinases (CDKs) are members of the serine-threonine protein 
kinase family and are key components in maintaining the systematic progression of 
cells in the cell cycle. The hallmark of cyclin-dependent kinases is that they are 
inactive in their monomeric form and require association with a specific cyclin partner 
for activation (Figure 8). 40 Also necessary for CDK activation is phosphorylation on 
a specific activation site (T-loop). This phosphorylation is carried out by the CDK-
Activating Kinase (CAK), itself a member of the CDK family, the details of which will 
be discussed later in this chapter. Since the discovery of the cdc2 protein (also 
known as CDK1) in the fission yeast Schizosaccharomyces pombe, a further 10 
CDK family members (CDK2 – CDK11) have been identified along with 25 proteins 
with homology in the cyclin box, found as a result of the sequencing of the human 
genome. 41 
 
Each CDK shares 40-75% sequence homology and all are of similar size, between 
30-40 kDa. CDKs are identified by a unique sequence of their amino acid code, the 
PSTAIRE motif (single letter amino acid code), corresponding to an α-helix in the 
active site that plays an important role in cyclin binding and phosphate transfer.  
Elucidation of the X-ray crystal structure of the CDK2/Cyclin A complex revealed the 
common kinase motif of a small N-terminal lobe consisting predominantly of β-
sheets, and a larger C-terminal lobe formed largely from α-helices. 42 
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Figure 8 
ATP bound within phosphorylated (T160P) CDK2/Cyclin A. 43 
 
Although 11 CDKs have been identified to date, only 8 are believed to play integral 
roles in regulating cell cycle progression (Figure 9). 40 
 
 
 
Figure 9 
Regulation of the cell cycle by CDK/Cyclin complexes. 40 
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CDK Cyclin partner Related phase of the cell cycle / Other functions 
CDK1 A, B G2, G2/M, M. Also active in nervous system and RNA 
transcription. 
CDK2 A, B, E G1, G1/S, M. Also active for apoptosis and in RNA 
transcription. 
CDK3 C, E G0/G1, G1 
CDK4 D G1 
CDK5 p25, p35, p29, 
p39 
Active for apoptosis and in nervous system 
CDK6 D G1 
CDK7 H Active as a CAK and in RNA transcription. 
CDK8 C Active in RNA transcription 
CDK9 T, K Active for apoptosis and in RNA transcription 
CDK10 Unknown G2/M 
CDK11 L M. Also active for apoptosis and in RNA transcription. 
 
Table 1 
The known CDKs, their cyclin partners and their roles in cellular biology. 44 
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The cellular levels of CDKs remain relatively constant throughout the cell cycle, and 
their ability to regulate the cell cycle relies primarily on the oscillatory expression of 
their activating cyclin partners. The sequential fluctuation in cellular levels of a 
particular cyclin dictates the activation of the partner CDK, allowing the timely 
phosphorylation of the relevant protein target. 45  The name ‘cyclin’ accounts for this 
peculiar cyclic pattern. Cyclins vary considerably in size (30-80 kDa) but show 
structural similarities in certain specific regions, particularly within a 100 amino acid 
sequence, known as the cyclin box, which is the domain used to bind and activate 
CDKs. 46 
 
2.2.1 The role of CDKs in regulating the cell cycle 
 
CDKs coordinate the cell cycle by acting as molecular on/off switches in response to 
raised and lowered cyclin levels, T-loop phosphorylation, and the expression of 
endogenous CDK inhibitors (CDKIs). When one CDK is activated (‘on’), the cell can 
progress through the transition that the particular CDK/Cyclin complex controls. 
Alternatively, when the activity of that kinase is inhibited (‘off’), cell cycle progression 
is halted. 
 
In the early stages of G1 phase, CDK4 and 6, in complex with D-type Cyclins 
(D1/D2/D3), participate in the phosphorylation of the retinoblastoma protein pRb. 47 
pRb is the product of the retinoblastoma tumour suppressor gene and is an 
important mediator of cell cycle progression, primarily influencing the transition from 
G1 to S. pRb represses DNA transcription by binding to and inactivating specific 
members of the E2F family of proteins that act as transcription factors. 
Phosphorylation of pRb inactivates it and releases the transcription factors, thus 
permitting correct entry into S phase (Figure 10). CDK2 in complex with Cyclin E 
also plays a role in phosphorylation of pRb. The activity of these CDKs accompanies 
the cells all through G1 and into S phase. 48 Upon entry into S phase, Cyclin A is 
expressed and binds to CDK1, activating the kinase. As a consequence, the cell 
passes smoothly from S into G2 phase, and E2Fs are deactivated following CDK2/A-
mediated phosphorylation, since transcriptional activity on their behalf is no longer 
needed. On completion of DNA synthesis and replication, and prior to the transition 
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from G2 to M, CDK1 is expressed and activated for the purpose of monitoring pre-M 
checkpoints before the initiation of cell division. 49 
 
 
 
 
Figure 10 
The retinoblastoma tumour suppressor pathway contains multiple oncogenes (green) and tumour 
suppressors (red). 50 
 
 
Oncogenic processes exert their greatest effect by targeting particular regulators of 
the G1 phase progression. 51 G1 progression normally relies on stimulation by 
mitogens and can be blocked by antiproliferative factors. As already explained 
above, it is during G1 that cells face the decision as to whether to proceed with the 
cell cycle or enter a quiescent phase. Cancer cells are not controlled at this crucial 
point and remain permanently in the cell cycle; all processes that may lead to 
permanent exit from the cell cycle are also subverted. 
As CDKs (CDK2, 3, 4 and 6 in complex with Cyclin A, D and E) are the key agents in 
controlling passage through the restriction point and entry into S phase, any 
malfunctioning or loss of control in their regulation directly causes uncontrolled cell 
proliferation, which may result in the development of cancer. 
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2.2.2 ‘Non-Cycling’ CDKs 
 
Members of the CDK family that are not involved directly in cell cycle regulation are 
described as ‘non-cycling CDKs’ and fulfil secondary or peripheral roles in controlling 
the cell cycle progression. 44, 52-53 A number of CDKs, including some that are also 
involved in the cell cycle, have been observed to target additional biological 
substrates whose functions are unrelated to the cell cycle, such as 
neurotransmission, transcription, differentiation and apoptosis (Table 2).  
 
CDK Cyclin Partner Function 
CDK1 A,B Nervous system, apoptosis 
CDK2 A, B, E Centrosome duplication, apoptosis 
CDK4 D Nervous system, apoptosis, cell differentiation 
CDK5 
p25, p35, p29, 
p39 
Neuronal functions, nervous system, 
apoptosis 
CDK6 D Nervous system, apoptosis, cell differentiation 
CDK7 H CAK (CDK-Activating Kinase), transcription 
CDK8 C Transcription 
 
CDK9 T, K Transcription, apoptosis, cell differentiation 
CDK11 L Transcription, apoptosis, nervous system 
 
Table 2 
Activities of ‘non-cycling’ CDKs. 53 
 
One of the most widely researched non-cycling CDK is CDK5, which is expressed in 
post-mitotic cells of the central nervous system and is recognised to play numerous 
key functions during neuronal differentiation and migration. 54-55 Unlike other CDKs, 
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CDK5 does not require CAK-mediated T-loop phosphorylation prior to activation, but 
is instead dependent on binding to cyclin-related proteins (e.g. p25, p35, p29 and 
p39). 56 CDK5 activity is deregulated in the pathogenesis of various 
neurodegenerative diseases, including Alzheimer’s. 52 CDK5 has therefore become 
an interesting target in the development of treatments for such diseases. 57  
 
As is evident from Table 2, involvement in RNA transcriptional activity is common 
within the CDK family. Transcription requires phosphorylation of the carboxy-terminal 
domain (CTD) of RNA polymerase II (RNA Pol II), a large subunit required for the 
elongation process. CTD phosphorylation by different kinases, including some 
CDKs, may control several key transcriptional events. 52 CDK9/Cyclin T and K 
complexes are components of the basal transcription elongation factor P-TEFb, 
which also phosphorylates the CTD on the largest subunit (RBB1) of RNA Pol II, 
thus promoting transcriptional elongation. CDK9 is also required for the kinase-
dependent HIV-1 Tat transactivation. The Tat-associated kinase (TAK) complex can 
bind to the human immunodeficiency virus (HIV) Tat1 and Tat2 components, which 
are important regulators of gene expression. 58 CDK11 is also believed to be very 
important in regulating RNA processing and transcription, in association with cyclin 
L. 52 Unlike CDK9, which has a positive effect on the transcriptional cycle, 
CDK8/Cyclin C and CDK1/Cyclin B suppress mRNA production during mitosis. 59 60 
As shown in Table 2, CDK7/Cyclin H, apart from having CAK activity, is also active 
in transcription. The details of the activity of this enzyme will be discussed in greater 
detail later in this chapter. 
 
2.3 The regulation of CDK activity 
 
Although CDKs are regulated by several different processes (phosphorylation, tight-
binding inhibitors, regulated assembly of holoenzymes and ubiquitin-mediated 
proteolysis of cyclins and CDK inhibitors), all processes implicated in CDK regulation 
are observed to induce extensive conformational changes, especially in the shape of 
the catalytic cleft. 61 Of the four main CDKs involved in the cell cycle (CDK1, 2, 4, 
and 6), only the crystal structures of CDK2 and 6 have been reported to date, even 
though the amino acid sequences of the other members have been determined. 
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CDK2/Cyclin A and CDK4/Cyclin D complexes are often used as prototypes for the 
major classes of regulatory pathways that control CDK activity. 62  
 
2.3.1 Cyclin binding 
 
Although monomeric CDK2 will bind ATP, the residues within the ATP-binding site 
are incorrectly positioned to align the triphosphate moiety of ATP for catalysis, 
conferring a poor catalytic ability to the monomeric unit, which is regarded as almost 
completely inactive. 45 Kinetic studies have shown that cyclin binding increases the 
affinity of CDK2 for ATP by 3-fold and decreases its release from the active site by 
up to 5-fold. 45 
Structural studies may provide an explanation as to why the monomeric form of 
CDK2 is inactive. Firstly, the T-loop which is the site for the activating 
phosphorylation of a CDK is situated, in the case of CDK2, in very close proximity to 
the substrate binding unit and actually occludes the close approach of peptide 
substrates to the catalytic site. Secondly, several catalytic residues are misaligned 
with respect to their positions in the active enzyme. 
Upon Cyclin A binding, which occurs spontaneously even in vitro, residues Asp145, 
Glu51 and Lys33 are altered in their positions and thereby succeed in orienting the 
ATP for catalysis. Moreover, the T-loop undergoes a large conformational change 
that displaces it from the vicinity of the substrate-binding cleft. 26, 63 
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Figure 11 
The structural change in CDK2 following Cyclin A binding. 56, 64 
 
Upon cyclin binding to CDK2, a continuous protein-protein interface is formed, as 
Cyclin A approaches the kinase subunit at one side of the catalytic cleft, interacting 
with both the N- and C-terminal lobes (see Figure 7 in Chapter 1). Thus, Cyclin A 
promotes CDK2 activation by inducing radical conformational changes, as illustrated 
in Figure 12, which compares the conformation of CDK2 in the monomeric and 
cyclin-associated forms. 62 The PSTAIRE helix is reoriented toward the catalytic cleft 
via a rotation of 90°, bringing the catalytic residue Glu51 inside the ATP-binding 
pocket. This residue, together with Lys33, Asp145 and a magnesium ion, 
coordinates the γ-phosphate group and correctly orients it for catalysis. As a result of 
the binding of Cyclin A, the T-loop structure and position are altered as well. The 
activation segment is repositioned, clearing the entrance of the catalytic cleft, which 
is blocked in the monomeric form. In addition, these changes also expose the key 
phosphorylation site on the T-loop (Thr160), allowing for full activation of the kinase.  
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Figure 12 
Structural alterations in monomeric CDK2 (right) following Cyclin A binding (left). 62 
 
The mechanism of activation of the CDK4/Cyclin D complex is more complicated, 
and regulated by the stability of both CDK4 and Cyclin D subunits and by their 
assembly. Newly synthesised CDK4 appears to be intrinsically unstable and 
assembles into a high molecular weight complex containing a variety of other 
proteins (Hsp90, p50/Cdc37). This chaperone complex is thought to stabilise and/or 
help fold CDK4, and this appears to be required for productive interaction with Cyclin 
D. 65 Once CDK4 is properly stabilised, it is released from the chaperone complex 
and is free to interact with Cyclin D, although it appears that free CDK4 and Cyclin D 
associate very poorly in the absence of an assembly factor. Like CDK2, CDK4 then 
requires phosphorylation in the T-loop for maximal activity. 66 
 
The regulation of CDK activity by cyclin binding implies, as a consequence, that the 
timing of CDK activation can be controlled by the expression of a particular cyclin 
subunit. 65 Cyclin association also plays a role in CDK substrate selectivity. These 
two aspects are linked together and provide the basis for kinase selectivity. 
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2.3.2 T-loop phosphorylation 
 
After CDK2/Cyclin A binding has occurred, CAK phosphorylates the complex on 
Thr160 (Thr161 in CDK1), 67 and in this way a complete activation of the cyclin-
dependent kinase is achieved. T-loop phosphorylation induces conformational 
changes of its own (Figure 13), as the phosphate group interacts with three separate 
arginine side-chains (Figure 14), each coming from a different part of the structure: 
Arg50, from the C-helix PSTAIRE motif within the N-terminal domain, Arg126, which 
is adjacent to the catalytic Asp145 in the C-terminal lobe, and finally Arg150, which is 
located at the beginning of the activation segment.  
 
 
Figure 13 
The structural change in CDK2 following T-loop phosphorylation. 56 
 
The arginine residues, once positioned, participate in hydrogen bonding interactions 
with other CDK and cyclin residues, resulting in complete reorganisation of the 
substrate-binding site. 25 
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Figure 14 
Phosphate binding site of CDK2. 25 
 
 
2.3.3 Endogenous CDK inhibition 
 
The third component of endogenous CDK regulation is the transcription and 
expression of endogenous CDK inhibitors (CDKIs). There are two main families of 
CDKIs, Cip/Kip and Ink4, classified according to their structure and CDK targets. 68 
CDKIs orchestrate and integrate various signalling pathways and regulatory 
mechanisms, complementing CDK activity in controlling cell cycle progression. 
Inhibitors, including p16Ink4a, p27Cip2, p15Ink4b, and p21Cip1, are induced by cellular 
events such as senescence, contact inhibition, extracellular anti-mitogenic factors 
(e.g. transforming growth factor beta, TGF-β), and cell cycle checkpoints (e.g. p53), 
respectively. 61 These CDK regulators are frequently altered in cancer, as a further 
proof of the vital role they play in controlling cell proliferation. 69 70 Members of the 
Cip family target the active CDK/Cyclin complex, while the INK4 family binds and 
inhibits monomeric CDKs, preventing cyclin association and therefore activation. The 
Ink4 inhibitors act specifically on CDKs involved in the G1 phase, whereas the Cip 
inhibitors have a broader CDK preference. 71  
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2.3.3.1 The Cip/Kip Family 
 
Members of the Cip/Kip family bind to cyclin and CDK substrates via conserved 
motifs found within their N-terminal domains. 68 Cip/Kip CDKIs inhibit cyclin D-, cyclin 
E- and cyclin A-dependent kinases, affecting G1, G1/S and G2 control mechanisms in 
the cell cycle. This family includes proteins such as p21, p27 and p57/KIP2, which 
contain a characteristic sequence of 65 amino acids at their N-terminal domain, an 
important site in recognising and binding to CDK complexes. 72 X-ray crystallography 
studies have identified three different ways of binding of p27 to the CDK2/Cyclin A 
complex, thus accounting for potential multiple inhibition mechanisms. 73 
 
A rigid coil from the N-terminus of p27 has been observed to interact with a 
conserved hydrophobic groove on Cyclin A. This weakens the heterodimeric 
complex and results in a loss of CDK activity (Figure 15). 73 
 
 
Figure 15 
p27 binds to the CDK2/A complex. 71 
 
The protein p27 can also induce rearrangements of the N-terminal domain of CDK2. 
Upon p27 binding, the catalytic cleft is reshaped, abolishing enzyme activity as a 
result of the glycine-rich loop no longer interacting with the ATP ribose. p27 co-folds 
p27
CDK2 Cyclin A
 into a new structure with CDK2, inserting some of its own 
terminal domain, and forming a new mixed hydrophobic core (
 
 
Figure 16 
p27 inserts into the CDK2/A N-terminal domain.
 
Finally, p27 inhibits the activity of CDK2/C
within the catalytic cleft of CDK2
adenine ring of ATP and its hydrogen bond interactions 
Tyr88 residue. 61  
 
Figure 17 
p27 mimics ATP binding within the CDK2/A catalytic cleft.
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p21 binds to the CDK2/Cyclin A complex 
fashion to p27. The expression of this gene is tightly controlled by the tumor 
suppressor protein p53, through which this protein mediates the p53
cycle G1 arrest in response to a variety of stress stimuli
p21 can mediate cellular senescence
p57. p57 and p27 are thought to operate together to control cell cycle exit and 
differentiation. 75 
 
2.3.3.2 The Ink4 Family 
 
Members of the Ink4 family, which include the p15, p16, p18 a
only to CDK4 and CDK6, 
inhibitors bind adjacent to the catalytic cleft of CDK4/6, 
Cyclin D binding site, and interact with both the N and C lobes to form a continuous 
interface (Figure 18). Ink4 family members inhibit the formation of CDK4/6/Cyclin 
complexes in an allosteric 
alter the conformation of the cyclin
 
Figure 18 
p16 (right) and p19 (left) bound to CDK6.
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p16 binds to CDK4/6, causing the N and C lobes to rotate by approximately 15° on a 
vertical axis. This leads to a misalignment between the N and C lobes and the 
PSTAIRE helix, which prevents cyclin binding, as shown in Figure 19. 
Both p16 and the cyclin need to interact with each CDK lobe to exploit their function, 
but it appears that they require them in different relative orientations. This new 
positioning of the N lobe in the p16 complex has been observed to be incompatible 
with cyclin binding, resulting in an inactive conformation. p16 seems to have a higher 
affinity toward the CDK target than the cyclin partner, as it has been reported to bind 
preferentially in in vivo studies. 71   
 
 
 
Figure 19 
p16 binding causes a misalignment between the N and C-lobes of CDK6, resulting in impeded cyclin 
binding. 61 
 
 
2.3.4 CDK-Inhibitory Phosphorylation  
 
Another mechanism by which CDK/Cyclin complexes may be inactivated is by 
dephosphorylation of threonine and tyrosine residues, e.g. Thr14 and Tyr15 in CDK1 
and CDK2. In monomeric CDK2, these residues are located within the ATP-binding 
site, under the T-loop, and are inaccessible to solvent. They become accessible for 
dephosphorylation only after cyclin binding and subsequent repositioning of the T-
loop. 76  
p16 twists the N and C lobes awayA
p16 N-lobe
N-lobe
C-lobe C-lobe
Cyclin A 
15°
p16-bound to CDK6  Cyclin A-bound to CDK2  
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The onset of mitosis is mediated by the regulatory activity of the CDK1/Cyclin B 
complex, which is tightly regulated by its phosphorylation status, both by an 
activating phosphorylation by CAK (Thr161) and inhibitory phosphorylations at Thr14 
and Thr15 residues by protein kinases Wee1 and Myt1. During the G2 phase of the 
cell cycle, cdc25, a protein phosphatase, dephosphorylates both residues on CDK1. 
This initiates the activation of CDK1/Cyclin B, which results in the onset of mitosis.77-
78
  
 
Figure 20 
A summary of regulatory activation mechanisms of CDKs. 61, 79 
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In summary, in order to guide the passage of cells through the cell cycle, CDKs 
undergo a number of regulatory processes, which are summarised in Figure 20. 
Faulty execution of these mechanisms can potentially lead to uncontrolled 
proliferation and the development of cancer. 
 
2.4 CDKs as anticancer Targets 
 
Phosphorylation and subsequent inactivation of Rb by CDKs is a key step in the 
regulation of cell cycle progression, promoting or inhibiting protein biosynthesis (i.e. 
G1/S transition). 32 CDKs play a pivotal role in the control of cell cycle checkpoints 
(e.g. G2/M via p53), effectively protecting the integrity of the genome. A direct link 
has been established between the molecular pathology of cancer and a number of 
CDK-related cellular aberrations, such as cyclin overexpression (especially D-type 
cyclins), amplification and mutation of CDKs (CDK2 and 4), direct (p16) and indirect 
(p53) loss of endogenous CDK inhibition, and alterations in the levels of CDK-
specific substrates (Rb loss or mutation). 37 The rationale for the development of 
synthetic CDK inhibitors relies on the assumption that these compounds might be 
able to counteract these effects, by reinstating the proliferative controls in 
transformed cells. Restoring cell cycle checkpoints may also induce apoptosis 
selectively in tumours, owing to high levels of constitutive DNA damage and genomic 
instability. 80  
Due to the multi-functional nature of CDKs, and their aberrant activity in a range of 
disease states, a large number of structurally diverse CDK inhibitors have been 
reported. Although their primary intended use is for treating cancer, CDK inhibitors 
have been shown to have potential for counteracting several diverse diseases, 
including neurodegenerative disorders (e.g. Alzheimer’s disease), cardiovascular 
disorders (e.g. atherosclerosis), and infections (e.g. HIV and malaria).37, 52, 81  
 
 
 
56 
 
2.4.1 ATP-Competitive Inhibition 
 
Despite the existence of several possible approaches to kinase inhibition (outlined in 
Chapter 1), the vast majority of CDK inhibitors reported to date are ATP-competitive. 
Although exhibiting a wide spectrum of chemical diversity, for the most part they all 
exploit the two key hydrogen bonding interactions with the hinge region of the active 
site described in Chapter 1. 24 
 
Elucidation of the X-ray crystal structure of the CDK2/Cyclin A/ATP complex reveals 
two important hydrogen bonds between ATP and backbone amino acid residues of 
the active site cleft. N1 of the purine accepts a hydrogen bond from the backbone NH 
of Leu83, while the N6-amino group donates a hydrogen bond to the backbone 
carbonyl of Glu81 (Figure 21). 26 There are additional hydrophobic and Van der 
Waals interactions between ATP and CDK2, most notably the hydrophobic pocket 
within which the ribose moiety of ATP resides. At least one of these interactions is 
replicated with most ATP-competitive CDK2 inhibitors, most frequently the hydrogen 
bonds with Leu83. 
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N
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O
OH
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Figure 21 
Hydrogen bonding interactions between ATP and CDK2. 
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2.4.2 CDK inhibitors 
 
During recent years, many novel and potent ATP-competitive CDK inhibitors have 
been developed, providing an extensive array of structurally diverse 
pharmacophores. Consequently, a variety of compounds have progressed to clinical 
and late preclinical evaluation, supplying a wealth of information as to the validity of 
CDKs as ‘druggable’ targets. 82  
Elucidation of the interactions between inhibitors and the CDK ATP-binding site has 
been facilitated by crystallographic studies. Similar to ATP, most of these inhibitors 
interact with CDKs through a donor-acceptor motif. This in turn has led to the design 
and development of new classes of inhibitors with modifications that target specific 
residues on the protein to improve potency. Recently, this effort has been directed at 
achieving selectivity toward one particular kinase or kinase subtype. Several classes 
of inhibitors have been successfully modified to improve the potency of CDK 
inhibition, and a number of inhibitors have shown moderate to significant subtype 
selectivity. 26, 83 
The literature contains a number of interesting CDK inhibitors, some of which have 
been acquired from natural sources and some of which, like R-roscovitine, have 
reached clinical trials. 52, 84-86 Examples are included in Table 3. 
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 CDK inhibitory activity (IC50) 
 CDK1/B     CDK2/A   CDK5/p25      CDK4/D 
O
N
Me
HO
OH O
Cl
HO
 
Flavopiridol (9) 
 
 
 
0.4 µM 
 
 
 
0.1 µM 
 
 
 
N. A. 
 
 
 
0.4 µM 
 
Indirubin (10) 
 
 
40 nM 
 
 
22 nM 
 
 
40 nM 
 
 
0.2 µM 
 
Staurosporine (11) 
 
 
 
6 nM 
 
 
 
7 nM 
 
 
 
N. A. 
 
 
 
<10 µM 
 
R-roscovitine (12) 
 
 
0.45 µM 
 
 
0.7 µM 
 
 
0.16 µM 
 
 
>100 µM 
N
N N
Me
N
HN
N
H
HO
 
Olomoucine (13) 
 
 
7 µM 
 
 
7 µM 
 
 
3 µM 
 
 
>1000 µM 
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 CDK inhibitory activity (IC50) 
 CDK1/B     CDK2/A   CDK5/p25      CDK4/D 
 
Purvalanol A (14) 
 
 
35 nM 
 
 
70 nM 
 
 
75 nM 
 
 
0.85 µM 
N
N N
N
HN
N
H
HO
Cl
COOH
 
Purvalanol B (15) 
 
 
6 nM 
 
 
6 nM 
 
 
6 nM 
 
 
>10 µM 
 
Aminopurvalanol (16) 
 
 
33 nM 
 
 
33 nM 
 
 
20 nM 
 
 
N. A. 
 
Table 3 
Literature CDK inhibitors and their IC50 values. 
 
Flavopiridol (9) is a synthetic flavonoid analog of a natural alkaloid extracted from the 
stem bark of the Indian plant Dysoxylum binectariferum, and shows activity as a 
rather promiscuous CDK inhibitor. Indirubin (10) is a minor constituent of a Chinese 
prescription (Danggui Longhui Wan, a preparation comprising some 11 herbal 
medicines) that is traditionally used to treat certain types of leukaemia. The microbial 
alkaloid staurosporine (11) is a very potent but also very unspecific CDK inhibitor, 
which exhibits too high a level of toxicity to be used in therapy. The family of 
purvalanols, of which purvalanol A (14), B (15) and aminopurvalanol (16) are 
prominent members, has been found to include many potent CDK inhibitors. 
Variations on the main purine scaffold have been explored 84 to yield a set of very 
potent but also nonspecific small-molecule CDK inhibitors. 
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R-roscovitine (12) was developed through a series of structure-based SAR studies 
from 6-dimethylaminopurine and is currently undergoing phase II clinical trials. 19 
The purine scaffold shared by roscovitine, olomoucine (13) and the purvalanols has 
been one of the most frequently used during the search for bioactive compounds, 
given the extensive natural abundance of purines in living organisms. Guanine and 
adenine, two of the most common purines, are essential components of nucleic 
acids, cofactors and a whole range of signalling molecules that modulate protein 
functions. Purine-based CDK inhibitors are benchmark ATP-mimetics. 
 
More recent work has shifted the attention from the purine core pharmacophore to 
alternative scaffolds, among which one of the most popular is the pyrimidine moiety. 
Pyrimidines provide a very effective scaffold for the development of CDK inhibitors.87-
89
 Among the best pyrimidine- and pyridopyrimidine-based CDK inhibitors in terms of 
potency are 2-anilino-4-pyrrol-3-ylpyrimidines 89 (e.g. 17), pyrido-2,3-pyrimidin-7-
ones 87 (e.g. 18) and 2-anilino-4-thiazolylpyrimidines 88 (e.g. 19). Examples of these 
compounds and their activity are shown in Table 4. 
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 CDK inhibitory activity (IC50) 
 CDK1/B        CDK2/A      CDK5/p25      CDK4/D 
 
17 
 
 
N. A. 
 
 
0.03 µM 
 
 
N. A. 
 
 
0.12 µM 
N
H
N
N
N O
N
MeN
 
18 
 
 
79 nM 
 
 
15 nM 
 
 
N. A. 
 
 
4 nM 
 
19 
 
 
80 ± 40 
nM 
 
 
2 ± 0.6 nM 
 
 
4 ± 3 nM 
 
 
53 ± 5 nM 
 
Table 4 
Pyrimidine-based CDK inhibitors and their IC50 values. 
 
In all cases, lead compounds were identified using virtual screening methods and 
then used as starting points for the generation of libraries of compounds, the most 
potent of which would be evaluated against different members of the CDK family to 
establish a selectivity profile. 87-89 
 
The pyrimidine scaffold proved suitable for the synthesis of a set of CDK4-selective 
inhibitors. 90-94 The pyrido-2,3-pyrimidin-7-one scaffold, previously mentioned as a 
source of potent but unspecific CDK inhibitors, was more extensively investigated by 
Van der Wel and co-workers 92-93 leading to the discovery of compounds 20 and 21 
in Table 5, which show a good degree of selectivity towards CDK4. 
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 CDK inhibitory activity (IC50) 
     CDK1/B             CDK2/A             CDK4/D 
 
20 
 
 
>5 µM 
 
 
>5 µM 
 
 
0.265 µM 
 
21 
 
 
N. A. 
 
 
>5 µM 
 
 
6 nM 
 
Table 5 
Pyrimidine-based CDK4-selective inhibitors and their IC50 values 
 
The pyrimidine scaffold is not the only one on which good CDK4-selective inhibitors 
have recently been based; other examples include indolo-6,7-pyrrolo-3,4-carbazoles 
90, 94
 (e.g. 22-26) and 5-pyrimidinyl-2-aminothiazoles 91 (e.g. 27, 28). Examples are 
shown in Table 6. 
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 CDK inhibitory activity (IC50) 
CDK1/B    CDK2/A   CDK4/D  CDK5/p25   CDK6/D   CDK9/T 
 
22 
 
 
N. A. 
 
 
>2 µM 
 
 
40 nM 
 
 
N. A. 
 
 
N. A. 
 
 
N. A. 
 
23 
 
 
N. A. 
 
 
>2 µM 
 
 
25 nM 
 
 
N. A. 
 
 
N. A. 
 
 
N. A. 
24 
N. A. 2.1 µM 4 nM N. A. N. A. N. A. 
 
25 
N. A. 1.1 µM 11 nM N. A. N. A. N. A. 
 
26 
 
 
2.1 µM 
 
 
0.5 µM 
 
 
76 nM 
 
 
N. A. 
 
 
N. A. 
 
 
N. A. 
 
27 
 
>10 µM 
 
>10 µM 
 
34 nM 
 
>10 µM 
 
>10 µM 
 
>10 µM 
28 
 
0.6 µM 
 
1.7 µM 
 
9.2 nM 
 
3 µM 
 
7.8 µM 
 
2.5 µM 
Table 6 
Other notable CDK4-selective inhibitors and their IC50 values 
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Within the Northern Institute for Cancer Research (NICR) at Newcastle the 
investigation of both purine and pyrimidine scaffolds has led to the discovery of 
potent and selective CDK1 and CDK2 inhibitors 95-96, 55 (Table 7). 
 
 
 
CDK inhibitory activity (IC50) 
 CDK1/B       CDK2/A        CDK4/D      CDK9/T 
 
29 
 
100 ± 10 
nM 
 
1 ± 0.3 
nM 
 
1.5 ± 0.5 
µM 
 
0.74 ± 0.1 
µM 
 
30 
 
 
56 ± 20 
nM 
 
 
0.7 ± 0.1 
nM 
 
 
1.5 ± 0.5 
µM 
 
 
2.63 ± 0.2 
µM 
 
31 
 
 
9.5 ± 1.3 
nM 
 
 
5.4 ± 1 
nM 
 
 
N. A. 
 
 
N. A. 
 
32 
 
7 ± 1 
µM 
 
17 ± 2 
µM 
 
 
N. A. 
 
 
N. A. 
 
Table 7 
Purine- and pyrimidine-based CDK1/2 selective inhibitors at Newcastle and their IC50 values, or 
percentages of inhibition at a specified concentration. 
 
Some of the many CDK inhibitors that have been described to date 52  are active at 
low nanomolar concentrations. Despite the fact that they show a wide range of 
chemical diversities, there are some common properties that they appear to share: 
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they are normally small molecules with a molecular weight no higher than 600, and 
they are flat and hydrophobic heterocycles; they are ATP-competitive and bind to the 
target kinase by hydrophobic interactions and hydrogen bonds (they are reversible 
ligands); and finally, they bind to more or less always the same hydrogen bond 
donors and acceptors on the carbonyl and amino side chain of the target enzyme. As 
can be seen in Tables 3-7, most inhibitors are not selective for any specific CDK 
(Table 3), while groups of them show selectivity towards CDK1 and 2 or CDK4 and 6 
(Tables 4-7). To date, CDK1, 2, 4 and 6 have been the most explored targets for 
anticancer drug development based on CDK inhibition, although CDK7, 8 and 9 have 
also been investigated more recently. 97-98 
 
 
2.5 CDK7 
 
Two non-overlapping sets of CDKs have been defined in metazoans: CDK1, 2, 4 and 
6 are solely dedicated to cell cycle control, whereas CDK8 and 9 are primarily 
devoted to transcriptional activity. 99 
 
One CDK, however, is less readily classified. CDK7 acts both as a CDK-Activating 
Kinase (CAK), phosphorylating other cell cycle CDKs within their activation segment 
(T-loop), and as a component of the general transcription factor TFIIH, whose 
function is to phosphorylate the C-terminal domain (CTD) of the largest subunit of 
Pol II. 99 
Ever since it was first understood that there existed a CAK whose role was to 
phosphorylate and activate CDK1 and 2, much interest was raised with regard to the 
structure and properties of such an enzyme. After the CAK was isolated and purified, 
it came as a surprising discovery that its catalytic subunit was structurally related to 
that of the other CDKs. It also appeared to be bound to a cyclin partner, which was 
subsequently named Cyclin H. At that point, the CAK was decreed a member of the 
CDK family and renamed CDK7. 100 
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CDK7 does not exclusively bind to Cyclin H, but it also interacts, in near-
stoichiometric amounts, with another protein. This protein has been isolated from 
humans, mice and starfish and structural studies have revealed that it contains an 
amino-terminally located putative zinc-binding domain conforming to a typical Ring-
Finger motif (Figure 22). 101 
 
Figure 22  
The three-dimensional structure of the human MAT1 Ring-Finger domain in the presence of Zn(I) 
(left) and Zn(II) (right). 101 
 
With regard to the functions of ring-finger motifs there is still much to be unveiled, but 
it appears likely, in this case at least, that this protein acts as an assembly factor, 
promoting a stable interaction between CDK7 and Cyclin H. Accordingly, the protein 
was named MAT1 (Mènage-á-trois). In vivo, MAT1 forms a trimeric complex with 
CDK7 and Cyclin H under most conditions, and it has not yet been observed in 
complex with any other CDK or protein. It appears, so far, to be completely specific 
towards CDK7. It may be assumed, even if there is no conclusive proof of this to 
date, that it has a role in modulating CAK activity. 
Structural studies have been carried out to investigate the characteristics of the 
interaction between CDK7 and MAT1, and it has been revealed that CAK activity is 
triggered by interaction of the CDK7/Cyclin H complex with the hydrophobic C-
terminal domain of MAT1. The ring-finger motif of MAT1 has a crucial role in basal 
transcription complex activity and, consequently, in the CTD phosphorylation 
process. 102 It has also been suggested that MAT1 plays an important part in 
directing CDK7 substrate preferences: the addition of the MAT1 subunit to 
recombinant CDK7-Cyclin H switches its substrate specificity to favour Pol II over 
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CDK2. 103 Whether this is connected to the stimulatory function of MAT1 towards 
CDK7 itself or to its structure remains to be established. 
 
The role of CDK7 both as a CAK and as a component of a transcription factor has 
been the subject of discussion. In vitro studies demonstrate that the CDK7/Cyclin 
H/MAT1 trimeric complex phosphorylates CDK2 at Thr160 in the activation loop, but 
evidence arguing against CDK7 being the physiological CAK for CDK2, or at least 
the only one, raises from two main observations. Firstly, a temperature sensitive 
mutation in the drosophila CDK7 homologue causes ovarian cells to arrest in mitosis, 
and also causes CDK1 to exhibit deficiency of T-loop phosphorylation, but this is not 
the case with CDK2. Secondly, the budding yeast ortholog of CDK7, Kin28, is very 
similar to CDK7 in being part of the general transcription factor TFIIH, but does not 
possess any CAK activity, either in vitro or in vivo. 104 
It had been suggested that another cell cycle-related kinase, p42, might serve as a 
CAK towards CDK2 when CDK7 is unavailable, 105 but more recent studies 
presented evidence arguing against a role for p42 as a CAK for CDK2. 106 It was 
demonstrated that monomeric p42 does not possess any CAK activity against CDK2, 
and the only circumstance in which it can actually show such activity is when CDK7 
is also present. 
It was therefore concluded that CDK7 acts as a CAK, and genetics also provided 
conclusive proof that CDK7 is a CAK in vivo: by mutating the Dmcdk7 gene 
responsible for the coding of CDK7, CDK7 activity was abated in Drosophila 
melanogaster. 107 As a result, CDK7 mutant embryos appeared to be deficient in 
physiological CAK activity. CDK phosphorylation and activation was absent, and 
therefore CDK activity stopped. This demonstrates that CDK7 is essential for in vivo 
CAK activity. CDK7 plays a dual role in metazoans but two proteins, Kin28 and 
Cak1, fulfil the two functions separately in budding yeast. 108 
 
2.5.1 CDK7 activation 
 
Like other CDK family members, the T-loop of CDK7 contains a site (Thr170) which 
is phosphorylated in vivo. Phosphorylation on this site favours Cyclin H binding, but it 
would appear that the MAT1-mediated stabilisation of the CDK7/Cyclin H complex is 
 independent of the Thr170 residue being phosphorylated
some highly significant conclusions. MAT1 is able to bypass the requirement for T
loop phosphorylation, showing that the CDK7/Cyclin H complex can form
distinct mechanisms. It is not clear which of the two mechanisms is favoured 
or even whether there is a 
the CDK7/Cyclin H complex forms with MAT1 may provide one solution to a 
fundamental problem: kinase cascades operating through T
not extend indefinitely. One
upstream regulator of CDK activity.
 
Regarding the mechanisms of activation of the complex
is still much to be unveiled. As a cyclin
a cyclin partner, Cyclin H (Figure 
 
Figure 23 
Crystal structure of Cyclin H. 109 
 
Human Cyclin H is a protein comprising 323 amino acids and has a molecular weight 
of 38 KDa. It was recently shown that Cyclin H binds to the growth suppressor 
protein p53, 110 and this leads to a down
vitro and in vivo. p53 is a growth suppressor and one of the regulators of cell cycle 
. 
100
 These results permit 
preferred mechanism at all, but the unique interaction that 
-loop phosphorylation do 
 protein is needed to begin the cascade and to act as an 
 34
 
 CDK7/Cyclin H/MAT1 there 
-dependent kinase, CDK7 requires binding to 
23). 
 
-regulation of CDK7 kinase activity both 
68 
-
 by two 
in vivo, 
 
in 
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progression, because it indirectly regulates kinase activity by transactivating inhibitor 
molecules for these enzymes. Cyclin H also possesses several potential 
phosphorylation sites, and this makes the protein a potential target for regulation by 
phosphorylation and dephosphorylation. It was recently shown 111 that the 
CDK8/Cyclin C complex phosphorylates Cyclin H, thereby inhibiting the formation of 
the CDK7/H complex. Cyclin H is also a substrate for another kinase, namely protein 
kinase CK2. Protein kinase CK2 is a holoenzyme composed of two regulatory β-
subunits and two catalytic subunits (α- and α’-). CK2 phosphorylates Cyclin H on 
Thr315 (while CDK8/Cyclin C phosphorylates Ser304), thereby inhibiting its ability to 
bind correctly to CDK7. 112 
 
2.5.2 CDK7 as a CTDK 
 
The cloning of the largest subunit of RNA polymerase II (Pol II) from mouse and 
Saccharomyces cerevisiae in 1985 113-114 revealed a remarkable and highly 
conserved domain known as the Pol II Carboxy-terminal Domain (CTD). The CTD is 
structurally very simple, consisting mainly of repeats of the 7-amino acid sequence 
Tyr-Ser-Pro-Thr-Ser-Pro-Ser (52 repeats in mouse and human; 27 repeats in 
budding yeast; 45 repeats in Drosophila). 
 
 
 
Figure 24 
Structure of RNA Pol II from Saccharomyces cerevisiae. 115 
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In contrast to this structural simplicity, the functions of the CTD are many and 
varied.116 The CTD is involved in all major steps of mRNA formation and performs 
important regulatory roles. It has been found to be phosphorylated, and 
phosphorylation levels vary during the transcription cycle, suggesting that a 
regulatory switch via an activating phosphorylation process/deactivating 
dephosphorylation process is in action. The natural question followed as to which 
kinase was responsible for this particular phosphorylation, and that activity was 
found to reside in the TFIIH transcription factor. TFIIH was found to consist in 
mammalians of ten subunits (schematically represented in Figure 25), 7 of which 
(XPD, XPB, p62, p52, p44, p34 and TTDA) form the core complex. The CDK 
activating kinase-subcomplex (CDK7, MAT1, and cyclin H) is linked to the core via 
the XPD protein. Two of the subunits, ERCC2/XPD and ERCC3/XPB, have helicase 
and ATPase activities and help create the transcription bubble. 117 
Phosphorylation of the CTD regulates protein-protein interactions between the CTD 
itself and the CTD-binding proteins, and these interactions have effects on 
transcription, initiation and elongation of RNA, leading to the processing and 
production of full-length mRNA. 
 
 
 
Figure 25 
The TFIIH transcription factor. 118 
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It is not clear how many CTDKs exist in nature, and what actually directs the 
substrate specificity of the CTDKs towards the different phosphorylation sites 
present on the CTD. It appears that serine residues 2 and 5 from the repeated 
sequence above are the favourite sites for phosphorylation over, for example, Thr4 
and Ser7, but the reason for this is still unknown and the relative ratio of 
phosphorylation of these two favourite residues is also unknown. Also, the CTD is 
known to undergo other particular modifications at the hands of different enzymes, 
for example glycosylation. The relationships between these other modifications and 
phosphorylation have still not been satisfactorily explained. 119 
 
Another interesting point to be discussed regards the nature of the CTD kinases 
currently known and the way in which they are regulated. The majority of those that 
have been described to date are CDKs. During the progression of the cell cycle, 
CDKs are regulated by cyclin binding, which oscillates accordingly to the level of 
activity required as the phases of the cell cycle succeed one another. Cyclin binding 
is required for activity towards the CTD as well, but the levels of the cyclins involved 
in CTD phosphorylation processes do not vary. 120 Another mechanism shared 
between the cell cycle CDKs and the CTDKs is phosphorylation within the T-loop. In 
CDK7 this mechanism cooperates with MAT1 binding and it has been demonstrated 
that when these two processes occur together, the CDK7/Cyclin H/MAT1 complex is 
highly stabilised and stimulated to act towards the CTD (while activity towards CDK2 
and other fellow kinases is not greatly affected). 121 The substrate-specific increase 
in activity caused by T-loop phosphorylation is entirely due to accelerated enzyme 
turnover. In other words, upon T-loop phosphorylation catalytic efficiency specific to 
the Tyr-Ser-Pro-Thr-Ser-Pro-Ser target sequence of the CTD is ~25-fold increased 
(kcat = 0.22  3.69 s-1). Thr170 phosphorylation is therefore a key step in regulating 
the rate of CTD phosphorylation by TFIIH during transcription. 121 
 
2.5.3 CDK7 as an anticancer drug target 
 
As a demonstrated crucial agent in the regulation of the activity of the CDKs 
throughout the cell cycle, CDK7 would be an interesting and important target for 
anticancer drug development. Therefore, much interest has recently been raised 
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towards this enzyme and its properties both in a normal and in a cancerous cell 
environment. 
Surveys of cell and tissue specificity, subcellular localisation and protein abundance 
of human CDK7 in a wide range of normal and cancer cell types, both in cellular and 
tissue cultures, led to the following observations: 122 
 
• CDK7 is ubiquitously expressed in all cell types examined; 
• It is located exclusively in the nucleus; 
• Its abundance is constant throughout the cell cycle; 
• It is moderately elevated in tumour cells when compared to normal cell 
counterparts; 
• It is clearly detectable even in quiescent cells. 
 
The protein partners that bind to CDK7, namely Cyclin H and MAT1, do not 
appreciably oscillate during the cell cycle. Cyclin H is also overexpressed in cancer 
cells as demonstrated by immunohistochemical studies on endometrial cancerous 
tissues. 123 
This experimental evidence is accounted for by the apparently universal role of 
CDK7 in performing the activating T-loop phosphorylation of CDKs operating during 
the G1, S, G2 and M phases of the cell cycle. In particular the ubiquitous expression 
of CDK7 in all cell types, the location in nucleus and the constant levels throughout 
the cell cycle are all consistent with a very broad function towards a wide range of 
other enzymes (the cell cycle CDKs). 104, 124 
The presence of CDK7 in quiescent cells agrees with the fact that CDK7 is, as 
discussed above, not only a CAK, but also a CTDK and is required not only for cell 
cycle regulation (which does not take place in quiescent cells) but also for 
transcriptional duties. 
 
Any consideration of CDK7 as a potential drug target must take into account its dual 
functions in cell cycle control and transcription. Inhibiting an enzyme that has a role 
in such a wide range of cellular activities, with the purpose of abating the growth of 
tumour cells, might prove prohibitively toxic to normal cells. However, it is possible to 
re-evaluate these assessments in the light of some recent encouraging evidence. 99 
73 
 
Firstly, it is possible to separate the two functions of CDK7 (the TFIIH-correlated 
transcriptional activity and the CAK activity) by specific mutations that selectively 
impair only one process 103, 121, 125-129 in two ways: by changing requirements for cell 
division and transcription at different times or by manipulating subunit composition 
and modification state of the CDK7 complex. 103, 121, 128-129 The enzyme has two 
separate classes of substrates for its two activities (the downstream cell cycle 
regulating CDKs and the CTD) and it is now apparent that they are recognised in 
different modes, and presumably even by different surfaces of the CDK7/Cyclin 
H/MAT1 complex. Selective inhibition of CAK or CTDK activity now seems at least 
possible. 
Secondly, not all transcription by Pol II depends on the catalytic activity of CDK7. If it 
were demonstrated in mammals (as already is the case in yeast) that CDK7 activity 
preferentially affects transcripts needed by dividing cells, inhibition of CDK7 could 
simultaneously deprive tumour cells of the CAK activity they require and crucially 
limit the synthesis of mRNA needed for other steps in cell division, without shutting 
down transcription globally in nondividing cells. 130-131 
Whether or not CDK7 inhibition could cause toxicity in relation to its role in 
transcription is still controversial, but encouraging evidence is accumulating that a 
selective CAK inhibition that would not be too detrimental to transcriptional activity is 
achievable. For example, using CDK7 temperature sensitive mutants in C. elegans 
embryonic blastomeres it was shown that loss of CAK function of CDK7 (and not 
loss of CTDK activity) caused cell cycle block. Defects were observed in both 
interphase and mitosis. In mice, MAT1 disruption severely affected mitosis but no 
decrease in transcription was observed. 132 Given that in Drosophila the complex 
CDK9/Cyclin T phosphorylates the CTD and regulates the elongation phase of 
transcription, it has been suggested that CDK9 might be able to compensate partially 
for CDK7 when the latter is absent. 125, 133-135 
 
Information on CDK7 inhibitors is limited. Inhibitors known to date include flavopiridol 
(9), purvalanol A (14), (R)-roscovitine (12) and, more recently, the compounds 
shown in Figure 25. 88, 91, 55 Purvalanol A (14) was tested at Newcastle for activity 
against CDK7 and was found to be a ~100 nM inhibitor (unpublished results). 
Referring back to Table 3 the values show that the potency of 14 is higher against 
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CDK1 and 2 than CDK7, and the same holds generally true for the CDK7-inhibitory 
activity of most of the other literature compounds included in Table 3 and in Figure 
26. 
 
 
 
Figure 26 
Known CDK7 inhibitors 
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It has been shown that resveratrol (40) can induce G2 arrest in cancer cell lines by 
preventing phosphorylation of CDK1 at its Thr161 residue. 136  
 
 
 
CDK1 is a key mediator of the transition from the G2 to the M phase in eukaryotic 
cells. It is associated with a cyclin partner, Cyclin B, but it is also necessary for the 
kinase to be phosphorylated at Thr161 to be completely active, and this 
phosphorylation is carried out by CDK7. Selected cell extracts exposed to 100 µM 
resveratrol do not show phosphorylation of p34 at the relevant site because of CDK7 
inactivation. 136 
In vitro, however, resveratrol is a poor CDK7 inhibitor, and so are flavopiridol and R-
roscovitine. The development of potent and selective CDK7 inhibitors would 
therefore provide new perspectives to the development of cancer treatments. 
 
To date, the only existing selective CDK7 inhibitor is BS-181 (39), developed and 
patented jointly by Emory University and Imperial College, London. 137 With a 40-fold 
selectivity over CDK2, it is the only CDK7-selective compound within the reported 
series. This compound will be discussed in more detail in Chapter 5. 
 
 
2.5.4 Structural information on CDK7 
 
The crystal structure of human CDK7 in complex with ATP at 3 Å resolution was 
recently determined by Professor L. N. Johnson and colleagues at the University of 
Oxford. 138 
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Figure 27 
The structure of monomeric CDK7 bound to ATP. 138 
 
CDK7 has a molecular weight of 39,141 KDa when monophosphorylated at Thr170 
(an additional phosphorylation at Ser164 is observed in 30% of the cases). 
The structure exhibits a typical kinase fold comprising the N-terminal lobe (residues 
13-96), which is constituted mostly by β-sheets with the presence of one α-helix, and 
a C-terminal lobe (residues 97-311), which on the contrary shows a majority of α-
helices. ATP is bound between the two domains. 
In the absence of the cyclin partner, the two structures of inactive CDK7 and CDK2 
are quite similar (Figure 28). Differences may be noted between the inactive 
(monomeric) and active (cyclin-associated) form of CDK7 in terms of three-
dimensional conformation, leading to stabilising interactions between amino acids 
that are necessary for correct ATP binding. 
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Figure 28 
Overlay of monomeric CDK2 (blue) and CDK7 (yellow). 138 
 
 
CDK7 has a 44% sequence identity with CDK2. Major changes are observed in three 
regions: 138 
 
• The activation segment (residues 155-174); 
• The region where the sections αD, β7/β38 loop and the C-terminal domain 
(residues 101-112, 146-149 and 297-311) come together; 
• Part of the recognition site for the Kinase-Associated Phosphatase (KAP), the 
enzyme that dephosphorylates CDK7 (residues 247-251). 
 
Over all, the number of Van der Waals contacts made between ATP and CDK7 and 
between ATP and CDK2 are quite similar, even though a number of the residues 
 involved are different (Figure 2
CDK2 ATP-binding sites occur a
This pocket lies at the bottom of the ATP
Phe23, Ala24 and Lys41 that constitutes the site for the hydrogen bonding of the 
three γ-phosphate oxygens of ATP.
 
Figure 29 
 ATP-binding pocket of CDK7 (left) and CDK2 (right)
 
In this hydrophobic pocket, some 
CDK7. For example, Gln85 is replaced by Thr96, a proline 
position 310 (which is absent in CDK2)
CDK2 is replaced by Val100 in CDK7.
 
2.5.5 ATP-competitive inhibition of CDK7
 
Elucidation of the X-ray crystal structure of CDK7 bound to ATP reveals the
interactions that are made between ATP and the backbone amino acid residues of 
its specific binding site (Figure 
• The adenine makes two hydrogen bonds to the backbone chain of the regio
containing Phe93 and Met94;
• The ribose is close to the pocket where Leu18, Gly19 and Asp20 are, and 
hydrogen-bonds to the carbonyl
hydroxyls; 
9). The major differences between
t the CDK2 Lys89 pocket (‘hydrophobic pocket
-binding site, opposite to the sequence of 
 
.
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amino acids that are found in CDK2 are different in 
residue is found at 
, and the residue corresponding to Lys89 in 
 
 
30): 138 
 
 oxygen of Leu18 by means of one of its two 
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• The γ-phosphate oxygens hydrogen-bond to the main chain nitrogens of 
Phe23, Ala24, Lys41 and Ser161. 
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Figure 30 
 Schematic representation of the interactions made by ATP in the CDK7 active site. 
 
The specificity pocket within the CDK7 active site has a much greater hydrophobic 
character than is the case for CDK2, and this pocket may be targeted with inhibitors 
that could form stable hydrophobic interactions that would not be possible with 
CDK2, thereby achieving selectivity (see Chapter 4).  
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2.6 CDK Redundancy and Selectivity Profile of inhibitors 
 
The pursuit of drugs that inhibit CDKs has been an intense area of research for 
several years and significant clinical progress has been made. Combinations of CDK 
inhibitors with cytotoxic drugs have also shown promise in a number of tumour 
models. 44 Newer CDK inhibitors were designed to exhibit decreased toxicity and 
more selective activity. However, the development of CDK inhibitors has been 
hindered by uncertainties as to the optimal selectivity profile. 139  
 
Research was focused initially on CDK2/Cyclin A as a therapeutic target. However, 
recent reports have questioned the validity of CDK2 as a target for the reinstatement 
of cell-cycle checkpoints in cancer. 140-142 It is becoming evident that the 
pharmacological effects of most CDK inhibitors do not emanate from CDK2 
inhibition, and that effects on CDK-mediated RNA Pol II CTD phosphorylation are 
important for the observed antiproliferative effects of, for example, flavopiridol (9) 
and (R)-roscovitine (12) through inhibition of CDK7, 8 or 9. 
 
The apparent redundancy of CDK2 in normal proliferating cells does not necessarily 
mean that CDK2 is not a valid target in anticancer drug design. 143 The expression of 
catalytically inactive CDK2 in cells results in cell cycle arrest and more closely 
resembles the pharmacological inhibition of CDK2 than the genetic knockout of 
CDK2. 144 Additionally, research on the inhibition of CDK2, combined with the 
disruption of DNA synthesis and replication, where a p53-induced response toward 
apoptosis is triggered, provides evidence in favour of CDK2 as a viable cellular 
target for cancer therapy. 145 The initial response to DNA damage in the cell is 
regulated by a family of protein kinases related to phosphatidylinositol 3-kinase 
(PI3K). Following DNA damage, members of this family, namely ATM and ATR, 
phosphorylate p53 modulating both cell cycle progression and apoptosis. 
Consequently, sustained CDK2 inhibition and the resulting disruption to DNA 
synthesis leads to amplification of ATM and ATR activity and, ultimately, p53-
induced apoptosis. 
 
81 
 
The high homology of the ATP-binding sites of CDK1, CDK2 and CDK9, has led to 
the assumption that it will be difficult to develop truly CDK-selective inhibitors. 37 
Optimal selectivity profiles for a particular cancer, such as pan-CDK inhibition versus 
CDK1/2, 4/6 or 7/9 specificity may represent a possible solution. However, little 
progress has been made to date in this direction, the notable exception being the 
highly CDK4/6-selective compound 21. 44 
 
A recent report detailing the kinase selectivity of 20 inhibitors, including imatinib (3), 
against a panel of 119 protein kinases, stated that selectivity varied widely and did 
not significantly correlate with chemical structure or the nature of the intended 
target.146 These observations further emphasised the difficulty of achieving complete 
kinase selectivity, but also suggested that this is not necessarily the most important 
factor in developing a successful drug candidate. Highly selective inhibitors of 
specific CDKs may be preferable to reduce toxicity, but selectivity may also diminish 
anticancer efficacy due to the inherent functional redundancy observed for this family 
of kinases. Thus, absolute selectivity might not be the best approach to treat such a 
complex disease as cancer, where multiple pathways are deregulated. A broader-
spectrum compound that inhibits CDK1, CDK2, CDK4 and CDK6 at low nanomolar 
concentrations may therefore be optimal. 147 The recent observation that selectively 
inhibiting CDK2 in certain tumour cell lines is not sufficient for antitumour activity 
would support this view, 142 as would the demonstration that the CDK2 knockout 
mouse shows no major abnormalities and, in particular, no effects on proliferation. 
141
  
 
As the CTD kinase associated with the general transcription factor TFIIH, CDK7 has 
long been suspected of playing an indispensable catalytic role in transcription. The 
belief that CDK7 is globally required for transcription by Pol II in vivo is based largely 
on hybridisation studies in budding yeast, in which the large majority of Pol II 
transcripts are repressed upon thermal inactivation of a temperature-sensitive Kin28. 
148
 Exceptions to this behaviour (e.g. promoters refractory to inactivation of the 
TFIIH-associated kinase) exist in budding yeast 149-150 and in Drosophila. 135 These 
exceptions might reflect compensation by other CTD kinases, such as the recently 
identified ortholog of metazoan CDK9. 151-152 Synthetic genetic interactions between 
82 
 
orthologs of CDK7 and CDK9 in both budding and fission yeast  indicate a degree of 
functional overlap. 153 This feature among the CDKs that phosphorylate the Pol II 
CTD to influence transcription is still hypothetical, but would be reminiscent of the 
apparent redundancy among the cyclins and CDKs that control cell-cycle 
progression. 
 
Interestingly, the essential role of CDK1/Cyclin B1 as the M phase-promoting factor 
appears to have survived unchallenged to date. Expression of CDK1 in proliferating 
cells has been observed to cause an arrest in the G2/M transition. Furthermore, a 
recent study demonstrated that selective cyclin B1 depletion inhibits proliferation and 
induces apoptosis in tumour cells, whereas normal cells are essentially unaffected. 44 
As cyclin B is frequently overexpressed, selective CDK1 inhibition may be an 
attractive therapeutic strategy. However, it remains unclear at this stage whether 
pharmacological CDK1 inhibition in tumour cells can result in the same effect as 
cyclin B1 depletion. At present, no truly selective ATP-competitive CDK1 inhibitor 
has been developed.  
Another approach, which is currently being investigated, involves the development of 
non ATP-competitive inhibitors. Targeting allosteric sites can potentially provide an 
increased selectivity for individual kinases. In particular, CDKs offer an interesting 
starting point for the design of corresponding inhibitors because of their complex 
network of mechanisms of regulation. 147 
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Chapter 3 – Project background 
 
3.1 Purine-based inhibitors of CDKs 
 
In the search for structures that closely reproduce the interactions made by ATP 
within the ATP-binding site, purines were early candidates as inhibitors of CDKs.  
The first purine compound to be identified as a CDK inhibitor was 6-
dimethylaminopurine or 6-DMAP (41). Originally designed to inhibit protein 
biosynthesis as a puromycin analogue, 6-DMAP inhibited mitosis in sea urchin 
oocytes without blocking protein synthesis. The mechanism of action of 6-DMAP was 
finally elucidated when it was demonstrated that this compound inhibited the recently 
discovered histone H1 kinase, or CDK1/Cyclin B, with an IC50 of 120 µM. 154 
 
 
 
Further screening experiments using a newly established in vitro kinase assay led to 
the identification of additional purine CDK inhibitors, including isopentenyladenine 
(42, IC50 = 55 µM) and olomoucine (13, IC50 = 7 µM). 155 Olomoucine was found to 
be selective for the CDK family with the exception of ERK2, a member of the MAP 
kinase family; this purine inhibits CDK2/Cyclin E and CDK7/Cyclin H with an IC50 of 
0.94 and 0.6 µM, respectively. 156 
X-ray crystal structure analysis of 13 bound to CDK2 showed the adenine group 
adopting a different binding orientation from that of ATP (Figure 31). 
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Figure 31 
ATP (left) and Olomoucine (right) bound to CDK2/A.  
 
The N7 of olomoucine accepts a hydrogen bond from the NH group of Leu83, whilst 
the exocyclic NH2 donates a hydrogen bond to the carbonyl of the same residue via 
the 6-amino group. In addition, a third hydrogen bond was identified between the 
hydroxyl group on the N6 substituent and the backbone carbonyl group of Gln131. 
The alternative binding mode of olomoucine projects the N6 substituent out of the 
conserved region in the binding pocket, allowing for interactions with the specificity 
surface of CDK2. The benzyl ring makes favourable Van der Waals interactions with 
residues Ile10, Phe82 and His84. 157 This avoids a steric clash between the benzyl 
group and the Phe80 sidechain. 
From the early screening of purines as CDK inhibitors, 2,6,9-trisubstituted purines 
gave the best inhibitory results. (R)-roscovitine (12), a derivative of olomoucine, is an 
inhibitor of CDK2, CDK7 and CDK9 (IC50 CDK2/Cyclin A = 2.2 µM; IC50 CDK7/Cyclin 
H = 0.46 µM; IC50 CDK9/Cyclin T1 = 0.78 µM). 156 
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Figure 32 
(R)-roscovitine bound to CDK2/A. 158 
 
(R)-roscovitine (12) binds to CDK2 in the same orientation as the parent olomoucine 
159
 (Figure 31), and the N9-isopropyl group fits inside a small hydrophobic pocket 
formed by the side-chains of Ala31, Phe80, Leu134 and Ala144. The stereoisomer 
bearing a side-chain with an (R)-configuration is more active against CDK1/Cyclin B 
than the corresponding (S)-enantiomer (IC50 = 0.95 µM). This was also observed for 
analogues with different side-chains at the 2-position, with the (R)-isomer being more 
active than the (S)-isomer. Selective interaction of this side-chain with Val-18 in the 
ribose-binding pocket has been suggested as the reason for this difference in activity 
between the two enantiomers. 160 Tested against a panel of 151 kinases, 12 
exhibited good selectivity for the CDK family, with the only other significant target to 
be recognised being pyridoxal kinase, the enzyme responsible for phosphorylation 
and activation of vitamin B6. 161 (R)-Roscovitine (12) can arrest cells in both the G1 
and G2 phase of the cell cycle, depending on the cell line. Studies have also shown 
that treatment of colorectal cancer cells with 12 resulted in a decrease in pRb 
phosphorylation, indicative of direct CDK2 inhibition, while G2/M checkpoint 
reactivation was attributed to inhibition of CDK1. 155 (R)-Roscovitine also blocks the 
degradation of p53 through inhibition of MDM2 expression, arising from inhibition of 
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CDK7 and CDK9.147 Upon successful completion of phase I clinical trials, 12 has 
undergone several phase II studies, including the treatment of haematological β-cell 
malignancies and breast cancer. 44, 69, 162  
Another important class of purine-based CDK inhibitors that share a similar binding 
mode to olomoucine and (R)-roscovitine is the purvalanols. Identified in 1998 158 as a 
result of screening numerous 2,6,9-trisubstituted purines against CDK2, purvalanols 
A (14) and B (15) have IC50 values of 4 and 6 nM against CDK1/Cyclin B, and 70 nM 
and 6 nM versus CDK2/Cyclin A, respectively. 147 Purvalanol A causes an arrest of 
the cell cycle of human fibroblasts in the G1/S and G2/M transitions, in line with the 
observed inhibition of CDK1 and CDK2. It also exhibits antiproliferative activity 
against different human tumour cell lines in contrast to purvalanol B, with average 
GI50 values of 2 µM. This is probably due to the higher membrane permeability of 14, 
although 15 is more active against the isolated CDKs. 37  
N
N N
N
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N
H
HO
Purvalanol A (14) (R = H), Purvalanol B (15) (R = CO2H)
Cl
R
 
 
Figure 33 
Purvalanol B bound to CDK2/A. 158 
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Crystallographic studies with CDK2 confirmed that the binding mode of the 
purvalanols mirrored that of other 2,6,9-trisubstituted purine inhibitors (Figure 33). In 
addition to the characteristic donor-acceptor motif with the backbone peptide, it has 
been argued that further stabilisation is gained from polar interactions between the 
chloro group and the side-chains of Asp86, whilst the (R)-isopropyl group is packed 
tightly to the backbone atoms of the glycine-rich loop (Val18). 37 When assessing the 
selectivity profile of the 2,6,9-trisubstituted purine derivatives the general trend was 
towards inhibition of CDK1, 2, 5, 7 and 9, rather than CDK4/6. MAP kinases ERK1 
and ERK2 were also sensitive but none of the other kinases tested showed 
significant inhibition. 155 
 
 
3.2 From NU2058 (32) to NU6247 (44) 
 
Previous work carried out at Newcastle University was focused on the synthesis and 
evaluation of O6-substituted guanine derivatives as potential inhibitors of the DNA-
repair protein O6-alkylguanine-DNA-alkyltransferase (AGT). 163 O6-
Cyclohexylmethylguanine (32, NU2058) emerged as inactive against AGT, but 
exhibited moderate inhibition of CDK1/Cyclin B and CDK2/Cyclin A, with IC50 values 
of 26 ± 1 µM and 17 ± 3 µM, respectively. 164 This compound also shows selectivity 
over CDK4/Cyclin D (IC50 > 100 µM).  165 
 
 
 
Elucidation of the crystal structure of 32 bound to CDK2/Cyclin A revealed a different 
binding orientation compared with the other known purine-based inhibitors, such as 
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olomoucine (13), (R)-roscovitine (12) and the purvalanols (14 and 15), indicating the 
formation of a unique triplet of hydrogen bonds within the hinge region. The N3 and 
2-amino groups of 32 accept and donate hydrogen bonds with the carbonyl and 
amide groups of Leu83, respectively, whereas the 9-NH donates a hydrogen bond to 
the carbonyl group of Glu81 (Figure 34). 164  
The O6-cyclohexylmethyl substituent of 32 makes significant hydrophobic 
interactions with various residues within the ribose-binding pocket, forming highly 
complementary packing against the glycine-rich loop. 165 In addition, Van der Waals 
interactions between the purine ring and the top and bottom of the ATP-binding cleft 
are observed, forming an edge-to-face aromatic-aromatic contact between the purine 
ring of 32 and Phe80. 
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Figure 34 
NU2058 (blue, left) and olomoucine (green, right) bound to CDK2/A. 165 
 
As previously described, the N6-benzyl group of olomoucine (13) projects out of the 
ATP-binding site of CDK2 and forms interactions with the specificity surface of the 
kinase. By comparing the binding modes of 32 and 13, it was suggested that suitable 
aromatic substituents could be introduced at the N2 position of 32, thus packing 
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against the specificity surface occupied by the N6-benzyl group of olomoucine, with 
potential for improving both potency and selectivity. 
Accordingly, the 2-anilino derivative 43 exhibited approximately a ten-fold increase in 
potency for CDK2 in comparison with its parent compound 32, with IC50 values of 10 
µM and 1.0 µM versus CDK1/Cyclin B and CDK2/Cyclin A, respectively. 43 It was 
confirmed via a crystal structure determination that, as predicted, the aniline group at 
the 2-position projects out of the ATP-binding domain and packs against the kinase 
specificity surface, forming a π-π stacking interaction with the peptide backbone 
between Gln85 and Asp86. The planes of the purine and the aniline rings are 
separated by an interplanar angle of 50°, closely r esembling the energetically 
favoured angle, estimated as approximately 48° ( Figure 35). 43  
 
 
Figure 35 
Purine 43 bound to CDK2/A. 43 
 
In order to probe the specificity pocket further, a variety of functionalities were 
introduced at different positions on the aniline ring. 95 The sulfonamide derivative 
NU6102 (31) proved to be an extremely potent CDK2 inhibitor (IC50 = 5 nM), as it 
makes two additional bonding interactions with the target kinase. One sulfonamide 
oxygen accepts a hydrogen bond from the backbone NH of Asp-86 (rNH-O = 3.1 Å), 
while the sulfonamide NH2 group donates a hydrogen bond to the side-chain 
carbonyl of Asp86 (rNH2-O = 2.9 Å) (Figure 36). 
  
 
 
Figure 36 
NU6102 (31) bound to CDK2/A 95
 
Unfortunately, tumour cell growth inhibition for 
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with high intracellular levels of ATP. Another increasingly plausible explanation has 
been suggested to be the redundancy of CDK2, as discussed in Chapter 2. 
 
To address the issue of presumed poor cellular uptake of 31, or the possibility that 
the arylsulfonamide moiety may be conferring affinity for other proteins, for example 
carbonic anhydrase, 166 systematic replacement of the sulfonamide group with 
isosteric functionalities was undertaken. An ideal sulfonamide isostere, in this case, 
would be a group that retains the ability to form the key hydrogen bonds with Asp-86, 
recognised as important to attain CDK2 potency, whilst gaining favourable cellular 
properties and losing features of promiscuous affinity. An innovative approach was 
adopted to generate a library of compounds based on the sulfone moiety. 167 The 
piperazin-1-ylethylsulfonyl compound NU6247 (44), whilst not one of the most potent 
compounds generated within this series (IC50 CDK2 = 120 nM), proved to be almost 
equipotent against CDK7 (IC50 = 230 nM), the first purine within this series to show 
activity against this member of the CDK family. 
 
 
 
 
 
Purine 44 was co-crystallised with CDK2 (Figure 37, right), showing that this 
compound binds in essentially the same orientation as 31 (left). The interaction of 
the sulfone moiety with the backbone amide NH of Asp-86 is retained, but the 
interaction with the backbone carbonyl of Asp-86 is lost and is not replaced by any 
meaningful interaction made by the terminal piperazine, which may account for the 
loss in potency. 
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Figure 37 
31 (left) and 44 (right) bound to CDK2/A. 95 
 
 
At the time that the sulfone series was developed, 44 was the most potent CDK7 
inhibitor synthesised at Newcastle. The following chapters outline the work 
conducted since then, aimed at designing out CDK2 activity from this family of 
compounds while improving CDK7 activity. 
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Chapter 4 – Development of analogues of 
NU6247 (44) 
 
4.1 Hydrophobic analogues of NU6247 (44) 
 
As discussed at the end of Chapter 2, the recently elucidated crystal structure of 
CDK7 provides guidance towards designing potent and selective ATP-competitive 
inhibitors of CDK7. As mentioned in Chapter 2, the specificity surface of CDK7 
exhibits some amino acid residues that have a hydrophobic character. These 
residues could, if appropriately targeted with specifically designed inhibitors, form 
productive interactions with CDK7 that would not be possible in CDK2, thereby 
providing selectivity. The bottom of the “hydrophobic pocket” 27 of CDK7 contains 
Thr96 and Val100 instead of Gln85 and Lys89 (the region in question also includes 
Asp97, Leu98 and Glu99; in the vicinity, residues Pro140, Asn141, Asn142, Asp143, 
Leu144 and Pro310 can also be found). 
 
 
 
Figure 38 
The ATP binding site of CDK7.138 
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Following the identification of 44 as a nanomolar CDK7 inhibitor, a small group of 
similar purines containing the ethylsulfonyl moiety was tested against the same 
kinase (Table 8), establishing the role of 44 as a structural lead within this family. 
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Interestingly, the aminoethanol derivative 45 was 100-fold less potent than 44. This 
suggested a different binding mode for the two compounds within the ATP binding 
pocket of CDK7, potentially providing a platform from which to develop potent and 
selective inhibitors of CDK7. 
 
The activity shown by 44 against CDK7 was retained in all four compounds in Table 
8. The presence of an alkyl substituent on the terminal piperazine nitrogen increased 
potency, with purines 47 and 48 being essentially equipotent and approximately 5-
fold more potent than the parent unsubstituted piperazine (46). These compounds 
are also selective over CDK9, thus retaining the selectivity profile seen with NU6102 
(31). 
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IC50 (µM) or percentages of inhibition 
at 100 µM 
R Code CDK2     CDK7 CDK9 
H 46 0.34 0.99 75 
Me 44 0.12 0.23 100 
Et 47 0.29 0.27 78 
iPr 48 0.34 0.48 46 
 
Table 8 
CDK2- and 7-inhibitory activity for compounds 44 and 46-48 
 
Compounds 46-48 lack selectivity for CDK7 over CDK2 but represent a good starting 
point for structural modifications targeting the “hydrophobic pocket” of CDK7. 
With a view to synthesising derivatives of 44 that are more hydrophobic, compounds 
49-52 were identified as initial targets. 
 
 
 
The aim was to investigate the effect of having an aromatic substituent on the 
terminal piperazine nitrogen of 44, and to explore the effect of an electron-donating 
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versus an electron-withdrawing substituent on the phenyl ring, with respect to the 
parent phenyl compound. 
The route chosen to the desired synthetic targets was one previously developed at 
Newcastle. 168 Starting from commercially available 2-amino-6-chloropurine and 4-
aminophenylthioacetic acid, the steps outlined in Schemes 1-3 were carried out. 
 
 
Scheme 1 
Reagents and conditions (i) DABCO, DMSO, 25°C; (ii)  Cyclohexylmethanol, NaH, DMSO, 25°C; (iii) 
HBF4, NaNO2, 0°C . 
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Scheme 2 
Reagents and conditions (i) Boc2O, TEA dioxane, H2O, 25°C; (ii) SOCl 2, piperidine, DMF, THF, 25°C. 
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Scheme 3 
Reagents and conditions (i) TFA, TFE, 25°C; (ii) Li AlH4,THF, 25°C. 
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The two key precursors to the target structures are compounds 55 and 58. The 
fluoropurine 55 was prepared from 2-amino-6-chloropurine via a three-step process 
involving nucleophilic substitution followed by a Balz-Schiemann reaction. 169 The 
commercially available 4-aminophenylthioacetic acid was Boc-protected and 
converted into the piperidine amide 58 via a Vilsmeier-Haack-like reaction, 170 
employing thionyl chloride, piperidine and DMF. 
In the presence of a catalytic amount of TFA the Boc protecting group was cleaved 
in situ from compound 58 and the desired compound 59 was obtained via an 
aromatic nucleophilic substitution on 55 with displacement of the fluoro substituent. 
The amide functionality of compound 59 was subsequently reduced, affording amine 
60. Oxidation followed by Cope-like elimination 167, 171 and reaction with the 
appropriate amine, afforded the target compounds 49-52 according to the 
mechanism outlined in Scheme 4. 
 
 
 
 
Scheme 4 
The mechanism for the formation of compounds 49-52 from 60.167 
 
 
The results shown in Table 9 demonstrate that these compounds failed to afford the 
desired activity and selectivity towards CDK7. Potency drops dramatically as the 
steric bulk on the terminal basic nitrogen of the piperazine ring increases, as does 
selectivity, with compounds 49-52 all being approximately ten-fold selective for 
CDK2. 
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IC50 µM 
R  Code CDK2    CDK7 
Me 44 0.12 0.23 
iPr 48 0.34 0.48 
Ph 49 1.2 33 
p-MeO-C4H6 50 1.25 11.3 
p-Cl-C4H6 51 3.3 37 
p-CF3-C4H6 52 3.5 26 
 
Table 9 
 CDK2- and CDK7-inhibitory activity for compounds 44 and 48-52. 
 
Several explanations can be proposed for the bulky N-substituents in 49-52 failing to 
form the desired interactions within the ‘hydrophobic pocket’ of CDK7. The planarity 
of the aromatic rings may not confer the desired binding orientation, or the steric bulk 
may be excessive; the reversal of selectivity may indicate that the ‘hydrophobic 
pocket’ is not targeted at all, and that these purines bind in a different orientation.  
The results indicated that it was necessary to select new and different targets to 
probe the ATP-binding site of CDK7, and gain new insight into how best to employ 
the available structural information to our advantage. In particular, structural biology 
studies carried out by collaborators at Oxford University focused on site-directed 
mutagenesis experiments with CDK2.  These could aid the structure-based design of 
CDK7 inhibitors, and are therefore presented in the following section. 
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4.2 Structural biology studies 
 
Although the crystal structure of CDK7 has been determined, efforts to solve a 
structure in complex with an inhibitor have been unsuccessful to date. 
Taking advantage of the fact that the crystal structure of CDK2 has been solved in 
complex with a number of Newcastle inhibitors (see Figure 37 in Chapter 3 for the 
crystal structure of 31 and 44 bound to CDK2), colleagues at the University of Oxford 
have prepared a number of mutant versions of CDK2, where one or more amino 
acids within the ATP-binding site have been replaced with those found in CDK7. In 
one of these mutants, referred to as K88E K89V CDK2(7), Lys88 and Lys89 of 
CDK2 have been replaced by a glutamic acid and a valine, respectively. In another 
mutant, referred to as Hinge CDK2(7), Leu83, His84 and Glu85 have been 
substituted with a methionine, a glutamic acid and a threonine, respectively. 
This approach has enabled the successful crystallisation of 44 in complex with 
CDK2(7) (Figure 39). 
 
        (a)                                                                                       (b) 
Figure 39 
Crystal structures of CDK2(7) mutant kinases in complex with NU6247 (44, in yellow) (a) ATP-binding 
site of CDK2 where Lys88 and 89 have been replaced by a Glu and a Val. (b) ATP-binding site of 
CDK2 where Leu83, His84 and Gln85 have been replaced by a Met, a Glu and a Thr. 
 
 Inspection of the 44-CDK2(7) complexes indicate
binding orientations of the 
type enzyme. This revealed the presence of an additional binding pocket 
amenable to probing with a suitably modified derivative
Figure 40 shows a comparison between the molecular surfaces of the complexes of 
44 with K88E K89V CDK2(7) (left) and Hinge CDK2(7) (right). The potential for the 
sidechain of 44 to orientate
enzyme is particularly evident in the Hinge mutant (red arrows).
 
 
Figure 40 
The molecular surface of K88E K89V CDK2(7) (left) and with Hinge CDK2(7) (right)
NU6247 (44) 
 
To explore the additional binding pocket
proposed: 
d the existence of two possi
sidechain of 44, one of which is not seen with the wild
 of 44. 
 in two different directions on the specificity surface of the 
 
, the following target compounds
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ble 
-
that may be 
 
, in complex with 
 were 
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These purines are “bifurcated”, in that they possess a hydrophobic sidechain 
intended to target the pocket identifiable in Figure 40, while retaining a polar 
functionality (a hydroxyl group) meant to target the same surface area of CDK7 as 
the piperazine ring of 44. 
The synthesis of racemic targets 63 and 64 was undertaken starting from 4-
(aminophenyl)thioacetic acid (56), and carried out following the steps outlined in 
Schemes 5 and 6. 
 
 
Scheme 5 
Reagents and conditions: (i) SOCl2, MeOH, 3 h, RT; (ii) Boc2O, TEA, THF/H2O, 12 h, 0 °C RT; (iii) 
mCPBA, CH2Cl2, 12 h, RT; (iv) NaH, CyCH2Br, DMF, 12 h, 0 °C. 
 
Compound 56 was converted into the methyl ester 67 using SOCl2 in methanol. The 
aniline moiety was then Boc-protected and mCPBA was used to convert the sulfide 
68 into a sulfone (69). Reaction of the sulfone 69 with one equivalent of sodium 
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hydride, followed by addition of cyclohexylmethyl bromide (CyCH2Br), resulted in 
alkylation α to the sulfur 172 giving the Boc-protected precursor 70.  
A carbamate NH is less acidic than a CH
 
α to both a sulfone and an ester moiety 
(pKa  ≈ 18 for the NH and 11 for the CH), but in the presence of 2 equivalents of NaH 
deprotonation occurs at both sites, with the least stable anion reacting with the alkyl 
halide to give the undesired N-alkylated product. The use of one equivalent of base 
allows deprotonation only at the most acidic site of 69 resulting in alkylation at the 
desired position to give 70. 
 
The Boc-protected precursor 70 was subjected to TFA/TFE conditions 173 which 
removed the Boc protecting group in situ. Following addition of 31 to the reaction 
mixture, the target purine 64 was obtained. 
Precursor 70 was reduced at the ester moiety by DIBAL in THF. This provided the 
primary alcohol 71 which was coupled with 55 under TFA/TFE conditions to yield 
target purine 63 (Scheme 6). 
 
 
 
Scheme 6 
Reagents and conditions: (i) DIBAH, THF, 12 h, -78 °C; (ii) 55, TFA, TFE, 48 h, reflux. 
 
With a view to gaining an understanding of the role of the sulfone moiety for CDK7 
inhibition, racemic target molecules 65 and 66 were also synthesised. 
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A synthetic scheme was proposed for the preparation of these compounds, starting 
from p-nitrophenylacetic acid (72), and including an LDA-mediated alkylation step for 
the introduction of the cyclohexylethyl residue. (Scheme 7). 
 
 
Scheme 7 
Reagents and conditions: (i) SOCl2, MeOH, 3 h, RT; (ii) nBuLi, iPr2NH, CyCH2CH2Br, THF, 12 h, -78 
°C; (iii) DIBAH, THF, 12 h, -78 °C; (iv) H 2/Pd/C, MeOH, 12 h, RT. 
 
The esterification step proceeded quantitatively to furnish compound 73, but the 
LDA-mediated alkylation reaction did not give a satisfactory result. The reaction was 
attempted using both commercial LDA and LDA generated in situ from n-butyl lithium 
and isopropylamine. Different ratios of LDA to cyclohexylethyl bromide were also 
employed, with the results shown in Table 10. 
 
Number of equivalents  
Result LDA CyCH2CH2Br 
3 3 Dialkylated product (78) isolated (quantitative) 
3 1.5 Dialkylated product (78) isolated (~50% yield) 
1.5 1.5 
Complex reaction mixture – no major product 
identifiable 
 
Table 10 
Conditions attempted for the alkylation of 73 
 
The use of an excess of base gave the dialkylated product 76, which precipitated out 
of the reaction mixture as colourless crystals. 
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Attempts at performing the reaction of 73 with cyclohexylethyl bromide in the 
presence of near-stoichiometric amounts of base were not successful. The reaction 
mixture was very complex and no significant amount of the desired product 74 was 
detected by LCMS or NMR analysis. As a straightforward alkylation reaction did not 
give good results, a different synthetic strategy was devised. 
Target compound 65 can be disconnected in a manner that suggests the application 
of a Henry-like reaction.  In a typical Henry reaction, 174 an anion derived from a 
nitroalkane  reacts with an aldehyde to give a β-nitroalcohol. 175 In the present case, 
the p-nitro function facilitates the condensation by increasing the acidity of the 
methylene protons in compound 73. (Scheme 8). 
 
 
Scheme 8 
Retrosynthetic Henry approach for the synthesis of aniline 77 as a precursor to targets 65 and 66 
 
This idea was initially explored with 73 using propanal as a model aldehyde. The 
reaction proceeded smoothly (3 h, RT) when propanal was used as a solvent with 
tetramethylguanidine (TMG) as a base, 176 but was considerably slower (12 h, with 
heating) when acetonitrile was used as a solvent and the aldehyde was present in a 
3 molar excess. Microwave irradiation was used to accelerate the reaction (15 
minutes, 120°C) and alcohol 82 was isolated, converted into the mesylate and 
underwent elimination as expected (Scheme 9). 
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Scheme 9 
Reagents and conditions: (i) Propanal, TMG (cat), CH3CN, µW, 15 min, 120 °C; (ii) MsCl, TEA, 
CH2Cl2, 12 h, RT; (iii) Toluene, 12 h, reflux. 
 
Having established successful reaction conditions with the model reaction, 2-
cyclohexylacetaldehyde (79), necessary for the synthesis of the target molecule, was 
prepared from commercially available 2-cyclohexylethanol. After attempting different 
oxidation methods for the conversion of 2-cyclohexylethanol to the corresponding 
aldehyde (Swern, Dess-Martin, TEMPO) 177 it was found that PCC oxidation 178 
converted 2-cyclohexylethanol into 2-cyclohexylacetaldehyde (79) in quantitative 
yield with minimal purification. 
 
Condensation of 73 with a 12 molar excess of 79 (30 min, 120 °C, µW) resulted in 
spontaneous elimination to give alkene 78, without the need to isolate and mesylate 
the alcohol intermediate. The following steps (reduction of the double bond and of 
the nitro group of 78 to yield the saturated aniline 83, reduction of the ester moiety of 
77 to give the alcohol 84 and TFA/TFE coupling to 55) as outlined in Scheme 10 
were successful, and provided both target purines 65 and 66 in a similar fashion to 
that described previously for 63 and 64. 
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Scheme 10 
Reagents and conditions: (i) SOCl2, MeOH, 3 h, RT; (ii) CyCH2CHO, TMG (cat), CH3CN, µW, 15 min, 
120 °C; (iii) H 2/Pd/C, MeOH, 12 h, RT; (iv) 55, TFA, TFE, 48 h, reflux; (v) DIBAH, THF, 12 h, -78 °C. 
 
Target compounds 63-66 were submitted for biological testing, and the results are 
summarised in Table 11. 
 
 
IC50 µM or percentage of 
inhibition at 10 µM 
R Code CDK2 CDK7 
 
 
64 
 
46.9 
 
19% 
 
 
63 
 
1.2 
 
33% 
108 
 
 
 
66 
 
43 
 
 
13% 
 
 
65 
 
3 
 
4% 
 
Table 11 
IC50 values, or percentages of inhibition at a given concentration, of compounds 64-67 against CDK2 
and CDK7 
 
The observed CDK-inhibitory activity of compounds 63-66 was much lower than 
predicted. In an attempt to understand the reason for this, compound 63 was 
submitted for co-crystallisation with K88E K89V CDK2(7). This was hoped to 
elucidate the binding mode of compound 63 within the ATP-binding site of CDK7. 
Although a crystal structure was obtained, this failed to provide any further insight 
into the binding mode of compound 63. With the resolution at which the data were 
collected, the sidechain of compound 63 was not clearly visible in the ATP-binding 
site of CDK2(7). This indicates that, while the purine core pharmacophore was 
making the usual interactions with the hinge region, the hydrophobic sidechain failed 
to make any useful interactions with the specificity surface of the enzyme. This 
confirmed the observations already made with compounds 49-52, and suggested 
that a highly hydrophobic sidechain for compounds of this family is not well tolerated 
within the CDK7 ATP-binding site. 
 
 
4.3 Exploring SARs for analogues of NU6247 (44) 
 
As the hydrophobic sidechains explored in the previous section failed to confer 
significant potency against CDK7, it was necessary to review existing data on CDK7 
inhibition by purines, in order to obtain information on what might constitute a good 
sidechain for a purine-based CDK7 inhibitor. 
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Table 12 summarises purines that were previously tested against CDK7 at 
Newcastle and found to have IC50 values of 500 nM or lower. 
 
 
CDK-inhibitory activity (IC50 µM) 
R Code CDK2 CDK7 
 
NU6247 (44) 0.12 ± 0.03 0.23 
 
47 0.29 ± 0.05 0.27 ± 0.01 
 
48 0.34 0.48 
 
85 0.31 0.44 
 
86 0.7 ± 0.1 0.38 ± 0.75 
 
87 
 
1.1 ± 0.1 
 
0.53 
 
Table 12 
6-cyclohexylmethoxypurines with activity against CDK7 at IC50 values lower than 0.5 µM 
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As it appears from Table 12, the best results for purines with sub-micromolar CDK7 
activity are seen when a piperazine or morpholine ring is present at the purine 2-
position. With this in mind, another small series of analogues of NU6247 (44) was 
synthesised, in which the piperazine ring was retained, but the linker between the 2-
arylamino moiety and the pendant piperazine ring was varied. The chosen linkers 
included carboxamides, sulfonamides, ureas and phenylethers. 
 
 
 
The urea moiety was first explored by a previous researcher when pursuing selective 
inhibitors of CDK1 (Andrew Henderson, unpublished results). The activity shown by 
purine 87 (see Table 12) against CDK7 (IC50 = 530 nM) justifies the interest in a 
urea analogue of NU6247 (44). The synthetic pathway for target compounds 88 and 
89, starting from commercially available p-nitrophenyl isocyanate (96), is shown in 
Scheme 11. 
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Scheme 11 
Reagents and conditions: (i) THF, 3 h, RT; (ii) H2/Pd/C, MeOH, 12 h, RT; (iii) 55, TFA, TFE, 48 h, 
reflux. 
 
The synthesis of target compounds 90-93 (Scheme 12) was generally 
straightforward and started with the corresponding p-nitrobenzoyl (or 
benzenesulfonyl) chloride (101, 102 respectively), which were reacted with the 
appropriate amine under standard conditions. 
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Scheme 12 
Reagents and conditions: (i) CH2Cl2, K2CO3, 4 h, RT; (ii) H2/Pd/C, MeOH, 12 h, RT; (iii) 55, TFA, TFE, 
48 h, reflux. 
 
 
Targets 94 and 95 were synthesised according to a literature procedure suitable for 
the generation of a library of compounds having the general structure R2N-CH2-CH2-
O-Ar. 179 The protocol described in this paper was followed to synthesise 97, a 
phenyl ether analogue of NU6247 (44). Reaction of p-nitrophenol (111) with 1,2-
dichloroethane gave compound 112 which, in the presence of N-methylpiperazine, 
underwent substitution at the chloro group to yield intermediate 113. Subsequent 
catalytic hydrogenation of 113 and 117 and coupling to purine 55 under previously 
described conditions completed the pathway (Scheme 13).  
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Scheme 13 
Reagents and conditions: (i) 1,2-Dichloroethane, K2CO3, CH3CN, 48 h, reflux; (ii) N-Methylpiperazine, 
CH3CN, µW, 30 min, 140 °C; (iii) H 2/Pd/C, MeOH, 12 h, RT; (iv) 55, TFA, TFE, 48 h, reflux. 
 
 
Similar conditions were employed for the synthesis of compound 95 (Scheme 14). 
 
 
 
 
Scheme 14 
Reagents and conditions: (i) 1,3-Dibromopropane, K2CO3, CH3CN, 48 h, reflux; (ii) N-
Methylpiperazine, CH3CN, µW, 30 min, 140 °C; (iii) H 2/Pd/C, MeOH, 12 h, RT; (iv) 55, TFA, TFE, 48 
h, reflux. 
 
 
Table 13 summarises the results of the biological evaluation of compounds 88-95. 
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CDK-inhibitory activity (IC50 µM) 
R Code CDK2 CDK7 
 
91 
 
0.012 
 
0.75 
 
90 
 
0.027 
 
0.67 
 
93 
 
0.35 
 
0.38 
 
92 
 
0.38 
 
0.23 
 
95 
 
0.52 
 
0.74 
 
94 0.63 0.37 
 
89 0.71 0.52 
H
N
H
N
O
N
N
 
88 0.64 0.52 
 
Table 13 
CDK-inhibitory activity for compounds 88-95 
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These results showed that for analogues of NU6247 (44) where the purine scaffold 
and the piperazine side-chain are retained, and the sulfone linker and 2-carbon 
spacer are varied, CDK-inhibitory activity was essentially unaffected with only minor 
changes in the IC50 values, that range from 230 nM (92) to 740 nM (95). The 
sulfonamide linker (90 and 91) confers high potency and selectivity (~45-fold) for 
CDK2 over CDK7. This was in keeping with the selectivity profile exhibited by 
NU6102 (31), and the IC50 values for compounds 90 and 91 (670 and 750 nM 
respectively), showed that the introduction of the NU6247 sidechain does not 
appreciably increase selectivity for CDK7. 
No compound in Table 13 was highly selective for CDK7, although a 2-fold 
selectivity is observed for compound 94. However, as no other compound to date 
exhibited selectivity for CDK7 over CDK2, further studies with 94 were undertaken. 
In an attempt to further improve activity and selectivity for CDK7, a small library of 
compounds was synthesised where the ether linker and terminal amine were varied 
in order to determine structure-activity relationships around the sidechain of 94. 
 
 
4.4 Synthesis of analogues of 94 
 
Five analogues of purine 94 were synthesised in which the ether linker was 
maintained and the amine was varied (Scheme 15). 
 
 
Scheme 15 
Reagents and conditions: (i) 1,2-Dichloroethane, K2CO3, CH3CN, 48 h, reflux; (ii) R1R2NH, CH3CN, 30 
min, 140 °C, MW; (iii) H 2/Pd/C, MeOH, 24 h, RT; (iv) 55, TFA, TFE, 48 h, reflux. 
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As described above, reaction of commercially available p-nitrophenol (111) with 1,2-
dichloroethane gave 112. The primary alkyl chloride underwent substitution by a 
range of amines (dimethylamine, pyrrolidine, piperidine, morpholine and 
benzylamine) and the products obtained (119-123) were hydrogenated to yield the 
corresponding anilines (124-128). These were reacted with fluoropurine 55 under 
TFA/TFE conditions to yield the final products 129-133, which were tested for 
inhibitory activity against CDK2 and CDK7 (Table 14). 
 
 
CDK-inhibitory activity (IC50 µM) 
NR1R2 Code CDK2 CDK7 
 
 
129 
 
 
0.85 
 
 
0.42 
 
 
 
130 
 
 
0.92 
 
 
0.32 
 
 
 
131 
 
 
0.96 
 
 
0.27 
 
 
 
132 
 
 
1.6 
 
 
0.94 
 
 
133 2.6 0.56 
 
Table 14 
CDK-inhibitory activity for compounds 129-133 
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As shown in Table 14, compounds 129-133 exhibited similar activity to 94 (IC50 
(CDK2) = 630 nM, IC50 (CDK7) = 370 nM), with all of the compounds being 
approximately 2-fold selective for CDK7. The best results were obtained in the case 
of compounds 130 and 131 (3-fold selective). Interestingly, replacing the piperidine 
group by a morpholine (132) diminished activity compared with the parent compound 
(94). 
For compound 133, the introduction of a benzyl group decreased CDK2-inhibitory 
activity more than for CDK7, and the compound was some 4-fold selective for CDK7. 
A comparison of this result with those obtained for the N-arylpiperazines 49-52 
discussed earlier suggests that conformational constraint to the side-chain might 
play a role in the activity of these particular inhibitors, and this will be discussed in 
more detail subsequently. 
 
As a further modification of 94, three compounds were synthesised where the 
terminal piperazine function was retained, but the ether linker was replaced by 
isosteres (thioether (134), amine (135) and methylene (136)). 
Thioether 134 was synthesised according to a procedure similar to that employed for 
the synthesis of 94 (Scheme 16). Thus, p-nitrothiophenol (137) was converted into 
138 by reaction with 1,2-dichloroethane. The primary chloride 138 was then 
subjected to nucleophilic substitution by N-methylpiperazine yielding compound 139, 
which was reduced to the aniline (140) and coupled with 55 to furnish the required 
purine 134. 
 
 
Scheme 16 
Reagents and conditions: (i) 1,2-Dichloroethane, K2CO3, CH3CN, 48 h, reflux; (ii) N-methylpiperazine, 
CH3CN, 30 min, 140 °C, MW; (iii) H 2/Pd/C, MeOH, 24 h, RT; (iv) 55, TFA, TFE, 48 h, reflux. 
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The amine analogue 135 was synthesised from commercially available p-
nitrofluorobenzene (141) following the steps outlined in Scheme 17. Compound 141 
was reacted with 2-(4-methylpiperazin-1-yl)ethanamine, affording 142, which was 
converted into the aniline 143 and then coupled to 55, yielding compound 135. 
 
 
 
Scheme 17 
Reagents and conditions: (i) 2-(4-methylpiperazin-1-yl)ethanamine, CH3CN, 30 min, 140 °C, MW; (ii) 
H2/Pd/C, MeOH, 24 h, RT; (iii) 55, TFA, TFE, 48 h, reflux. 
 
The analogue 136 was synthesised from commercially available 3-
chloropropylbenzene (144) (Scheme 18). The first step entailed introduction of a 
nitro group at the 4-position of the aromatic ring, which was performed with a 
standard mixture of nitric acid and sulfuric acid (2:1) 180 and proceeded in 70% yield. 
The unwanted ortho-nitro isomer was separated from the desired product 145 by 
column chromatography. Compound 145 underwent substitution at the primary 
chloride to yield compound 146, which was reduced to the aniline 147. Final coupling 
with 55 afforded the target purine 136. 
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Scheme 18 
Reagents and conditions: (i) HNO3/H2SO4, 3 h, 0°C to RT; (ii) N-methylpiperazine, CH 3CN, 30 min, 
140 °C, MW; (iii) H 2/Pd/C, MeOH, 24 h, RT; (iv) 55, TFA, TFE, 48 h, reflux. 
 
Compounds 137-139 were tested for CDK-inhibitory activity and the results are 
shown in Table 15. 
 
N
X
N
H
N
N
N
H
N
O
N
 
CDK-inhibitory activity (IC50 µM) 
X Code CDK2 CDK7 
S 134 0.17 0.36 
NH 135 0.35 0.53 
CH2 136 0.48 0.31 
 
Table 15 
CDK-inhibitory activity for compounds 134-136 
 
The activity of compounds 134-136 (Table 15) does not notably differ from that of 
the parent purine 94, and the alternative linkers offer no evident advantage over the 
ether. The result for 136 suggests that no hydrogen bond acceptor (O, S) or donor 
(NH) function is needed at this position of the sidechain, and that activity depends on 
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the terminal basic centre(s), as exemplified by the cyclohexylethyl analogue 186 
discussed in the next chapter. 
 
The results obtained for compound 133 posed an interesting question when 
compared with those of compounds 49-52, described at the beginning of this 
chapter. The reduced activity of 49-52 with respect to the parent compound NU6247 
(44) was ascribed to the relatively bulky sidechain. The sidechain of compound 133, 
however, appears to match that of 49 in length, and yet 133 is 60-fold more potent 
than 49 against CDK7. 
One possible explanation for this observation may reside in the rigidity and/or 
directionality of the sidechain of these compounds. Compound 49 incorporates a 
piperazine ring which adds an element of conformational constraint to the sidechain, 
and this may influence the direction in which the terminal aromatic ring is oriented 
within the ATP-binding domain of CDK7. 
To test this hypothesis, conformationally constrained derivatives 148-150 were 
proposed as synthetic targets. 
 
N
O
N
H
N
N
N
H
N
O
N
O
N
H
N
N
N
H
N
O
N
O
N
H
N
N
N
H
N
O
148
149
150
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Compounds 148 and 149 were prepared according to a synthetic strategy analogous 
to that previously employed for the synthesis of the parent compound 94 (Scheme 
19). 
 
 
Scheme 19 
Reagents and conditions: (i) 1,2-Dichloroethane, K2CO3, CH3CN, 48 h, reflux; (ii) 1,2,3,4-
Tetrahydroisoquinoline or isoindoline, CH3CN, 30 min, 140 °C, MW; (iii) H 2/Pd/C, MeOH, 24 h, RT; 
(iv) 55, TFA, TFE, 48 h, reflux. 
 
To approach 150 as a synthetic target, a retrosynthetic strategy involving the 
disconnection of the sidechain C-O bond was originally considered  
(Scheme 20). 
 
 
 
Scheme 20 
C-O bond disconnection approaches to compound 157. 181,182 
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Strategy a) required the synthesis of secondary triflate 158. This was undertaken 
starting from benzoyl chloride (162) and 3-hydroxypiperidine (163) which were 
reacted under standard conditions to generate amide 164. Triflation of this precursor 
was subsequently attempted as a model reaction (Scheme 21). 
 
 
Scheme 21 
Reagents and conditions: (i) TEA, CH2Cl2, 10 min, 0 °C; (ii) See Table 16. 
 
 
Triflating agent/conditions Result 
Tf2O, TEA, CH2Cl2, 0° C 
Complex reaction 
mixture 
N-phenyl bis-triflamide, K2CO3, THF, RT 
Tf2O, TEA, CsCO3, CH2Cl2, 0 °C 
Tf2O, pyridine, CH2Cl2 -20 °C 
 
Table 16 
Attempted conditions for the generation of secondary triflate 165 in Scheme 21 
 
 
Unfortunately, triflate 165 could not be synthesised and all attempts resulted in the 
isolation of complex fluorinated decomposition products (19F NMR evidence). 1H 
NMR analysis of the crude reaction mixture showed evidence for possible elimination 
of the triflate to give an alkene derivative. 
Approach b) involved a copper-catalysed coupling reaction between an unprotected 
secondary alcohol (160) and an aryl iodide (161). The reaction was attempted with 
161 and 164 using copper iodide and tetramethylphenanthroline as catalysts, but no 
coupling was observed to take place, even after 24 h at 100 °C. 
 
Following the failure of both strategies, an alternative synthetic scheme was devised 
where the 2-alkoxypiperidine moiety was synthesised from ornithine hydrochloride 
183
 (Scheme 22). Ornithine hydrochloride (166) was cyclised to amide 167. 
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Diazotisation of 167 with isoamyl nitrite afforded compound 168 which was coupled 
with 159 using rhodium acetate dimer as catalyst. The amide functionality of 169 was 
subsequently converted into an amine (170) which was coupled with benzaldehyde 
in the presence of phenylsilane and dibutyltin dichloride affording compound 157. 
 
 
Scheme 22 
Reagents and conditions: (i) NaOH, alumina, H2O/Toluene, reflux, Dean-Stark; (ii) isoamylnitrite, 
AcOH, CHCl3, reflux; (iii) tert-butyl (4-hydroxyphenyl)carbamate (159), [Rh(CH3CO)2]2, THF, RT; (iv) 
LiAlH4, THF, 0 °C to RT; (v) PhCHO, PhSiH 3, Bu2SnCl2, THF, 100 °C, MW. 184 
 
Compound 157 was coupled to 55 under TFA/TFE conditions, yielding target 
compound 150 as a racemate. The results of the biological evaluation of compounds 
148-150 are shown in Table 17. 
 
 
CDK-inhibitory activity (IC50 µM) 
R Code CDK2 CDK7 
 
148 2.6 1.8 
 
149 1.3 1.5 
 
150 1.9 0.9 
 
Table 17 
CDK-inhibitory activity for compounds 148-150 
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Conformationally constrained purines 148-150 exhibited IC50 values against both 
CDK2 and CDK7 intermediate between those obtained for compounds 49 and 133. 
This indicates that conformational constraint in the sidechain does play a role in the 
binding mode of these molecules within the CDK2 and CDK7 active sites, but it 
appears that none of the ring systems employed in compounds 49, 148-150 provides 
the optimal directionality, and the parent compound 133 remained the one with the 
best activity and selectivity for CDK7. 
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Chapter 5 – Pharmacophore mapping and 
scaffold hopping around NU6247 (44) 
 
5.1 Pharmacophore mapping around NU6247 (44) 
 
The results described in the previous chapter addressed the problem of determining 
SARs for CDK7 inhibition by modifying the sidechain of NU6247 (44). The 
compounds synthesised permitted a number of valuable observations to be made, 
but failed to identify a strong correlation between the nature of the sidechain moieties 
and CDK7 binding affinity. 
In order to broaden the scope of the SARs around NU6247 (44), some analogues 
were synthesised where identifiable pharmacophores in NU6247 (44) (Figure 40) 
were systematically varied. It was hoped that these studies would result in the 
identification of the structural parameters necessary for CDK7-inhibitory activity. 
 
 
Figure 40 
Pharmacophore mapping for NU6247 (44). 1, pendant basic functionality; 2, 2-carbon chain spacer; 3, 
sulfone linker; 4, aromatic ring; 5, purine core pharmacophore; 6, 6-cyclohexylmethoxy substituent. 
 
In the following section, the importance of each of the pharmacophores identified in 
Figure 40 for CDK7-inhibitory activity is discussed. 
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5.1.1 Benzyl sulfone analogue of NU6247 (44) 
 
As stated in the introductory paragraph of this chapter, the rationale for the 
development of a pharmacophore mapping profile around NU6247 (44) was to 
identify structural features that maintain or improve CDK7-inhibitory activity but 
diminish or abolish CDK2-inhibitory activity. For a small series of compounds 
previously synthesised within the research group, the following results were 
obtained: 
 
171, IC50 CDK2 = 470 nM 
N
H
N
N
N
H
N
O
X
N
H
N
 
172, X = SO2, IC50 CDK2 = 530 nM 
173, X = CO, IC50 CDK2 = 1 µM. 
 
Although the compounds were originally prepared as potential inhibitors of a different 
kinase, interestingly, the introduction of a CH2 between the carbonyl (or sulfonyl) 
group and the aromatic ring reduced potency against CDK2 with respect to the 
parent compounds. As a result of these observations, it was reasoned that 
introducing an extra methylene between the aromatic ring and the sulfone moiety in 
NU6247 (44) may diminish potency against CDK2 but not against CDK7. Therefore, 
homologue 174 was synthesised. 
 
 
174 
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Purine 174 was synthesised starting from benzyl mercaptan (175) according to the 
procedure outlined in Scheme 23. 
 
 
Scheme 23 
Reagents and conditions: (i) 1,2-Dichloroethane, K2CO3, CH3CN, 48 h, reflux; (ii) mCPBA, CH2Cl2,24 
h, RT; (iii) HNO3/H2SO4, 3 h, 0 °C to RT ; (iv)  N-methylpiperazine, CH3CN, 30 min, 140 °C, MW; (v) 
H2/Pd/C, MeOH, 24 h, RT; (vi) 55, TFA, TFE, 48 h, reflux. 
 
 
Alkylation of 175 with 1,2-dichloroethane in the presence of potassium carbonate 
afforded compound 176, which was oxidised to the corresponding sulfone with 
mCPBA. Nitration conditions analogous to those utilised for the preparation of 149 
were employed to convert 177 into the nitro derivative 178. Microwave-assisted 
nucleophilic substitution to yield compound 180, reduction of the nitro functionality 
and coupling to 55 afforded the final compound (174). 
 
Compound 174 was tested against CDK2 and CDK7 and the IC50 values were 400 
nM and 800 nM, respectively. The selectivity profile was thus the same as for 
NU6247 (44) (2-fold selective for CDK2) although compound 174 was 4-fold less 
potent than 44. This suggests that the binding mode within CDK2 and CDK7 of 
compound 174 is essentially the same as for 44, and if introducing the extra CH2 is 
responsible for decreased activity against CDK2, this modification has the same 
effect on CDK7. 
128 
 
5.1.2 Removing the O6-substituent from NU6247 (44) 
 
Early structural biology studies with NU6102 (31) bound within the ATP-binding 
pocket of CDK2 showed that, in addition to the usual triplet of hydrogen bonds with 
the hinge region (Glu81, Leu83), hydrophobic interactions were made by the 
cyclohexyl ring with an apolar pocket in the glycine-rich loop (residues 9-19), 
especially with Gly11 and Val18. 43 This binding mode was found to be conserved 
among all the purine- and pyrimidine-based CDK2 inhibitors synthesised. 
The co-crystal structure of CDK2 in complex with NU6247 (44) (see Figure 35 in 
Chapter 3) showed a similar binding mode, with the cyclohexylmethyl group binding 
in the same pocket for both compounds within the ATP-binding site. 
In the absence of a co-crystal structure of CDK7 with an inhibitor, in the early stages 
of this project it was assumed that NU6102 (31) (IC50 CDK7 = 4.82 µM) and NU6247 
(44) interacted with the ribose-binding pocket of CDK7 and CDK2 in a similar 
manner. The glycine loop of CDK7 shares a 66% sequence identity with CDK2, with 
6 out of 9 residues being conserved, including the key residues Gly11, Gly13 and 
Val18. 138  
Supporting evidence for the hypothesis that the cyclohexylmethyl group at the 6-
position of the purine makes important interactions within the ribose-binding pocket 
of CDK7 was provided by 181 and 182, two urea compounds synthesised within the 
research group and tested against CDK7. Urea 181 shows a selectivity profile not 
unlike 88 and 89, but 182, where the substituent at the 6-position of the purine has 
been removed, is more than 100-fold less active against CDK2 and CDK7. The 
results are summarised in Table 18. 
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CDK-inhibitory activity (IC50 
µM or percentage of 
inhibition at 100 µM) 
X  Y Code CDK2    CDK7 
NMe 
 
89 0.64 0.52 
O 
 
88 0.71 0.52 
CH2 
 
181 0.86 0.45 
CH2 H 182 30% 64.6 
 
Table 18 
CDK-inhibitory activity for compounds 88, 89, 181 and 182 
 
Definitive evidence of the importance of the O6-cyclohexylmethyl substituent in 
NU6247 (44) and related CDK7 inhibitors could potentially be provided by the 6-
unsubstituted analogue (183), which was therefore identified as a target molecule. 
 
N
N
S
N
H
N
N
N
H
N
O O
 
183 
 
 
 
Scheme 24 
Reagents and conditions: (i) HBF4, NaNO2, H2O, 75 min, RT; (ii) HCOONH4, Pd(OH)2, MeOH, 3 h, 
reflux. 
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2-Amino-6-chloropurine (53) was converted into 2-fluoro-6-chloropurine (184) using 
standard Balz-Schiemann conditions. 185-186 Removal of the 6-chloro substituent was 
achieved by Pd-catalysed hydrogenation, affording 185, the 6-unsubstituted 
analogue of 55 (Scheme 24). 
 
 
Scheme 25 
Reagents and conditions: (i) Boc2O, TEA, Dioxane/H2O, 24 h, RT; (ii) SOCl2, piperidine, THF, 24 h, 
RT ; (iii)  LiAlH4, THF, 24 h, 0 °C to RT; (iv) mCPBA, N-methylpipera zine, CH2Cl2, 24 h, RT. 
 
To achieve the synthesis of 183 from 185, compound 187 was required. This 
arylsulfone was synthesised from commercially available 2-(4-
aminophenylthio)acetic acid (56) using a synthetic sequence analogous to that 
employed for the synthesis of NU6247 (44) and analogues (Scheme 25, see 
Chapter 4). 
 
 
 
Scheme 26 
Reagents and conditions: (i) TFA, TFE, 24 h, reflux. 
 
As a final step, 185 and 187 were mixed in TFE containing TFA, under which 
conditions the Boc group of 187 was removed and the aniline thus generated in situ 
reacted with 185 to afford the required purine derivative 183 (Scheme 26). 
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Compound 183 was tested against CDK2 and CDK7 and the IC50 values were 46.9 
µM and 20.8 µM, respectively. The values obtained showed a 400-fold decrease in 
potency against CDK2 and a 100-fold decrease in potency against CDK7 with 
respect to NU6247 (44). The effect of removing the C6-substituent appears to be 
more pronounced in the case of CDK2, but nonetheless this drastic modification is 
not tolerated by either CDK2 or CDK7.  
 
 
5.1.3 Removing the terminal basic moiety of NU6247 (44) 
 
Another prominent functional group identified in Figure 40 is the terminal piperazine 
ring. All CDK7 inhibitors synthesised to date contain a basic sidechain, which may be 
a desirable feature for providing water solubility. Lack of information on the binding 
interactions made by the basic moiety within CDK7, however, required further 
investigation into the usefulness of this group. 
Compound 188, including a sidechain the same size as NU6247 (44) but lacking the 
basic centres, was therefore identified as a synthetic target: 
 
 
 
The synthesis of purine 188 is outlined in Scheme 27. p-Nitrobenzenethiol was 
heated in the presence of base and the resulting thiolate coupled in situ with 
cyclohexylethyl bromide. The sulfide moiety was oxidised to sulfone 190 using 
mCPBA, and the nitro moiety reduced to the aniline prior to coupling with 55 under 
TFA/TFE conditions. 
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Scheme 27 
Reagents and conditions: (i) Cyclohexylethyl bromide, K2CO3, CH3CN, reflux; (ii) mCPBA, CH2Cl2, 
RT; (iii)  H2/Pd/C, MeOH, RT; (iv) 55, TFA, TFE, 24 h, reflux. 
 
 
Compound 188 was tested for CDK2 and CDK7 activity and found to be essentially 
inactive (11% inhibition at 10 µM for CDK2 and 13% inhibition at the same 
concentration for CDK7). These results are in line with the values obtained for the 
‘bifurcated’ analogues described in the previous chapter, with which compound 188 
shares the essential properties of the sidechain. A pendant cyclohexyl ring is 
detrimental for CDK7-inhibitory activity and a terminal basic moiety is essential for 
the sidechain to interact effectively with the specificity pocket of the kinase. 
 
 
5.1.4 Replacement of the sulfone linker of NU6247 (44) 
 
Systematic replacement of the sulfone linker by a number of isosteres was carried 
out as part of the investigation of analogues of 94 discussed in Chapter 4 (see 
Tables 13 and 15). In particular, the result obtained for compound 136 in Table 15 
demonstrated that the sulfone linker was not an essential pharmacophore of NU6247 
(44) and that its removal and replacement by a CH2 group was not detrimental to 
activity. 
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5.1.5 Introducing a substituent at the purine 8-position of NU6247 
(44) 
 
As discussed in Chapter 3, crystal structures of CDK2 in complex with purine-based 
inhibitors (NU6102 (31) and NU6247 (44), Figure 36, NU2058 (32), Figure 35) 164 
indicated that the purine C8-position is directed towards the gatekeeper residue 
Phe80 within the ATP-binding domain. 43 
 
         
 
Figure 41 
NU2058 (32) bound within the ATP binding pocket of CDK2.164 
 
 
It has been observed that C8-substituted purine-based CDK2 inhibitors tend to adopt 
a ‘flipped’ binding mode within the active site (Figure 42). In the ‘normal’ binding 
orientation seen in Figure 41, the isopropyl substituent of 191 would sterically clash 
with Phe80 and therefore the binding orientation is reversed, allowing for the 
expansion of the purine C8-substituent into the specificity pocket of the enzyme. 
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Figure 42 
The binding mode of NU2058 (32) and of its C8-cyclopropyl derivative (191) within the ATP binding 
pocket of CDK2. 
 
The data published regarding the crystal structure of CDK7 in complex with ATP 138 
show that the gatekeeping residue in CDK7 is also a phenylalanine (Phe91) (Figure 
43). 
 
 
 
 
 
 
 
 
 
 
Figure 43 
ATP bound within the active site of CDK7 (left) and CDK2 (right). 138 
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To probe the area around Phe91 in CDK7 and to determine whether or not 
substitution at the C8-position of the purine would be tolerated in the case of CDK7 
inhibitors, a C8-methylpurine analogue of NU6247 (44) was synthesised (192). 
 
 
192 
 
The initial choice of a methyl substituent for the C8-position was based on the 
assumption that a smaller group than isopropyl will not trigger flipping of the inhibitor 
with subsequent expulsion from the binding pocket. This is because it is expected 
that the side-chain of 44 will not be tolerated on account of its size should the 
inhibitor flip 180° within the pocket. 
To approach 192 as a synthetic target, the Pfleiderer variant of the Traube synthesis 
of purines was selected as the best strategy. The Traube synthesis of purines 187 is 
based on the cyclisation of 5,6-diaminopyrimidine to purine when reacted with formic 
acid. The Pfleiderer variant of this synthesis 188-189 employs 5-nitroso-6-
acylaminopyrimidine, which is ring-closed via an intramolecular aza-Wittig reaction in 
the presence of triphenylphosphine. This approach allows the synthesis of purines 
with a wide variety of substituents at the C8-position depending on the starting acyl 
group introduced at the 6-amino position (Scheme 28). 
 
 
Scheme 28 
General cyclisation of 6-acylamino-5-nitrosopyrimidine into an 8-substituted purine. 
 
Scheme 29 shows the synthetic route adopted to synthesise target compound 192 
from 2,6-diamino-4-chloropyrimidine (193). 
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Scheme 29 
Reagents and conditions: (i) Cyclohexylmethanol, Na, 3 h, 180 °C; (ii) NaNO 2, AcOH, 40 min, 80°C ; 
(iii)  Ac2O, 30 min, 80°C; (iv) PPh 3, o-xylene, 48 h, reflux; (v) HBF4, LiBF4, NaNO2, H2O, 0 °C to RT, 
24 h; (vi) 187, TFA, TFE, 48 h, reflux. 
 
 
Pyrimidine 193 was reacted with sodium cyclohexylmethoxide in cyclohexylmethanol 
and converted into 2,6-dichloro-4-cyclohexylmethoxypyrimidine (194). Pyrimidine 
194 was nitrosated at the 5-position and then selectively monoacetylated at the 6-
amino group, affording 2-amino-6-cyclohexylmethoxy-5-nitrosopyrimidin-4-
ylacetamide (196). This compound was heated at reflux in o-xylene in the presence 
of triphenylphosphine to generate 2-amino-6-cyclohexylmethoxy-8-methylpurine 197, 
which was converted into the 2-fluoro derivative (198) and coupled with 187 to give 
the final compound 192. 
Purine 192 was submitted for biological evaluation against CDK2 and CDK7, and 
found to be a poor inhibitor of CDK2 (47% inhibition at 100 µM). Since no C8-
substituted purine tested at Newcastle until this point had contained a sidechain at 
the 2-position of the purine, it may be reasonable to infer that the presence of such a 
sidechain is not compatible with the ‘flipped’ binding mode adopted by compound 
191. However, 192 was found to be a respectable inhibitor of CDK7, with an IC50 
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value of 5.3 µM. This compound was further evaluated against other members of the 
CDK family (CDK1, 2, 4, 5, 9), and found to be essentially inactive against all except 
CDK7. Purine 192 was further evaluated for growth-inhibitory activity against an 
MCF-7 human breast adenocarcinoma cell line and found to have a GI50 value of 
approximately 10 µM (Figure 44). 
 
 
 
Figure 44 
Growth inhibition of MCF-7 adenocarcinoma cell line by compound 192. 
 
 
While 10-fold less potent than the parent compound NU6247 (44), 192 is at least 20-
fold more effective against CDK7 than CDK2 and such a difference in activity is most 
likely explained by a difference in the binding orientation within the active sites of the 
two enzymes. Without the aid of structural biology, this question may be addressed 
by the synthesis and biological evaluation of a small number of analogues of 195, 
where either the sidechain or the C8-substituent of the purine are systematically 
modified. Compounds 199-201 were therefore identified as synthetic targets. 
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The sidechain at the 2-position of purines 199-201 was chosen for its ease of 
synthesis and has been a feature of a number of compounds since the identification 
of 94 as a 2-fold selective inhibitor of CDK7.  The size of the substituent at the 8-
position of the purine was increased from methyl (199) to ethyl (200) to isopropyl 
(201). 
With a view to synthesising three closely related purine analogues, the strategy 
outlined in Scheme 29, successfully employed to synthesise 192, was deemed 
inefficient. It was necessary to find a synthetic strategy for the preparation of 
compounds 199-201 via C8-alkylation of a common purine intermediate. Therefore 
an approach based on a metal-mediated C-C bond-forming reaction was 
investigated (Scheme 30). 190 
 
 
Scheme 30 
Lithium-mediated C8-alkylation of a purine; E+ = electrophile. 
 
 
Carbon substituents have been successfully introduced at the 2-, 6- and 8-position of 
a purine via metal-mediated reactions employing a number of conditions. 191 In the 
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case of 6-halo-N9-protected purines, LDA- and LTMP-mediated lithiation occurs 
selectively at the 8-position over the 2-position when both are unsubstituted, 192 and 
the lithiated product can subsequently react with electrophiles to generate a variety 
of 8-substituted purines. In the case of 8-methylation with methyl iodide in the 
presence of excess base, the methyl carbon at the 8-position is liable to further 
deprotonation and reacts with excess MeI to generate 8-ethyl- and 8-
isopropylpurines. 193-194 
Taking all of the above into consideration, the synthetic approach outlined in 
Scheme 31 was devised for the preparation of target compounds 198-201. 
 
 
 
Scheme 31 
Reagents and conditions: (i) DHP, EtOH, 60 °C; (ii)  iPr2EtN, nBuLi, MeI, -78 °C; (iii)  TFA, iPrOH, 
H2O, RT; (iv) 114, TFA, TFE, 48 h, reflux. 
 
 
The second step in Scheme 31 was carried out initially with one equivalent each of 
LDA and MeI to obtain the 8-methyl purine 203. Increasing the number of 
equivalents to two afforded the ethyl derivative 204 as the major product, while using 
three equivalents resulted in the isopropyl derivative 205 being the main product 
isolated. The three 2-fluoro-8-alkylpurines (203-205) thus generated were heated in 
aqueous isopropanol in the presence of TFA to remove the THP protecting group 
and then coupled to aniline 114 to generate the final target compounds 199-203. 
140 
 
The results of the biological evaluation on compounds 192 and 199-201 against 
CDK2 and CDK7 are summarised in Table 19. 
 
 
N
H
N
N
N
H
N
O
X
N
N
R
 
IC50 µM or percentages 
of inhibition at 100 µM 
X  R Code CDK2    CDK7 
SO2 Me 192 47% 5.3 
O Me 199 11.6 16.2 
O Et 200 45% 12.5 
O iPr 201 41% 18.5 
 
Table 19 
CDK-inhibitory activity for compounds 192, 199-201 
 
 
With the exception of purine 199, all compounds were essentially inactive against 
CDK2; compounds 199-201 were 2 to 3-fold less effective against CDK7 than 192. 
These results were difficult to interpret: there is no apparent reason for compound 
199 to be 3-fold less potent than 192 against CDK7 but 10-fold more potent against 
CDK2. The sidechain alone does not explain these results, as seen with NU6247 
(44) and 94. However, there clearly appears to be a difference in the binding mode 
of compounds 192 and 199-201 within the CDK2 and CDK7 active site, and it would 
seem that, unlike CDK2, the CDK7 ATP-binding site has the flexibility to 
accommodate substituents as large as isopropyl at the purine 8-position in the 
gatekeeper pocket.  
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5.2 Scaffold-hopping from the literaturepublished CDK7 
inhibitors 
 
5.2.1 The Purvalanol A analogue of NU6247 
 
Purvalanol A (14) was identified by Gray et al. in 1998 85 as a result of screening 
numerous 2,6,9-trisubstituted purines against CDK2. The interest in the purine 
scaffold was motivated by olomoucine (13), which exhibits good selectivity for 
members of the CDK family over other kinases but only moderate inhibition (IC50 = 7 
µM). 53, 195-196 The binding mode of olomoucine within the ATP-binding site of CDK2 
is rotated almost 160° relative to that of the aden osine ring of ATP. Thus, it seemed 
that the introduction of new substituents at the 2, 6, and 9 positions of the purine ring 
might lead to enhanced binding affinity and selectivity. 85 
 
     
        Purvalanol A (14)               (R)-Roscovitine (12)                     Olomoucine (13) 
      IC50 (CDK2) = 21 nM 
 
Crystal structure studies of 12 bound within the ATP-binding pocket of CDK2 159 
showed hydrogen-bonding interactions of the purine with the same amino acids of 
the hinge region (Glu81, Leu83) as for the Newcastle inhibitors (e.g. 31). However, 
the binding mode in this case is different, with the hydrogen atom at the 8-position of 
the purine 12 donating a hydrogen bond to Glu81, while Leu83 interacts with the 
purine N7 (via its backbone NH) and with the NH of the 6-anilino substituent (via its 
backbone carbonyl) (Figure 45). 
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Figure 45 
Schematic representation of (R)-roscovitine (12) bound within the CDK2 ATP-binding domain. 158 
 
As a result of this binding mode, the substituent at the 2-position of 12 binds into the 
ribose binding pocket, while the aniline substituent at the 6-position of the purine 
binds into the specificity pocket (Leu83-Asp86) with the terminal two carbons of the 
aromatic ring pointing out towards solvent. Analogous studies with 14 85 have shown 
similar results, and predictably, on account of the similar substitution pattern around 
the purine core pharmacophore, 14 binds to CDK2 in a similar orientation to the 
parent 12 (Figure 46). 
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Figure 46 
Schematic representation of Purvalanol A (14) bound within the CDK2 ATP-binding site. 85 
 
Notably, the valinol-derived isopropyl group of 14 interacts with the glycine loop 
(Gly11-Gly13) in a similar manner to the Newcastle 6-cyclohexylmethoxypurines and 
pyrimidines (e.g. NU2058 (32), NU6102 (31) and NU6094 (43)). In addition, the polar 
hydroxyl group of 14 donates a hydrogen bond to the backbone carbonyl of Gln131. 
Purvalanol A (14) is a reasonably potent inhibitor of both CDK2 and CDK7 (IC50 = 21 
and 100 nM respectively). As a result of these observations, it was inferred that an 
analogue of NU6247 (44), where the 6-cyclohexylmethoxy substituent on the purine 
was replaced by a valinol-related alkoxy group, would make additional interactions 
within the ribose-binding pocket of CDK7, where the key residues Gly11, Glu12, 
Gly13 and, most importantly, Gln131 (Gln130 in CDK7) are conserved. 
 
209 
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To allow compound 209 to be prepared via the same synthetic approach already 
known to be suitable for the generation of 6-alkoxypurines, 197 2-isopropyl-1,2-
ethanediol was introduced at the purine 6-position instead of valinol. However, 
introducing an unsymmetrical diol at the 6-position of 209 posed problems of 
selectivity. 
The route devised for the synthesis of 209 is shown in Scheme 32. 
 
 
Scheme 32 
Reagents and conditions: (i) BnOH, Na, 48 h, 180°C;  (ii) 54, NaH, DMSO, 48 h, RT; (iii) HBF4, LiBF4, 
NaNO2,TFE/H2O, 3 h, 0°C RT; (iv) 187, TFA, TFE, reflux, 48 h; (v) H2/Pd/C, MeOH. 
 
The ring opening of 2-isopropyloxirane (210) 198 proceeded smoothly to yield 
derivative 211. This was reacted with 1-(2-amino-9H-purin-6-yl)-4-aza-1-azonia-
bicyclo[2.2.2]octane chloride (54) under previously developed conditions 199 to yield 
compound 212. 
Previously optimised conditions for the Balz-Schiemann reaction 185 proved 
unsuitable for the conversion of 212 into 213, as 212 was not stable to the acidic 
reaction conditions and product 213 was isolated in extremely poor yields (<10%). 
To render the reaction medium less acidic, an initial modification to the reaction 
conditions was to decrease the molar equivalents of HBF4 used from 22 to 2. The 
remaining 20 equivalents of fluorinating agent reportedly required for the reaction to 
proceed were introduced by using lithium tetrafluoroborate. As a result, the 
approximate pH of the reaction mixture increased from 1 to 5.5, and under these 
conditions product 213 was isolated in 40% yield. 
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This yield was further improved by introducing TFE as a cosolvent after observing 
that 212 was poorly soluble in water. By performing the reaction in a 4:1 mixture of 
water and TFE, the yield was increased to 58%. 
The studies performed towards optimisation of the third step in Scheme 32 are 
summarised in Table 20. Yields are estimated from LCMS analysis of the crude 
reaction mixture. 
 
HBF4 LiBF4 Solvent Temp. Time Yield 
22 eq / H2O 0°C  RT 48 h  10% 
22 eq / H2O 0°C 3 h 15% 
2 eq 20 eq H2O 0°C  RT 12 h 40% 
2 eq 20 eq H2O 0°C 3 h 20% 
2 eq 20 eq H2O/TFE 4:1 0°C RT 3 h  58% 
 
Table 20 
Summary of reaction conditions employed for Balz-Schiemann fluorination of 212. 
Having established that the use of a cosolvent increased the yield of the Balz-
Schiemann reaction, the conditions were considered satisfactory. Compound 213 
was converted into 214 under standard TFA/TFE conditions. Removal of the benzyl 
protecting group, however, proved unexpectedly difficult. As shown in Table 21, 
catalytic hydrogenation was attempted under a variety of conditions, but the 
formation of compound 209 was not observed. 
 
Catalyst/conditions (solvent: methanol) Result 
10% Pd/C  
 
No reaction 
Pd(OH)2 
10% Pd/C, H-cube: 60°C, room press. 
Pd(OH)2, H-cube: 60°C, 30 bar  60 bar 
10% Pd/C, H-cube: 60°C, 60 bar 
Pd(OH)2, H-cube: 60°C, 60 bar 
 
Table 21 
Summary of reaction conditions employed for catalytic hydrogenation of 214. 
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Compound 214 was submitted for biological evaluation and was found to inhibit 
CDK2 with an IC50 value of 5.6 µM and CDK7 with an IC50 value of 7.5 µM. All 
attempts at synthesising compound 209 were subsequently abandoned. 
 
5.2.2 The ‘Cyclacel’ analogue of NU6247 (44) 
 
2-Anilino-4-(thiazol-5-yl)pyrimidines were identified by Wu et al. 200 as CDK2 
inhibitors using virtual screening methods. Wang et al. then developed the series 88 
and discovered compound 36, which was reported to be active against CDK family 
members with the values shown in Table 22. 
 
Protein kinase Ki (nM) 
CDK1/Cyclin B 80 ± 40 
CDK2/Cyclin E 2 ± 0.6 
CDK4/Cyclin D1 53 ± 5 
CDK7/Cyclin H 70 ± 10 
CDK9/Cyclin T1 4 ± 3 
 
Table 22 
Kinase inhibition for 36 against CDK family members. 88 
 
Crystal structure studies of 36 bound within the CDK2 ATP-binding site 88 (Figure 
47) revealed that the pyrimidine H4 donates a hydrogen bond to the Glu81 backbone 
carbonyl; the NH proton at the pyrimidine 2-position and the nitrogen atom at the 3-
position form hydrogen bonds with the Leu83 backbone carbonyl and NH 
respectively. 27 The nitrophenyl moiety interacts with Gln131 via the nitro group and 
an alternative conformation is observed where a weaker interaction with Lys89 takes 
place. The thiazole ring binds within the ribose binding pocket and interactions are 
observed between the NH2 at the thiazole 2-position and Asp145, and between the 
nitrogen atom at the thiazole 3-position and Asn132. 
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Figure 47 
Crystal structure of 36 bound within the CDK2 ATP-binding site. 88 
 
Studies carried out by Kim et al. 201 identified N-phenylacetyl-2-aminothiazoles as 
potent CDK2 inhibitors, and subsequent development of a related series of N-
(cycloalkylamino)acyl-2-aminothiazoles 202 resulted in the identification of 215, 
reported to inhibit CDK family members with IC50 values shown in Table 23.203 
 
 
 
 
 
 
 
 
 
Table 23 
Kinase inhibition for compound 215 against CDK family members.  
 
Crystal structure studies of 215 bound to CDK2 202 showed the thiazole ring binding 
to the hinge region and the piperidine ring extending towards the specificity pocket 
and Leu134. The t-butyloxazole ring folds back towards the ribose-binding pocket to 
avoid unfavourable interactions with the gatekeeper residue Phe80 (Figure 14). 
 
Protein kinase IC50 (µM) 
CDK1/Cyclin B 0.48 
CDK2/Cyclin E 0.038 
CDK4/Cyclin D1 0.93 
CDK7/Cyclin H 0.062 
CDK9/Cyclin T1 0.004 
 Figure 48 
Crystal structure of 215 bound within the CDK2 
 
Compounds 36 and 215 are also potent against CDK7 and this could be explained 
by a similar binding mode to that observed with CDK2. 
thiazole ring of 36 and the oxazole ring of 
of CDK7 is correct, replacing t
aminothiazole may confer favourable interactions and lead to enhanced potency
against CDK7. 
N
To approach 216 as a synthetic target, a 
catalysed Stille coupling reaction was considered
coupled to either a thiophene, a pyrrole, or a simple thiazole derivative.
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reports were found in the literature of a purine or a pyrimidine being coupled to a 
thiazole using a Suzuki approach. 
Starting from commercially available 2-amino-4-methylthiazole (217) the route 
described in Scheme 33 was initially devised for the synthesis of 216. 
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Scheme 33 
Reagents and conditions: (i) NBS, AcOH, 3 h, RT; (ii) nBuLi, Bu3SnCl, THF, 2 h, -78 °C. 
 
A literature procedure 212 involving the use of N-bromosuccinimide in acetic acid was 
used to convert 217 into the brominated derivative 218, and the reaction proceeded 
successfully. It was not possible, however, to convert 218 into the stannyl derivative 
219. 
Compound 219 is not reported in the literature; a standard stannylation reaction 
involving lithiation at the 5-bromo position of 218 using an alkyllithium reagent 
(nBuLi), followed by tin-lithium exchange using an alkyltin halide (Bu3SnCl) as 
reported for a simple thiazole, 211 was tried without success. The reaction was 
attempted using increasing amounts of n-butyllithium, taking into consideration the 
possibility of deprotonation at both the 2-amino and the 4-methyl moiety of 218 
(Wang et al., unpublished observations), but in no case was the formation of the 
desired product (219) observed. The results are summarised in Table 24. 
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Equivalents of nBuLi Temperature Result 
1 -78 °C Complex reaction 
mixture; no product 
detected by NMR or LC-
MS analysis. 
2 -78 °C  RT 
3 -78 °C  RT 
4 -78 °C  RT 
 
Table 24 
Attempted reaction conditions for lithiation of compound 218. 
 
As a result of these observations, the Stille approach to compound 216 was 
abandoned; a stepwise approach to the 2-fluoro derivative 224 was then investigated 
as shown in Scheme 34. 
 
 
Scheme 34 
Proposed synthetic strategy to target molecule 216. 
 
The synthesis of 224 (where PG = THP) was attempted following a literature 
procedure 213 as exemplified in Scheme 35, where 2-amino-6-chloropurine (53) was 
converted into the 2-fluoro derivative (225) under standard Balz-Schiemann  
conditions and subsequently protected at the N9-position using DHP in EtOAc. 
Alkylation of 226 at the 6-chloro position was unsuccessful. Compound 226 was 
observed to degrade under the reaction conditions and no formation of product was 
observed; this route, too, was therefore abandoned. 
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Scheme 35 
Reagents and conditions: (i) HBF4, NaNO2, H2O, 75 min, RT; (ii) DHP, EtOAc, 24 h, 60 °C; (iii) Ethyl 
acetacetate, sodium salt, THF, 3 h, RT 
 
 
 
5.2.3 Replacement of the purine core pharmacophore of NU6247 
(44) by a pyrazolo-pyrimidine 
 
The pyrazolo[1,5α]pyrimidine pharmacophore was first reported as a scaffold for 
CDK inhibitors by  Williamson et al. in 2005, 214 from a high-throughput screen of a 
commercially available kinase-directed compound library. The authors discovered 
that compound 227 had an IC50 value of 1.8 µM against CDK2 but inhibited GSK-3β 
kinase with similar potency. Due to the structural similarity of 227 with (R)-roscovitine 
(13) and other purine-based inhibitors such as NU6102 (31), SAR studies around the 
pyrazolo[1,5α]pyrimidine core pharmacophore ultimately resulted in the identification 
of compounds such as 228, which exhibited similar potency and selectivity for CDK2 
as NU6102 (31) and a binding mode analogous to roscovitine (Figure 49). 
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Figure 49 
Crystal structure of 228 bound within the CDK2 ATP-binding site. 214 
 
Researchers at Emory University and Imperial College recently developed a series 
of compounds with CDK inhibitory activity based on the pyrazolo[1,5α]pyrimidine 
core pharmacophore. 137 The results obtained, while varying quite widely in the 
selectivity for specific members of the CDK family, proved of interest due to the 
discovery of compound BS-181 (39), an inhibitor of CDK7 with 40-fold selectivity 
over CDK2. 
N
N
N
NH
N
H
F
H2N
BS-181 (39)
IC50 M = 0.018 (CDK7), 0.75 (CDK2)
 
 
No structural data have been published to date concerning the binding mode of 39 
within CDK7 or CDK2, but the structural similarity with 13 would suggest a binding 
orientation similar to that shown in Figure 49. The sidechain at the 5-position of the 
heterocycle is similar in both cases; a lack of a sulfonamide moiety in the para-
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position of the aromatic ring at the 7-position would account for the loss of CDK2-
inhibitory activity with respect to both 228 and NU6102 (31), but identifying a 
structural feature which would account for the selectivity of compound 39 for CDK7 
over CDK2 is not straightforward without the aid of structural biology studies. 
In order to establish a direct comparison between 39 and NU6247 (44), compound 
229 was identified as a synthetic target. 
 
N
N
N
H
S
N
N
O O
N
O
229
 
 
From available information regarding the binding orientation of the Newcastle 
purines within the CDK2 ATP-binding site, it was decided that a cyclohexylmethoxy 
substituent at the 5-position, an ethylsulfone sidechain at the 7-position, and removal 
of the isopropyl substituent at the 3-position would provide the closest overlay with 
NU6247 (44). 
To synthesise target 229, dimethyl malonate and 3-amino-pyrazole were reacted in 
the presence of sodium etoxide, followed by phosphoryl chloride-mediated reaction 
to generate 5,7-dichloropyrazolo[1,5α]pyrimidine 233 (Scheme 36). Compound 233 
could selectively be coupled with an aniline at the 5-position, 215 enabling the 
introduction of the desired aniline sidechain via standard TFA/TFE conditions. No 7-
addition product was observed in the reaction mixture at this stage. With compound 
234 in hand, a palladium-catalysed C-O bond formation reaction was attempted to 
introduce the cyclohexylmethoxy substituent at the 5-position of the heterocycle. 216  
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Scheme 36 
Reagents and conditions: (i) EtONa, EtOH, 24 h, reflux; (ii) POCl3, µW; (iii) 187, TFA, TFE, 48 h, 
reflux; (iv) 235, Pd(OAc)2, Cs2CO3, CyCH2OH, µW 
 
Inhibitor 229 was tested for CDK2- and 7-inhibitory activity and found to exhibit IC50 
values of 1.6 µM and a 19.1 µM, respectively. The results show that the compound 
does not interact with the ATP-binding domain of CDK7 as effectively as BS-181 
(39), and the useful interactions made by 31 and 44 with the ATP-binding sites of 
CDK2 and CDK7 respectively are also not replicated. Structural biology studies 
would be needed to assess whether 39 and 229 bind in a similar orientation to 13 or 
to 31. 
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Chapter 6 – NU6300, an irreversible CDK2 
inhibitor 
 
6.1 Irreversible enzyme inhibition 
 
Enzyme inhibitors can interact with their intended protein target in either a reversible 
or an irreversible manner. Reversible inhibitors form non-covalent interactions with 
their target enzyme such as hydrogen bonds, hydrophobic and Van Der Waals 
interactions and ionic bonds. Multiple weak bonds between the inhibitor and the 
binding site can combine to produce strong and specific binding. Reversible 
inhibitors generally do not undergo chemical reactions when bound to the enzyme 
and can be removed by dilution or dialysis. 217 
Irreversible inhibitors invariably react with a specific site on the target protein to form 
one or more covalent bonds. This results in chemical modification and subsequent 
inactivation of the enzyme. The formation of the covalent bond is normally relatively 
slow, and so irreversible inhibitors display time-dependent inhibition. Their potency 
cannot be characterised by an IC50 value, because at any time the amount of active 
enzyme at a given concentration of inhibitor will be dependent on the time the 
enzyme is pre-incubated with the inhibitor. Instead, kobs/C values are used 218 where 
kobs is the observed pseudo-first order rate of inactivation (obtained by plotting the 
log of % activity vs. time) and C is the concentration of inhibitor. 
 
 
 Scheme 37 
Representation of the kinetic constants for reversible and irreversible enzyme inhibition.
= inhibitor, S = substrate. 
 
 
Scheme 37 summarises the kinetic constants involved in reversible and irreversible 
enzyme inhibition. The rate at which the Enzyme
is called kinact. At the point where the enzyme is saturated with the inhibitor, 
kinact. 
Irreversible inhibitors can be classified into two groups depending on their mode of 
action. 219 Active site-directed inhibitors
recognition that can initially interact with the target enzyme in
The reactive group, or ‘warhead’, subsequently reacts with what is usually a 
nucleophilic residue on the target protein such as 
tyrosine) or sulfhydryl (tyrosine
complex. Mechanism-based inhibitors
inhibitors that bind to the active site where they are chemically modified through the 
enzyme’s own catalytic mechanism
to the enzyme to form a stable complex
some component of the target enzyme’s catalytic mechanism to promote enzyme 
inactivation, usually by covalently modifying a key amino acid invo
catalytic mechanism. 221 
Mechanism-based irreversible enzyme inhibition was first reported in 1968 
active site-directed irreversible enzyme inhibition in 1976. 
 
-Inhibitor covalent adduct is formed 
, or affinity labels, contain an element of 
 a reversible manner. 
hydroxyl (serine, threonine
, cysteine) to form the irreversible enzyme
, or suicide inhibitors, are initially competitive 
 to produce a reactive group that covalently binds 
. 
220
 Mechanism-based inhibitors exploit 
223
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Active site-directed inhibitors have the ability to bind selectively to individual 
enzymes or specific enzyme families. This enables them to be used as tools to 
elucidate characteristics such as abundance, interactions, cellular localisation and 
function of a protein under investigation. 224 
The vinyl sulfone moiety is known for its ability to participate in Michael-type 
additions and has therefore been widely employed in irreversible cysteine protease 
inhibitors. 225 Vinyl sulfones are less reactive toward nucleophiles than the analogous 
vinyl ketones or esters, 226 which allows the design of inhibitors that are unreactive 
toward other proteases, non-active-site cysteines and circulating thiols such as 
glutathione. The vinyl sulfone moiety also exhibits the capability to form a hydrogen 
bond with the active site, which helps to align the warhead for attack by the catalytic 
cysteine residue. Examples of cysteine proteases that have been irreversibly 
inhibited by vinyl sulfones are the cathepsins, caspases, de-ubiquitinases and 
falciparin-2. 227-230 
An advantage of affinity labelling is that permanent inactivation of the enzyme 
provides a long duration of action, since de novo protein synthesis is required for 
restoration of enzyme activity, and such a process is usually slow. Plasma levels of 
the irreversible inhibitor can then decrease between treatments without enzyme 
inactivation being reduced, allowing reduced dosages of the drug and longer 
intervals between doses. 231 On the other hand, if the affinity label is too reactive, it 
can interact with low-molecular-weight nucleophiles or other cellular macromolecules 
prior to reaching its intended target, diminishing specificity and increasing the risk of 
off-target activity and toxicity. 232 
A recent example of irreversible kinase inhibition is the development of ErbB or 
epidermal growth factor receptor (EGFR) tyrosine kynase inhibitors. The synthesis of 
a library of irreversible EGFR inhibitors based on the 4-anilinoquinazoline 
pharmacophore was undertaken to overcome the problem of resistance associated 
with gefitinib (4) and erlotinib (6), arising as a result of a mutation (T790M) within the 
kinase domain of EGFR. 233 Reversible analogues where the ‘warhead’ functionality 
was removed for control purposes were also synthesised. The library included 
compounds such as 236 and 237 (earlier work by Kwak et al. identified vinyl sulfone 
238 234) but, ultimately, the results showed that this new generation of inhibitors were 
not as effective as initially hoped, and their activity required combination with either 
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cytotoxic agents or inhibitors of other kinases acting downstream of EGFR, such as 
MEK or PI3K. 
 
 
                 236                                          237                                     238 
 
 
Another recent example of an irreversible ErbB receptor tyrosine kinase inhibitor is 
neratinib (239). 235 Neratinib is a potent, low-molecular-weight, orally administered 
irreversible pan-ErbB (i.e. Erb 1, 2 and 4) receptor tyrosine kinase inhibitor currently 
in Phase II clinical trials. Recent results have shown that Neratinib is clinically active 
both on its own and in combination with trastuzumab, a monoclonal antibody that 
binds specifically to the ErbB-2 tyrosine kinase receptor, or cytotoxic drugs such as 
taxanes and anthracyclines. 236 
 
 
239 
 
There is currently no known irreversible cyclin-dependent kinase inhibitor in the 
literature. 237-239  CDK2 does not have a catalytic cysteine, although a catalytic 
aspartic acid and two lysines (Lys88 and Lys89) are present and may be correctly 
positioned to react with a Michael acceptor within the ATP-binding site. 
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6.2 NU6300 as an irreversible inhibitor of CDK2 
 
The vinyl sulfone purine intermediate NU6300 (63), generated as part of the Cope 
elimination reaction (see Chapter 4), has the potential to irreversibly inhibit CDK2. 
As noted above, the vinyl sulfone moiety can be involved in Michael addition-type 
reactions with nucleophilic cysteines, although no precedent for a similar reaction 
with a nucleophilic lysine appears to exist. 
 
 
NU6300 (63) 
IC50 (CDK2) = 22.4 nM 
 
 
Early studies to test vinyl sulfone 63 as an irreversible inhibitor of CDK2 were aimed 
at demonstrating that the compound showed a time-dependent inhibition of the 
enzyme, with enzyme activity decreasing as a function of the time of exposure to the 
inhibitor.  
To do this, the catalytically active enzyme (pCDK2/cyclin A) was incubated with 
NU6300 and, at various time intervals, an aliquot was taken and assayed for 
enzymatic activity. 240 The results (figure 50a) showed that, comparing with a non-
incubated control, the kinase loses activity proportionally to the inhibitor exposure 
time, suggesting that a covalent modification is taking place. 
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a)                                                                b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50 
a) Time-dependent inhibition of CDK2 by NU6300. b) The same experiment run with NU6310 shows 
no decrease in activity over time 
 
To further validate the hypothesis that the vinyl sulfone moiety is covalently 
modifying a nucleophilic residue of CDK2, a parallel experiment was run on NU6310 
(240), in which the vinyl sulfone has been replaced with an unreactive ethyl sulfone. 
As expected for a reversible inhibitor, the activity of CDK2/Cyclin A did not decrease 
in a time-dependent manner after incubation with NU6310 (Figure 50b). 
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6.2.1 Surface Plasmon Resonance experiments 
 
Through a collaboration with Beactica, Sweden the interaction of the same two 
compounds with CDK2 was investigated using a surface plasmon resonance 
biosensor. Exposure to NU6300 for several hours decreased the binding capacity of 
CDK2 for NU6310 (Figure 51). 
 
 
 
Figure 51 
Binding responses for 10 µM NU6310 to CDK2 surfaces. CDK2 showed a decreased binding capacity 
for NU6310 when incubated with 10 µM NU6300.  
 
At the interface between two transparent media of different refractive index (e.g. 
glass and water, or glass and air, or glass and vacuum), when the angle at which the 
light strikes the interface (the angle of incidence, or θ) is greater than a critical value 
(the critical angle, or θ
c
), the light is completely reflected. If the surface of the glass is 
coated with a thin layer of a noble metal (e.g. gold), the reflection is not total. Energy 
from the incident light is absorbed by mobile electrons on the gold surface (or 
“plasma”), which oscillate resulting in a wave called a surface plasmon. There 
exists an angle, greater than the critical angle, at which the quantity of absorbed 
energy is greatest and the intensity of the reflected light reaches a minimum. This 
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angle is called the surface plasmon resonance angle, or θ
spr. If incident light is 
monochromatic and p-polarised, and has the same wavelength of the surface 
plasmon, the electrons ‘resonate’, resulting in the phenomenon of surface plasmon 
resonance (SPR). 
Since the wave is on the boundary of the metal and the external medium (e.g. water, 
air or vacuum), the oscillations are very sensitive to any change of this boundary, 
such as the adsorption of molecules to the metal surface. Linear relationship is found 
between resonance energy and mass concentration of biochemically relevant 
molecules. The SPR signal, expressed in resonance units, is therefore a measure of 
mass concentration at the sensor surface. In order to detect an interaction, one 
molecule (the ligand; in the present case, CDK2) is immobilised onto the sensor 
surface. A binding partner (the analyte; in the present case, a reversible CDK2 
inhibitor) is injected in solution (sample buffer) under continuous flow. As the analyte 
binds to the ligand, the accumulation on the surface results in an increase in the 
refractive index. This change in refractive index is measured in real time, and the 
result plotted as response or resonance units (RUs) versus time (a sensorgram). 
This means that the analyte and ligand association and dissociation can be observed 
and rate constants as well as equilibrium constants can be calculated. 
 
A CDK2 crystal surface incubated with 10 µM NU6300 was tested for binding 
capacity for NU6310 after various time intervals (0, 4, 20 h) and the results 
compared with a CDK2 surface incubated with buffer. The surface exposed to 
NU6300 displayed only 55% of the binding capacity after 20 h (Figure 52). 
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Figure 52 
SPR sensorgrams (reference subtracted) for the interaction between immobilised CDK2 and 10 µM 
NU6310 after incubation with A) buffer including 10 µM NU6300 and B) buffer.  
 
 
6.2.2 Band shift assays 
 
As a means to confirm that prolonged exposure to NU6300 covalently modifies and 
therefore inactivates pCDK2/cyclin A, a standard band shift assay versus pRb was 
implemented. Three aliquots of enzyme were incubated overnight with 100 µM 
NU6300, 100 µM NU6310 and DMSO respectively. They were then transferred to a 
dialysis unit whereby any non-covalent inhibitors would be eliminated from the active 
site by means of successive dilutions. The dialysed enzyme samples were then 
utilised to catalyse a test phosphorylation reaction of the substrate pRb, carried out 
in the presence of ATP and monitored over a time course of 15 min. 
 
pRb is a natural substrate of CDK2/Cyclin E and D-dependent CDKs (see Chapter 
2). 241 CDK1 and 2 phosphorylate pRb on at least five recognised sites (Ser249, 
Thr252, Thr373, Ser807 and Ser811). 242-243 Mass and charge increase sensibly in 
pRb as a result of hyperphosphorylation, rendering this protein a useful tool for 
detecting CDK2-mediated phosphorylation in standard band shift assays by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
 
As shown in Figure 53, pRb was phosphorylated by CDK2 previously incubated with 
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DMSO, and (at a slightly lower rate) by CDK2 previously incubated with NU6310, 
suggesting that after dialysis NU6310, the reversible inhibitor, is almost completely 
removed from the active site. The enzyme incubated with NU6300, however, 
remained inactive after dialysis and phosphorylation of pRb was not observed during 
the time course. This appeared to suggested a possible covalent modification, likely 
within the ATP-binding site of CDK2, which eliminated could be responsible for the 
elimination of kinase activity. 
 
 
 
 
Figure 53 
Phosphorylation of GST-pRb by wild type CDK2/A. A) Lane 1, molecular weight markers (170, 130, 
95, 72, 55, 43, 34, 26 and 17 kDa). Lanes 2-6, negative control. GST-pRb incubated with 50 mM Tris-
HCl pH 7.5, 10 mM magnesium chloride, 1.0 mM ATP after 0’, 1’, 5’, 10’, 15’. In the absence of 
CDK2/A, no phosphorylation occurs resulting in no band shift.  Lanes 7-11, positive control. GST-pRb 
incubated with the same as above and 8 ng/µl CDK2/A, at the same time intervals as above. 
Hyperphosphorylated GST-pRb has a lower electrophoretic mobility. B) Lane 1, molecular weight 
markers; lanes 2-6, phosphorylation of GST-pRb carried out using a sample of CDK2/A incubated 
overnight with 100 µM NU6310 and then dialysed. Enzyme activity is recovered after dialysis and 
phosphorylation of GST-pRb is achieved, resulting in a band shift; lanes 7-11, phosphorylation 
reaction carried out using a CDK2/A sample incubated overnight with 100 µM NU6300 and then 
dialysed. Enzyme activity is not recovered after dialysis and GST-pRb is not phosphorylated. Proteins 
were visualized by Coomassie stain following 15% SDS-PAGE. Reactions were carried out under the 
conditions described in Chapter 7. 
 
 
 
 
1  2  3  4   5  6      7   8   9  10 
B A 
1  2   3  4  5  6      7  8  9 1011 
 6.2.3 Mass spectrometry experiments
 
A mass spectrometry experiment performed on CDK2/
with 2.5 mM NU6300 demonstrate
increase in the mass of the protein after overnight incubation with NU6300 (
54c). This result is compatible with one nucleophilic residue from CDK2 (a lysine 
NH2, cysteine SH or aspartate COO
NU6300 (molecular weight 413 Da)
resulting in the formation of a covalent bond.
overnight with NU6310 at the same concentration 
mass with respect to the control sample incubated with DMSO (
 
 
Figure 54 
Mass spectra of 3 mg/ml CDK2/A pre
mM NU6300. 
 
 
It should be noted that, despite the high concentration
a 50:1 stoichiometric excess with respect to CDK2)
was incorporated after overnight incubation. This suggest
NU6300 does not react 
residues, such as Cys327 in C
 
Cyclin A samples incubated 
d covalent modification by sho
-) reacting with the vinyl sulfone moiety of
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 positioned amino acid after having assumed the correct orientation within the CDK2 
ATP-binding site. 
Assuming a similar binding orientation of NU630
CDK2 to that observed with NU6102, 
react with the vinyl sulfone group to form a covalent bond 
Lys89. 
Figure 55 
Superposition of the crystal conformation of NU6102 (green sticks) with the best
of NU6300 (magenta sticks). 
 
 
In a first attempt to determine the exact site of covalent modification, a 
stained gel band corresponding to the CDK2
corresponding to unmodified CDK2 were 
analysed by MALDI-TOF MS
peak at 1664 Da, corresponding to the Asp86 and Lys88
peptide, was present in the control spectrum and appear
spectrum of the adduct, suggesting that Asp86 and
formation of the covalent bond.
0 within the ATP
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 the potential nucleophilic residues that could 
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Unfortunately, the Lys89-containing peptide (expected 
seen in traces in the control spectrum, due to a markedly hydrophobic nature that 
prevents this peptide from bei
mass for the same peptide if Lys89 were the site of covalent modification would be 
2230 Da, and again only traces of this appear
NU6300 adduct (Figure 56
Figure 56 
A) Detail of MALDI-TOF TOF spectrum of wild type CDK2, highlighting the peaks 1664 and 1686 Da. 
B) Detail of MALDI-TOF TOF spectrum of the CDK2
at 1664 and 2230 Da. 
 
 
The evidence from the MALDI
NU6300 and Lys89, but this hypothesis needs further confirmation.
Additional evidence excluding any involvement of Asp86 was provided by site
directed mutagenesis studies. A CDK2 mutant enzyme, where Lys88 and Lys89 
were substituted by a glutamic acid and a valine
Overnight incubation of this mutant enzyme with 2.5 mM NU6300 did not result in an 
increase in the mass of the protein (
residue involved in the Michael addition to the vinyl sulfone moiety of NU6300 was 
either Lys88 or Lys89. As a consequence, the K88E K89V mutant CDK2 does not 
possess any nucleophilic residue correctly positioned for Michael
NU6300, which therefore acts as a pur
mass 1686 Da) 
ng ionised under MALDI conditions. The expected 
ed in the spectrum of the CDK2
). 
-NU6300 covalent adduct, highlighting the peaks 
-TOF TOF experiment suggested a reaction between 
, respectively, was synthesised. 
Figure 57). This result suggested that the 
ely reversible inhibitor of this mutant kinase.
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 Figure 58 
Mass spectra of 3 mg/ml K88E K89V CDK2/cyclin A pre
mM NU6300. 
 
To confirm that NU6300 acts purely as a reversible inhibitor of the K88E K89V 
mutant CDK2, three aliquots of mutant enzyme were incubated overnight with 100 
µM NU6300, 100 µM NU6310 and DMSO
the experiment already conducted on the wild
phosphorylation reaction of the substrate pRb, carried out and monitored 
same conditions as for the wild
NU6300-incubated sample of mutant 
confirming the hypothesis that no irreversible inactivation of the enzyme 
place (Figure 58). 
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under the 
was taking 
  
Figure 58 
Phosphorylation of GST-pRb by K88E K89V mutant CDK2/cyclin A. 
markers (170, 130, 95, 72, 55, 43, 34, 26 and 17 kDa). 
positive control. Hyperphosphorylated GST
phosphorylation of GST-pRb carried out usin
100 µM NU6310 and then dialysed. Enzyme activity is recovered after dialysis; 
phosphorylation reaction carried out using a mutant CDK2/A sample incubated overnight with 100 
NU6300 and then dialysed. Enzyme activity is recovered after dialysis and GST
phosphorylated. Lane 12, molecular weight markers. Proteins were visualized by Coomassie stain 
following 15% SDS-PAGE. Reactions were carried out under the conditions described under 
“Experimental Details”. 
 
The results obtained from the MS experiments and enzyme a
the wild-type and K88E K89V mu
vinyl sulfone NU6300 is an irreversible inhibitor of CDK2. The MS/MS ex
conducted on the wild-type enzyme, and the MS experiments and enzyme activity 
assays conducted on the K88E K89V mutant CDK2, exclude
Asp86 in the formation of the covalent bond. These results also suggest
involvement of Lys89 over Lys88, although this hypothesis needs further 
corroboration.  
The formation of a covalent bond between NU6300 and 
modelled starting from the
structures were minimised
complexes showed that a Lys88 complex would be 9.2 kcal/mol lower in energy than 
a Lys89 complex, and therefore more favourable (
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 crystal structure of NU6102 within CDK2. The resulting 
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hydrogen bonds formed between the sulfone oxygens, the Lys88 NH2 and the Asp86 
COO-. 
 
 
Figure 59 
NU6300 (red sticks) docked into the ATP-binding pocket of CDK2 while covalently bound to A) Lys88 
and B) Lys89. The neighbouring lysine residues 88 and 89 are rendered as green sticks in the 
foreground. 
 
The issue could possibly be resolved by further site-directed mutagenesis 
experiments. The synthesis of the K88E and K89V CDK2 single mutants is in 
progress, and MS experiments on NU6300-incubated samples of these single 
mutant enzymes may clarify which residue is involved in the formation of the 
covalent bond. Crystallography studies with NU6300 and wild-type CDK2/A are also 
in progress, and a cocrystal structure may provide evidence for the formation of the 
covalent bond and its location. 
 
6.3 CDK2 redundancy 
 
The results obtained with NU6300 and CDK2, in combination with CDK redundancy 
patterns discussed in Chapter 2, raise the question of whether a permanent 
inactivation of CDK2 through irreversible inhibition would cause cell cycle arrest, and 
A B
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whether an irreversible CDK2 inhibitor would be considered a useful investigative 
tool.  
A series of studies published between 2003 and 2005 141-142, 244-245 has questioned 
the essentiality of the role played by CDK2 in the regulation of the cell cycle. A 
possible mechanism behind this redundancy was further investigated in 2006 246 
when it was shown that when transcription of either CDK2 or CDK1 is eliminated 
using siRNA, there were complex shifts of cyclin A towards its reciprocal partner, i.e. 
when CDK2 is ablated, cyclin A redistributes to CDK1; when CDK1 is absent, cyclin 
A forms more abundant complexes with CDK2. Knockdown of both CDK1 and CDK2 
using siRNA results in G2 arrest. 
CDK2 has shown emerging roles in DNA damage response, 247 proliferation of 
melanoma cells, 248 mitosis, 249 S-phase histone gene transcription 250 and 
centrosome duplication, 251-252 but to what extent these roles are conserved in 
different cell types, and which kinase takes over these roles in the absence of CDK2, 
is not known. It is suggested 253 that selective chemical inactivation of CDK1 and 
CDK2 (as well as CDK4) in different conditions, and across different cell types, 
would be a worthwhile endeavour towards elucidating how different cells have 
evolved diverse requirements for CDK activity.  
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Conclusions 
 
 
Previous structure-activity relationship studies had identified NU6247 (44) as a 
promising purine-based CDK7 inhibitor. Research was thus conducted to expand the 
purine series, leading to the synthesis of compounds, e.g. 94 and 133, with improved 
selectivity for CDK7 over CDK2. 
 
 
 
Guided by a structure-based inhibitor design approach, systematic structural 
modifications have been made at the purine 2-, 6- and 8-positions. A versatile and 
efficient route to 8-alkylpurines has been discovered, leading to the synthesis of 
compound 192 and analogues. Purine 192 is a selective, albeit not very potent, 
CDK7 inhibitor with growth-inhibitory activity in a cancer cell line. The apparent ability 
of CDK7 to accommodate 2- and 8-substituted purines with higher flexibility with 
respect to CDK2 opens a number of new perspectives in the pursuit of CDK7-
selective, purine-based inhibitors. 
 
 
 
The initial objective of this research, namely the enhancement of CDK7 activity and 
selectivity over CDK2 of NU6247 (44) via specific sidechain modifications, was 
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unsuccessful for the inhibitors tested to date. However, the results obtained for 
compounds 192 and 39 indicated that the identification of different binding modes, as 
well as the modification of the purine core pharmacophore, may offer new 
possibilities for the achievement of a CDK7-selective inhibitor in the future. 
The possible redundancy of CDK2 and other members of the CDK family in 
proliferating cells has raised the question of the validity of CDK inhibition for the 
treatment of cancer. The emerging issue in the discovery of such inhibitors is the 
selectivity within the CDK family. The development of inhibitors selective for 
individual CDKs is important in further assessing the potential of CDK inhibition in 
cancer therapeutics. Evaluation of the 8-substituted purine series against CDK2 and 
CDK7 may reveal potential opportunities for achieving kinase selectivity within the 
CDK family. Elucidation of their binding mode via the co-crystallisation with both 
enzymes should provide a starting point for the rational design of CDK7-selective 
inhibitors. 
Additionally, the isolation and biological evaluation of the vinyl sulfone intermediate 
NU6300 (62) indicated time-dependent inhibition of CDK2 (from radioactive kinase 
assays), loss of enzymatic activity following incubation (from SPR and bandshift 
assays) and covalent modification of the kinase following incubation (from mass 
spectrometry experiments). These results are in accordance with NU6300 being the 
first irreversible inhibitor of CDK2 to be reported. A selective, covalent inhibitor of 
CDK2 would potentially be a powerful tool towards a better understanding of the role 
of CDK2 in both normal and cancer cells. 
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Chapter 7 - Experimental 
 
7.1 Chemicals and Solvents 
 
Reagents were purchased from reputable suppliers. Unless otherwise stated, 
laboratory grade reagents and solvents (dichloromethane, diethyl ether, ethyl acetate 
and petrol) were used. Petrol (petroleum ether) refers to that fraction of pentanes 
and hexanes in the boiling range 40-60 °C.  
Anhydrous solvents such as acetonitrile, N,N-dimethylformamide, 1,2-
dimethoxyethane, dimethyl sulfoxide, dioxane, ethanol, methanol, pyridine, 
tetrahydrofuran and toluene were obtained from Sigma-Aldrich in SureSeal™ bottles.  
HPLC gradient acetonitrile and methanol were employed for chromatography. 
Moisture sensitive reagents such as sodium hydride were stored in a dry box under a 
nitrogen atmosphere. mCPBA (ca. 75% purity from Sigma-Aldrich, confirmed by 
iodometric titration) was obtained and used directly without further purification.  
 
 
7.2 Chromatography 
 
Thin layer chromatography (TLC) was conducted on Merck aluminium backed plates 
pre-coated with 0.2 mm of silica gel 60F254 using a variety of mobile phase solvents. 
TLC plates were subsequently dried and visualised either by using short (254 nm) 
and long (365 nm) wave ultraviolet light or by treatment with additional agents, 
defined generally as ‘stains’, such as ninhydrin, potassium permanganate or iodine.  
Column chromatography was carried out in glass columns under medium pressure 
using Davisil silica gel (particle size of 40-63 µm, porosity of 60 Å). A Biotage SP1 
automated parallel chromatography system was employed as well, using prepacked 
cartridges of different kinds: FLASH+ Silica columns (40-63 µm, 60 Å), KP-NH 
FLASH+ cartridges (40-75 µm, 100 Å) and reverse phase C18 FLASH+ cartridges 
(40-63 µm, 90 Å). The crude product was either loaded onto the column directly (as 
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an oil or dissolved in the minimum amount of suitable solvent) or pre-loaded onto 
silica or prepacked samplets.  
Purification by semi-preparative HPLC was conducted on a Jones C18 column (15 × 
22.5 cm) using a Varian Prostar Model 410 Autosampler, in combination with a 
Model 320 UV-VIS Detector, Model 710 Fraction Collector and a Model 210 Solvent 
Delivery Module. Both H2O:MeOH and H2O:MeCN were used as gradient solvent 
systems. 
 
 
7.3 Analytical Techniques and Instrumentation 
 
Liquid chromatography-mass spectra (LC-MS) were recorded on a Micromass 
Platform LC, in combination with a Waters 996 Photodiode Array Detector, a Waters 
600 Controller and a Waters 2700 Sample Manager. The instrument was run in 
positive or negative ion electrospray mode. Chromatography was carried out using 
either a 5 min or a 12 min method. 
• 5 min method: 
Column: Waters Symmetry Shield RP18 3 µm, 4.6 x 20 mm (P/No. 
186002092). 
Mobile Phase: A/ 0.1 %v/v formic acid (aqueous), B/ acetonitrile. 
Flow Rate: 3.0 mL/min. 
Gradient: 
Time (min) % A % B 
0.0 95 5 
3.3 5 95 
4.0 5 95 
4.05 95 5 
5.0 95 5 
 
• 12 min method: 
Column: Waters Atlantis dC18 3 µm, 4.6 x 50 mm (P/No. 186001329). 
Mobile Phase: A/ 0.1 %v/v formic acid (aqueous), B/ acetonitrile. 
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Flow Rate: 1.0 mL/min. 
Gradient:  
Time (min) % A % B 
0.0 95 5 
4.0 5 95 
9.3 5 95 
10.0 95 5 
12.0 95 5 
 
 
Accurate mass analyses were measured using a Finnigan MAR 95 XP or a Finnigan 
MAR 900 XLT at Swansea EPSRC National Mass Spectrometry Service Centre 
(EPSRC, Chemistry Department, University of Wales Swansea, Wales, SA2 8PP). 
 
Proton (1H) and Carbon (13C) Nuclear Magnetic Resonance (NMR) spectra were 
recorded using a Bruker Spectrospin AC 300E (1H at 300 MHz, 13C at 75 MHz), 
Bruker Spectrospin AC 500E (1H at 500 MHz, 13C at 125 MHz), or a Jeol JNM-LA500 
spectrometer (1H at 500 MHz, 13C at 125 MHz), using as solvents CDCl3, d6-DMSO, 
d3-MeCN or d4-MeOH.  
Chemical shifts (δ) are reported in parts per million (ppm), referenced to the known 
signals of the deuterated solvent employed as internal standards. Coupling 
constants (J) are given in Hertz (Hz) units. Multiplicities are indicated by s (singlet), d 
(doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet) and br 
(broad). 
Melting points were determined using a Stuart-Scientific SMP3 apparatus and are 
uncorrected. Infrared (IR) spectra were recorded as a neat sample on a Bio-Rad 
Excalibur FTS 3000MX diamond ATR spectrometer, equipped with a solid sampling 
device, in the range 4000-600 cm-1. UV spectra were recorded on a Hitachi U-2001 
spectrophotometer with samples prepared as solutions in HPLC ethanol.  
Elemental combustion analyses were either recorded on Carlo-Erba instrument 1106 
analyser, in-house, or were performed either by Medac Ltd (Brunel Science Centre, 
Egham, Surrey, TW20 0JZ) or by the School of Pharmacy at London University (29-
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39 Brunswick Square, London, WC1N 1AX) using an Elemental Analyser, Model 
1108 (Carlo-Erba) and a Sartorius Ultra Micro Balance 4504MP8.  
Parallel syntheses were carried out in a ‘Green House’ system (Radleys). Reactions 
needing microwave irradiation were carried out in a Biotage InitiatorTM Sixty 
Microwave apparatus. The ‘hold temperature’ mode was activated in all the 
experiments, unless otherwise stated. All samples were prepared under argon and 
pre-stirred in the reactor for 30 seconds before being irradiated. 
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7.4 Index of Compounds Synthesised 
 
6-Cyclohexylmethoxy-9H-purin-2-ylamine (32)……………………………………….180 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-isopropylpiperazin-1-yl)ethyl)sulfonyl)phenyl)-9H-
purin-2-amine (48)……………………………….…………………………..…………...185 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-(4-methoxyphenyl)piperazin-1-
yl)ethyl)sulfonyl)phenyl)-9H-purin-2-amine (50)…………………………...………….187 
N-(4-((2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl)sulfonyl)phenyl)-6-
(cyclohexylmethoxy)-9H-purin-2-amine (51)............................................................188 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)ethyl)sulfonyl)phenyl)-9H-purin-2-amine (52)………………………………………188 
1-(2-Amino-(H-purin-6-yl)-4-aza-1-azoniabicyclo[2.2.2]octane chloride (54)………180 
6-Cyclohexylmethoxy-2-fluoro-9H-purine (55)……………………………………...…181 
2-(4-(Tert-butoxycarbonylamino)phenylthio)acetic acid (57)……………………...…182 
Tert-butyl 4-(2-oxo-2-(piperidin-1-yl)ethylthio)phenylcarbamate (58)…………….…182 
2-(4-(6-(Cyclohexylmethoxy)-7H-purin-2-ylamino)phenylthio)-1-(piperidin-1-
yl)ethanone (59)…………………………………………………………………………..183 
6-(Cyclohexylmethoxy)-N-(4-(2-(piperidin-1-yl)ethylthio)phenyl)-7H-purin-2-amine 
(60)…………………………………………………………………………………………184 
3-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-benzenesulfonyl]-
propan-1-ol (63).......................................................................................................193 
3-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-benzenesulfonyl]-
propionic acid methyl ester (64)……………………………………………………...…193 
4-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-phenyl]-butan-1-ol 
(65)…………………………………………………………………………………………198 
Methyl-4-cyclohexyl-2-(4-(6-(cyclohexylmethoxy)-9H-purin-2-
ylamino)phenyl)butanoate (66)................................................................................197 
Methyl 2-(4-aminophenylthio)acetate (67)……………………………………………..189 
Methyl 2-(4-(tert-butoxycarbonylamino)phenylthio)acetate (68)..........................…190 
Methyl 2-(4-(tert-butoxycarbonylamino)phenylsulfonyl)acetate (69)………………..190 
Methyl-2-(4-(tert-butoxycarbonylamino)phenylsulfonyl)-3-cyclohexylpropanoate 
(70)…………………………………………………………………………………………191 
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[4-(1-Cyclohexyl-3-hydroxy-propane-2-sulfonyl)-phenyl]-carbamic acid tert-butyl 
ester (71)…………………………………………………………………………………..192 
 (4-Nitro-phenyl)-acetic acid methyl ester (73)………………………………………...194 
2-Cyclohexylacetaldehyde (79)…………………………………………………………195 
4-Cyclohexyl-2-(4-nitro-phenyl)-but-2-enoic acid methyl ester (78)………………...195 
2-(4-Amino-phenyl)-4-cyclohexyl-butyric acid methyl ester (83)…………………….196 
2-(4-Amino-phenyl)-4-cyclohexyl-butan-1-ol (84) ………………………………….…197 
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)phenyl)-3-(3-(4-methylpiperazin-1-
yl)ethyl)urea (88)......................................................................................................212 
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)phenyl)-3-(3-(4-methylpiperazin-1-
yl)propyl)urea (89)...................................................................................................206 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)ethyl)benzenesulfonamide (90)............................................................................209 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)propyl)benzenesulfonamide (91).........................................................................203 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)ethyl)benzamide (92) ..........................................................................................210 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)propyl)benzamide (93).........................................................................................203 
6-(Cyclohexylmethoxy)-N-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-9H-purin-2-
amine (94)…………………………………………………………………………………204 
N-(4-(3-(4-Methylpiperazin-1-yl)propoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (95)…………………………………………………………………………………214 
1-(3-(4-Methylpiperazin-1-yl)propyl)-3-(4-nitrophenyl)urea (97)………………….…205 
1-(3-(4-Methylpiperazin-1-yl)ethyl)-3-(4-nitrophenyl)urea (98)………………………211 
1-(4-Aminophenyl)-3-(3-(4-methylpiperazin-1-yl)propyl)urea (99)…………………..205 
1-(4-Aminophenyl)-3-(3-(4-methylpiperazin-1-yl)ethyl)urea (100)…………………..211 
N-[3-(4-Methyl-piperazin-1-yl)-ethyl]-4-nitro-benzamide (103)………………………207 
N-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-nitro-benzenesulfonamide (104)…………199 
N-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-nitro-benzamide (105)…………………….199 
N-[3-(4-Methyl-piperazin-1-yl)-ethyl]-4-nitro-benzenesulfonamide (106)…………..207 
4-Amino-N-[3-(4-methyl-piperazin-1-yl)-ethyl]-benzamide (107)……………………209 
4-Amino-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzenesulfonamide (108) ………201 
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4-Amino-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide (109) ………………….202 
4-Amino-N-[3-(4-methyl-piperazin-1-yl)-ethyl]-benzenesulfonamide (110)………...208 
1-(2-Chloro-ethoxy)-4-nitro-benzene (112) ……………………………………………200 
1-Methyl-4-[2-(4-nitro-phenoxy)-ethyl]-piperazine (113) …………………………….201 
4-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-phenylamine (114)………………………...…202 
1-(3-Bromopropoxy)-4-nitrobenzene (116)…………………………………………….213 
1-(3-(4-Nitrophenoxy)propyl)-4-methylpiperazine (117)……………………………...213 
4-(3-(4-Methylpiperazin-1-yl)propoxy)benzenamine (118)…………………………..214 
N,N-dimethyl-2-(4-nitrophenoxy)ethanamine (119)…………………………………..217 
1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine (120)…………………………………………..218 
1-(2-(4-Nitrophenoxy)ethyl)piperidine (121)…………………………………………...218 
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(132)………………………………………………………………………………………..225 
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7.5 General Procedures 
 
Several related compounds have been synthesised using similar procedures. These 
general protocols are described below. All experiments were conducted under an 
inert atmosphere (N2 or Ar), unless otherwise stated. Any variation to these 
specifications is indicated within the synthetic procedure and analytical 
characterisation of a specific compound. 
 
7.5.1 General procedure I: TFA/TFE coupling of anilines to 
fluoropurines 
 
N
H
N
N
N
H
NN
N NH
N
F
R2
R
R3HN
X
+
X
R2
R
 
 
 
 
To a stirred solution of the appropriate free or Boc-protected aniline (2 equiv.) in a 
5% solution of TFA in TFE (5 mL) was added the appropriate 2-fluoropurine (1 
equiv.). The reaction mixture was heated to reflux and stirred for 48 h. The mixture 
was concentrated under reduced pressure, and the residue was taken up in 
saturated aqueous NaHCO3 (15 mL) and extracted with CH2Cl2 (2 x 15 mL). The 
combined organic layers were dried over Na2SO4 and evaporated, and the crude 
product was purified by column chromatography on either silica or KP-NH FLASH+ 
cartridges. In some cases further purification by preparative HPLC (CH3CN/0.1% 
aqueous formic acid 1:1) was required to obtain the title compound as a white solid. 
R  =  H  or  o-cyclohexylmethyl; 
R2 =  H  or tert-butyloxycarbonyl; 
R3 =  H, methyl, ethyl or isopropyl; 
X  =  Sidechain. 
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7.5.2 General procedure II: Solution-Phase Library Synthesis of 6-
(cyclohexylmethoxy)-N-(4-((2-aminoethyl)sulfonyl)phenyl)-9H-purin-
2-amines 
 
 
 
To a stirred solution of 6-(cyclohexylmethoxy)-N-(4-(2-(piperidin-1-
yl)ethylthio)phenyl)-7H-purin-2-amine (59) (100 mg, 0.21 mmol) in CH2Cl2 (5 mL) 
was added mCPBA (170 mg, 1.0 mmol) and the reaction was stirred at room 
temperature for 5 min. The appropriate amine (1.29 mmol) was added and the 
reaction mixture was stirred at room temperature for 18 h. The reaction mixture was 
diluted with CH2Cl2 (30 mL) and washed with saturated aqueous NaHCO3 (2 x 30 
mL), dried over Na2SO4 and concentrated under reduced pressure to yield a crude 
product that was purified by flash chromatography on KP-NH silica cartridges (EtOAc 
or EtOAc/MeOH 9:1). 
 
7.5.3 General procedure III: Solution-phase library synthesis of 4-
nitroarylethyleneamines 
 
O2N
X
Cl
O2N
X
N
R1
R2
        
 
 
In a microwave vial, to a stirred solution of the appropriate chloride (1 equiv.) in 
acetonitrile (10 mL) was added the appropriate amine (6 equiv.). The reaction 
mixture was heated for 30 min at 140 °C under micro wave irradiation. The mixture 
X  =  O, NH, S, CH2, CH2SO2 
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was concentrated under reduced pressure and the residue was taken up in water (20 
mL) and extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were dried 
over Na2SO4 and evaporated. Unless otherwise stated, the product obtained was 
used in the following step without further purification. 
 
7.5.4 General procedure IV: Catalytic hydrogenation of nitroarenes 
 
O2N
X
H2N
X
 
 
To a stirred solution of the appropriate nitrobenzene derivative in MeOH (25 mL) was 
added a catalytic amount of palladium on activated carbon (10% w/w). The system 
was stirred at room temperature under a hydrogen atmosphere for 18 h. The 
reaction mixture was filtered through a pad of celite and the filtrate was evaporated 
in vacuo to yield the desired product in quantitative yield and without need for further 
purification unless otherwise stated. 
 
 
7.5.5 General procedure V: 8-alkylation of purines 
 
 
To a stirred solution of diisopropylamine in THF (1.5 mL) at -78 °C was added nBuLi 
(2.5 M in hexane). The mixture was stirred at -78 °C for 5 minutes before adding 
dropwise to a stirred solution of 6-(cyclohexylmethoxy)-2-fluoro-9-(tetrahydro-2H-
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pyran-2-yl)-9H-purine (55) in THF (2.5 mL) at -78 °C. After 5 minutes, a sol ution of 
MeI in THF (1 mL) was added dropwise, and the mixture was allowed to warm up to 
room temperature and stirred for 18 h. The mixture was concentrated under reduced 
pressure and the crude product was purified by flash chromatography on silica 
(EtOAc/Hexane 3:7). 
 
7.5.6 General procedure VI: Deprotection of 9-THP purines 
 
 
To a solution of the starting purine in 5 mL of isopropanol were added 0.5 mL TFA 
and 0.5 mL water. The solution was heated at 75 °C for 2 h. The mixture was 
concentrated under reduced pressure and the crude product was purified by flash 
chromatography on silica (EtOAc/Hexane 1:1).  
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7.6 Experimental procedures  
 
1-(2-Amino-(H-purin-6-yl)-4-aza-1-azoniabicyclo[2.2.2]octane chloride (54) 254 
 
N
N N
H
N
H2N
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N N
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Cl Cl
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DABCO (6.6 g, 0.58 mol) was added to a solution of 2-amino-6-chloropurine (54) (5 
g, 0.29 mol) in DMSO (75 mL) and the mixture was stirred at room temperature for 
18 h. The precipitate formed was filtered, washed with ether and dried to give the 
title compound as a white solid (10.5 g, 100%). 
mp: decomposes at 230 °C; 1H NMR (300 MHz, D2O) δ 3.37 (6H, t, J = 10 Hz, 
N(CH2)3), 4.15 (3H, t, J = 10 Hz, N+(CH2)3), 8.17 (1H, s, H-8); 13C NMR (75 MHz, 
D2O) δ 38.7 (NCH2), 53.4 (NCH2), 116.0, 143.7, 151.2, 158.2 (C-2). 
 
6-Cyclohexylmethoxy-9H-purin-2-ylamine (32) 254 
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Cyclohexylmethanol (17.6 mL, 0.14 mol) was added dropwise to a suspension of 
NaH (2.6 g, 0.10 mol) in DMSO (50 mL), and the mixture was stirred at room 
temperature for 1 h. 54 (9.9 g, 0.34 mol) was added in portions and the mixture was 
stirred at room temperature for 24 h. The reaction was quenched with water (250 
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mL) and glacial acetic acid was added until pH neutral. The white precipitate formed 
was filtered, washed with water and ether and dried, yielding the title compound as a 
white solid (6.9 g, 84%). 
 
Rf = 0.41 (EtOAc/MeOH 9:1); m.p.: 195-197 °C 1H NMR (300 MHz, DMSO) δ 1.21 
(5H, m, cyclohexyl), 1.74 (6H, m, cyclohexyl), 4.21 (2H, d, J = 6 Hz, CH2O), 6.21 
(2H, s, NH2), 7.81 (1H, s, H-8); 13C NMR (75 MHz, DMSO) δ 25.6, 26.4, 29.6, 37.2, 
70.8 (CH2-O), 153.3, 142.9, 159.3 (C-2), 160.1 (C-O); MS(ES+) m/z 248.2 [M + H]+. 
 
6-Cyclohexylmethoxy-2-fluoro-9H-purine (55) 95 
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A 50% (w/w) aqueous solution of HBF4 (40 mL) was brought to -5 °C. 32 (6.9 g, 0.28 
mol) was then added in one portion. NaNO2 (4.2 g, 0.76 mol) was dissolved in water 
(50 mL) and added dropwise, ensuring that the temperature remained below 0 °C. 
The temperature was raised to 20 °C and the mixture  was stirred for 18 h. The 
solution was neutralised with Na2CO3 and the resulting precipitate was filtered and 
stirred in EtOAc (3 x 100 mL). The combined filtrates were concentrated under 
reduced pressure, yielding the title compound as a white solid (2.3 g, 35%). 
 
Rf = 0.45 (EtOAc/MeOH 9:1); m.p.: 173-175 °C 1H NMR (300 MHz, DMSO) δ 1.20 
(5H, m, cyclohexyl), 1.79 (6H, m, cyclohexyl), 4.33 (2H, d, J = 6 Hz, CH2O), 8.38 
(1H, s, H-8); 13C NMR (75 MHz, DMSO) δ 24.5, 25.8, 30.1, 36.8, 72.9 (CH2-O), 
154.5, 144.2, 160.1 (C-2), 162.0 (C-O), 168.0 (C-F); MS(ES+) m/z 251.2 [M + H]+. 
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2-(4-(Tert-butoxycarbonylamino)phenylthio)acetic acid (57) 255 
 
 
 
                             56                                                         57 
 
To 2-(4-aminophenylthio)acetic acid (5.0 g, 0.27 mol) in a 2:1 mixture of dioxane and 
water (75 mL) was added triethylamine (7.2 mL, 0.54 mol), followed by di-tert-butyl 
dicarbonate (11.9 g, 0.54 mol). The reaction mixture was stirred at room temperature 
for 18 h. The mixture was concentrated under reduced pressure and 3 M HCl was 
added until pH neutral. The resulting precipitate was filtered, washed with water and 
dried, yielding the title compound as a light yellow solid (7.2 g, 93%). 
 
Rf = 0.54 (EtOAc/MeOH 9:1); m.p.: 153-155 °C 1H NMR (300 MHz, DMSO) δ 1.47 
(9H, s, tBu), 3.66 (2H, s, SCH2), 7.30 (2H, d, J = 10 Hz, Ar-H), 7.40 (2H, d, J = 10 
Hz, Ar-H), 9.42 (1H, s, NH); 13C NMR (75 MHz, DMSO) δ 28.4, 36.9, 79.5, 127.6, 
130.7, 138.7, 153.0, 175.5 (NHCO), 181.1 (COOH); MS(ES+) m/z 284.5 [M + H]+. 
 
Tert-butyl 4-(2-oxo-2-(piperidin-1-yl)ethylthio)phenylcarbamate (58) 167 
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To 2-(4-(tert-butoxycarbonylamino)phenylthio)acetic acid (9.85 g, 0.25 mol) in THF 
(25 mL) was added thionyl chloride (17.6 mL, 0.38 mol), followed by DMF (0.1 mL). 
The mixture was stirred for 3 h at room temperature, then concentrated under 
reduced pressure and the residue was taken up in THF (25 mL). The resulting 
solution was added dropwise to piperidine (10 mL, 0.10 mol) in THF (10 mL). The 
mixture was stirred for 18 h at room temperature, concentrated under reduced 
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pressure and the residue was dissolved in CH2Cl2 (30 mL). The solution was washed 
with brine (30 mL) and the organic phase was dried over Na2SO4 and evaporated to 
give an orange oil. The crude product was purified by flash chromatography using a 
gradient solvent system (EtOAc\Hexane 3:7  1:1), yielding the title compound as a 
white solid (5.4 g, 77%). 
 
Rf = 0.31 (EtOAc/MeOH 9:1); mp: 118-120 oC; IR (cm-1) 3233, 3048, 2940, 2162, 
1697, 1593; 1H NMR (300 MHz, CDCl3) δ 1.43 (9H, s, tBu), 1.54 (6H, m, piperidine), 
3.32 (2H, t, J = 6 Hz, NCH2), 3.46 (2H, t, J = 6 Hz, NCH2), 3.60 (2H, s, SCH2), 6.80 
(1H, s, NH), 7.26 (2H, d, J = 9 Hz, Ar-H), 7.31 (2H, d, J = 9 Hz, Ar-H); 13C NMR (75 
MHz, CDCl3) δ 24.7, 25.9, 26.8, 28.7, 38.4, 43.5, 48.0, 81.0, 119.3, 128.1, 132.9, 
138.7, 153.0 (CONR2), 167.4 (NHCOOtBu); MS(ES+) m/z 351.2 [M + H]+. 
 
2-(4-(6-(Cyclohexylmethoxy)-7H-purin-2-ylamino)phenylthio)-1-(piperidin-1-
yl)ethanone (59) 167 
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The compound was prepared according to General Procedure I from tert-butyl 4-(2-
oxo-2-(piperidin-1-yl)ethylthio)phenylcarbamate (3.6 g, 0.10 mol) and 6-
(cyclohexylmethoxy)-2-fluoro-9H-purine (1.3 g, 0.05 mol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1), yielding the title 
compound as an off-white solid (1.4 g, 61%). 
Rf = 0.41 (EtOAc/MeOH 9:1); mp: 198-200 oC; IR (cm-1) 3302, 2916, 1580, 1592, 
1447; 1H NMR (300 MHz, CDCl3) δ 1.05-1.85 (17H, m, cyclohexyl + piperidine), 3.40 
(2H, t, J = 6 Hz, NCH2), 3.49 (2H, t, J = 6 Hz, NCH2), 3.81 (2H, s, SCH2), 4.33 (2H, 
d, J = 6 Hz, CH2O), 7.34 (2H, d, J = 9 Hz, Ar-H), 7.81 (2H, d, J = 9 Hz, Ar-H), 7.99 
(1H, s, H-8), 9.41 (1H, s, NH); 13C NMR (75 MHz, CDCl3) δ 25.5, 25.7, 26.3, 29.6, 
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37.2, 37.6, 42.6, 47.0, 71.4, 119.1, 131.6, 155.5 (purine C-2), 166.5 (CONR2); 
MS(ES+) m/z 481.8 [M + H]+. 
 
 
6-(Cyclohexylmethoxy)-N-(4-(2-(piperidin-1-yl)ethylthio)phenyl)-7H-purin-2-
amine (60) 167 
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To 2-(4-(6-(cyclohexylmethoxy)-9H-purin-2-ylamino)phenylthio)-1-(piperidin-1-
yl)ethanone (1.4 g, 0.29 mol) in anhydrous THF (20 mL) cooled to 0 °C was added 
LiAlH4 (1M in THF, 6 mL, 0.05 mol) dropwise. The reaction mixture was allowed to 
warm to room temperature and stirred for 3 h. The mixture was quenched adding 
dropwise: water (0.2 mL), 15% (w/v) aqueous NaOH (0.2 mL) and water (0.6 mL). 
The resulting grey suspension was stirred for 30 min. The white precipitate was 
filtered through a pad of celite and the filtrate was evaporated to give an oil. This was 
taken up in CH2Cl2 (20 mL) and the solution was washed with water (2 x 20 mL), 
dried over Na2SO4, evaporated and the resulting beige solid was purified by flash 
chromatography (CH2Cl2/MeOH 95:5), yielding the title compound as an off-white 
solid (0.8 g, 60%). 
 
Rf = 0.25 (EtOAc/MeOH 9:1); mp: 125-126 oC; 1H NMR (300 MHz, CDCl3) δ 1.08-
1.68 (11H, m, cyclohexyl), 1.75-1.86 (6H, m, piperidine), 2.39 (2H, t, J = 6 Hz, 
NCH2), 2.52 (2H, t, J = 6 Hz, NCH2), 2.65 (2H, t, J = 6 Hz, NCH2), 2.94 (2H, t, J = 6 
Hz, SCH2), 4.24 (2H, d, J = 6 Hz, CH2O), 7.21 (2H, d, J = 9 Hz, Ar-H), 7.42 (2H, d, J 
= 9 Hz, Ar-H), 8.02 (1H, s, H-8), 9.36 (1H, s, NH); 13C NMR (75 MHz, CDCl3) δ 24.4, 
25.5, 25.9, 26.4, 29.6, 32.2, 37.3, 54.2, 58.5, 71.5, 119.5, 126.9, 131.0, 140.3, 155.7 
(purine C-2); MS(ES+) m/z 467.2 [M + H]+. 
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6-(Cyclohexylmethoxy)-N-(4-((2-(4-methylpiperazin-1-yl)ethyl)sulfonyl)phenyl)-
9H-purin-2-amine (44). 
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Compound 44 was prepared from N-methylpiperazine (0.14 mL, 1.29 mmol) 
according to General Procedure II and was obtained as an off-white solid (92 mg, 
75%). 
Rf  = 0.28 (EtOAc/MeOH 9:1); mp: 135-137 °C; IR (cm-1) 2926, 2844, 1590, 1535, 
1499, 1444; λmax (EtOH)/nm: 312; 1H NMR (300 MHz, CDCl3) δ 0.78-1.18 (5H, m, 
cyclohexyl), 1.65-1.84 (6H, m, cyclohexyl), 2.18 (3H, s, NMe), 2.37 (8H, m, 
piperazine ring), 2.73 (2H, t, J = 7 Hz, CH2N), 3.29 (2H, t, J = 7 Hz, CH2SO2), 4.27 
(2H, d, J = 6 Hz, CH2Cy), 7.41 (1H, s, NH), 7.72 (2H, d, J = 9 Hz, Ar-H), 7.76 (2H, d, 
J = 9 Hz, Ar-H), 7.83 (1H, s, H-8); 13C NMR (75 MHz, CDCl3) δ 26.0, 26.7, 30.1, 
37.6, 46.0, 51.6, 52.8, 54.1, 55.0, 72.9, 115.6, 118.0, 129.6, 130.8, 139.6, 145.8, 
155.1, 161.1; MS(ES+) m/z 514.3 [M + H]+; anal. calcd for C25H35N7O3S: C, 58.46, H, 
6.87, N, 19.09%; found: C, 58.65, H, 6.49, N, 19.11%. 
 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-isopropylpiperazin-1-
yl)ethyl)sulfonyl)phenyl)-9H-purin-2-amine (48). 
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Compound 48 was prepared from N-isopropylpiperazine (0.19 mL, 1.29 mmol) 
according to General Procedure II and was obtained as an off-white solid (90 mg, 
51%). 
Rf  = 0.16 (EtOAc/MeOH 9:1); mp: 110-112 °C; IR (cm-1) 2924, 2851, 1589, 1531, 
1496, 1446; λmax (EtOH)/nm 313 ; 1H NMR (300 MHz, CDCl3) δ 1.0 (6H, d, J = 6 Hz, 
CH(CH3)2), 1.27-1.78 (11H, m, cyclohexyl), 2.50 (8H, m, piperazine), 2.71 (1H, 
septet, J = 6 Hz, CH(CH3)2), 2.80 (2H, t, J = 7 Hz, CH2N), 3.31 (2H, t, J = 7 Hz, 
CH2SO2), 4.33 (2H, d, J = 6 Hz, CH2Cy), 7.61 (1H, s, NH), 7.78 (2H, d, J = 9 Hz, Ar-
H), 7.82 (2H, d, J = 9 Hz, Ar-H), 7.93 (1H, s, H-8); 13C NMR (75 MHz, CDCl3) δ 18.8, 
27.3, 28.0, 31.2, 39.1, 46.5, 53.0, 53.8, 54.6, 56.2, 73.6, 119.1, 130.7, 132.0, 141.7, 
148.1, 157.1, 161.7; MS(ES+) m/z 542.4 [M + H]+; anal. calcd for C27H39N7O3S: C, 
59.86, H, 7.26, N, 18.10%; found: C, 59.68, H, 7.01, N, 16.25%. 
 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-phenylpiperazin-1-yl)ethyl)sulfonyl)phenyl)-
9H-purin-2-amine (49). 
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Compound 49 was prepared from N-phenylpiperazine (0.195 mL, 1.29 mmol) 
according to General Procedure II and was obtained as a light yellow solid (125 mg, 
92%). 
Rf  = 0.27 (EtOAc); mp: 140-142 °C; IR (cm-1): 2925, 2848, 1591, 1531, 1495, 
1448; λmax (EtOH)/nm: 312.5; 1H NMR (300 MHz, CDCl3): δ 1.00-1.81 (11H, m, 
cyclohexyl), 2.47 (4H, t, J = 5 Hz, NCH2), 2.77 (2H, t, J = 7 Hz, CH2N), 3.02 (4H, t, J 
= 5 Hz, NCH2), 3.28 (2H, t, J = 7 Hz, CH2SO2), 4.26 (2H, d, J = 6 Hz, CH2Cy), 6.77 
(2H, t, J = 8 Hz, Ar-H), 7.14 (2H, t, J = 7 Hz, Ar-H), 7.75 (6H, m, Ar-H + H-8); 13C 
NMR (125 MHz, CDCl3): δ 5.1, 8.2, 9.0, 15.1, 18.5, 25.7, 26.4, 29.8, 37.3, 48.7, 48.9, 
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49.1, 51.5, 52.9, 72.7, 76.8, 77.1, 77.3, 100.0, 109.0, 116.2, 117.9, 120.1, 129.22, 
129.5, 145.3, 151.0, 154.9; MS(ES+) m/z 576.3 [M + H]+; anal. calcd for 
C30H37N7O3S: C, 62.59, H, 6.48, N, 17.03%; found: C, 62.58, H, 6.47, N, 17.01%. 
 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-(4-methoxyphenyl)piperazin-1-
yl)ethyl)sulfonyl)phenyl)-9H-purin-2-amine (50). 
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Compound 50 was prepared from 1-(4-methoxyphenyl)piperazine (0.245 g, 1.29 
mmol) according to General Procedure II and was obtained as a yellow solid (122 
mg, 91%). 
Rf  = 0.30 (EtOAc); mp: 185-187 °C; IR (cm -1): 2927, 2848, 2158, 2023, 1980, 1591, 
1531, 1496, 1448; λmax (EtOH)/nm : 313; 1H NMR (300 MHz, CDCl3): δ 1.11-1.92 
(11H, m, cyclohexyl), 2.57 (4H, t, J = 5 Hz, NCH2), 2.89 (2H, t, J = 7 Hz, CH2N), 3.00 
(4H, t, J = 5 Hz, NCH2), 3.37 (2H, t, J = 7 Hz, CH2SO2), 3.75 (3H, s, OMe), 4.35 (2H, 
d, J = 6 Hz, CH2Cy), 6.82 (2H, d, J = 9 Hz, Ar-H), 6.86 (2H, d, J = 9 Hz, Ar-H), 7.40 
(1H, s, NH), 7.83 (2H, d, J = 9 Hz, Ar-H), 7.87 (2H, d, J = 9 Hz, Ar-H), 7.95 (1H, s, H-
8); 13C NMR (125 MHz, CDCl3): δ 25.7, 26.4, 29.8, 37.3, 48.8, 50.4, 51.4, 52.9, 53.8, 
55.6, 66.5, 72.7, 76.9, 114.5, 117.8, 118.4, 129.4, 130.8, 145.4, 154.1, 154.9; 
MS(ES+) m/z 606.4 [M + H]+; anal. calcd for C31H39N7O4S: C, 61.47, H, 6.49, N, 
16.19%; found: C, 61.18, H, 6.41, N, 16.01%. 
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N-(4-((2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl)sulfonyl)phenyl)-6-
(cyclohexylmethoxy)-9H-purin-2-amine (51). 
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Compound 51 was prepared from 1-(4-chlorophenyl)piperazine (0.250 g, 1.29 mmol) 
according to General Procedure II and was obtained as a light yellow solid (102 mg, 
84%). 
Rf  = 0.23 (EtOAc); mp: 149-151 °C; IR (cm-1): 2924, 1726, 1591, 1532, 1494, 
1449; λmax (EtOH)/nm: 292; 1H NMR (300 MHz, CDCl3): δ 1.14-1.95 (11H, m, 
cyclohexyl), 2.55 (4H, t, J = 5 Hz, NCH2), 2.86 (2H, t, J = 8 Hz, CH2N), 3.06 (4H, t, J 
= 5 Hz, NCH2), 3.35 (2H, t, J = 8 Hz, CH2SO2), 4.37 (2H, d, J = 6 Hz, CH2Cy), 6.80 
(2H, d, J = 9 Hz, Ar-H), 7.19 (2H, d, J = 9 Hz, Ar-H), 7.35 (1H, s, NH), 7.83 (2H, d, J 
= 9 Hz, Ar-H), 7.87 (2H, d, J = 9 Hz, Ar-H), 10.0 (1H, s, H-8); 13C NMR (125 MHz, 
CDCl3): δ 15.0, 19.0, 21.0, 21.5, 23.0, 25.7, 26.4, 29.8, 37.3, 48.9, 49.0, 51.4, 52.6, 
53.8, 60.5, 64.5, 72.6, 117.4, 117.8, 124.9, 129.0, 129.4, 129.6, 130.7, 145.5, 149.6, 
154.8; MS(ES+) m/z 610.3 [M(35Cl) + H]+, 612.3 [M(37Cl) + H+]; anal. calcd for 
C30H36ClN7O3S: C, 59.05, H, 5.95, N, 16.07%; found: C, 59.08, H, 6.15, N, 16.03%. 
 
6-(Cyclohexylmethoxy)-N-(4-((2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)ethyl)sulfonyl)phenyl)-9H-purin-2-amine (52). 
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Compound 52 was prepared from 1-(4-(trifluoromethyl)phenyl)piperazine (0.30 g, 
1.29 mmol) according to General Procedure II and was obtained as a yellow solid 
(120 mg, 95%). 
Rf = 0.28 (EtOAc); mp: 160-162 °C; IR (cm-1) 2937, 2338, 2112, 2083, 1596, 1524, 
1494, 1448; λmax (EtOH)/nm: 292; 1H NMR (500 MHz, CDCl3): δ 1.28-1.78 (11H, m, 
cyclohexyl), 2.56 (4H, t, J = 5 Hz, NCH2), 2.87 (2H, t, J = 8 Hz, CH2N), 3.19 (4H, t, J 
= 5 Hz, NCH2), 3.36 (2H, t, J = 8 Hz, CH2SO2), 4.38 (2H, d, J = 6 Hz, CH2Cy), 6.89 
(2H, d, J = 9 Hz, Ar-H), 7.33 (1H, s, NH), 7.48 (2H, d, J = 8.7, Ar-H), 7.83 (2H, d, J = 
9 Hz, Ar-H), 7.87 (2H, d, J = 9 Hz, Ar-H),  9.58 (1H, s, H-8). 13C NMR (125 MHz, 
CDCl3): δ 15.2, 18.7, 25.7, 26.4, 29.8, 37.3, 47.8, 48.8, 51.4, 52.6, 53.9, 66.5, 66.7, 
72.7, 76.8, 77.1, 77.3, 114.7, 117.8, 121.0, 124.5, 126.4, 129.4, 130.9, 145.3, 153.1, 
154.9; MS(ES+) m/z 644.3 [M + H]+; anal. calcd for C31H36F3N7O3S: C, 57.84, H, 
5.69, N, 14.38%; found: C, 57.69, H, 5.69, N, 14.38%. 
 
Methyl 2-(4-aminophenylthio)acetate (67) 256 
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To a stirred solution of 2-(4-aminophenylthio)acetic acid (4 g, 14 mmol) in MeOH (50 
mL) at 0 °C was added thionyl chloride (5 mL, 70 mm ol). After 10 min at 0 °C, the 
reaction mixture was heated to reflux and stirred for 4 h. The mixture was 
concentrated under reduced pressure and the residue was taken up in saturated 
aqueous NaHCO3 (30 mL) and extracted with EtOAc (2 x 30 mL). The combined 
organic layers were dried over Na2SO4 and evaporated to yield the title compound as 
a light yellow solid (4.1 g, 99%). 
Rf  = 0.35 (EtOAc/Hexane 2:3); mp: 166-170 °C  1H NMR (300 MHz, CDCl3) δ 3.39 
(2H, s, SCH2), 3.67 (3H, s, COOMe), 6.53 (2H, d, J = 9 Hz, Ar-H), 7.21 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 32.1, 51.2, 115.4, 126.4, 142.1, 170.4; 
MS(ES+) m/z 199.0 [M + H]+. 
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Methyl 2-(4-(tert-butoxycarbonylamino)phenylthio)acetate (68) 257-258  
 
 
 
                            67                                                         68 
 
To a stirred solution of methyl-2-(4-aminophenylthio)acetate (400 mg, 2 mmol) in a 
2:1 solution of dioxane and water (15 mL) was added triethylamine (0.5 mL, 4 mmol), 
then di-tert-butyldicarbonate (873 mg, 4 mmol). The mixture was stirred at room 
temperature for 18 h. The mixture was concentrated under reduced pressure and 3 
M HCl was added until pH neutral. The resulting white precipitate was filtered, 
washed with water and dried, to give the title compound as a white solid (610 mg, 
99%).  
Rf  = 0.35 (EtOAc/Hexane 2:3); mp: 146-149 °C  1H NMR (300 MHz, CDCl3) δ 3.47 
(2H, s, SCH2), 3.57 (3H, s, COOMe), 7.03 (2H, d, J = 9 Hz, Ar-H), 7.81 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 28.4, 33.0, 52.8, 116.6, 122.5, 144.4, 172.7; 
MS(ES+) m/z 298.7 [M + H]+. 
 
Methyl 2-(4-(tert-butoxycarbonylamino)phenylsulfonyl)acetate (69) 257-258 
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To a stirred solution of methyl 2-(4-(tert-butoxycarbonylamino)phenylthio) acetate 
(400 mg, 1.35 mmol) in CH2Cl2 (10 mL) was added mCPBA (1.2 g, 6 mmol). The 
mixture was stirred at room temperature for 2 h. The mixture was concentrated 
under reduced pressure and the residue was taken up in EtOAc (15 mL) and washed 
with saturated aqueous NaHCO3 (2 x 20 mL). The organic layer was dried over 
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Na2SO4 and evaporated. The crude product was purified by column chromatography 
(EtOAc/Hexane 1:2) to yield the title compound as a white solid (300 mg, 75%). 
 
Rf  = 0.35 (EtOAc/Hexane 2:3); mp: 158-160 °C  1H NMR (300 MHz, CDCl3) δ 3.72 
(2H, s, SCH2), 4.11 (3H, s, COOMe), 6.99 (2H, d, J = 9 Hz, Ar-H), 7.91 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 28.4, 33.0, 52.8, 79.7, 118.2, 128.5, 132.1, 
143.0, 152.7; MS(ES+) m/z 330.9 [M + H]+. 
 
Methyl 2-(4-(tert-butoxycarbonylamino)phenylsulfonyl)-3-
cyclohexylpropanoate (70) 
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To stirred methyl 2-(4-(tert-butoxycarbonylamino)phenylsulfonyl) acetate (200 mg, 
0.6 mmol) in DMF (10 mL) at 0° C was added NaH (14 mg, 0.6 mmol). After 10 min, 
(bromomethyl)cyclohexane (0.33 mL, 2.4 mmol) was added and the mixture was 
allowed to warm up to room temperature and stirred for 18 h. Saturated aqueous 
NH4Cl (25 mL) was added and the mixture was extracted with Et2O (2 x 30 mL). The 
combined organic layers were dried over Na2SO4 and evaporated. The crude 
product was purified by medium pressure column chromatography (EtOAc/Hexane 
2:3) to give the title compound as a white solid (154 mg, 61%). 
 
Rf  = 0.8 (EtOAc/Hexane 2:3); mp: decomposes > 211.7 °C; IR (cm -1) 2924, 2850, 
2333, 2360, 1737, 1579, 1523, 1446; λmax (EtOH)/nm: 245.5; 1H NMR (300 MHz, 
CDCl3) δ 0.89-1.85 (13H, m, CH2Cy + Cy), 3.72 (3H, s, COOMe), 4.03 (1H, dd, J = 
10; 4 Hz, SO2CH), 6.92 (1H, s, NH), 7.57 (2H, d, J = 9 Hz, Ar-H), 7.76 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3): δ 25.5, 25.6, 25.9, 26.2, 29.4, 33.2, 37.3, 
47.8, 68.8, 71.9, 113.4, 117.3, 127.4, 130.0, 139.9, 146.9, 155.1, 155.3, 160.0, 
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167.2; MS(ES+) m/z 426.3 [M + H]+; anal. calcd for C21H31NO6S: C, 59.27, H, 7.34, 
N, 3.29%; found: C, 59.29, H, 7.38, N, 3.28%. 
 
 
[4-(1-Cyclohexyl-3-hydroxy-propane-2-sulfonyl)-phenyl]-carbamic acid tert-
butyl ester (71) 
 
BocHN
S COOMe
O O
BocHN
S
O O
OH
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To stirred methyl 2-(4-(tert-butoxycarbonylamino)phenylsulfonyl)-3-
cyclohexylpropanoate (100 mg, 0.2 mmol) in THF (5 mL) at -78 °C was added 1 M 
DIBAH in THF (0.25 mL, 0.2 mmol). After 3 h of stirring at -78 °C, the reaction 
mixture was allowed to warm to room temperature. DIBAH (0.77 mL) was added and 
the reaction mixture was stirred for 18 h. Saturated aqueous potassium sodium 
tartrate (70 mL) was added to the mixture, which was extracted with CH2Cl2 (6 x 50 
mL). The combined organic layers were dried over Na2SO4 and evaporated. The 
crude product was purified by medium pressure column chromatography 
(EtOAc/Hexane 1:2) and the title compound was isolated as a white solid (56 mg, 
55%). 
 
Rf  = 0.5 (EtOAc/Hexane 2:3); mp: 251.1-252.6 °C; IR (cm-1) 2900, 2842, 2633, 
2450, 1700, 1580, 1577, 1540, 1484; λmax (EtOH)/nm: 245.0; 1H NMR (300 MHz, 
CDCl3) δ 0.68-1.64 (13H, m, CH2Cy + Cy), 3.00 (1H, t, J = 5 Hz, OH), 3.10 (1H, m, 
SO2CH), 3.82 (2H, t, J = 5 Hz, CH2OH), 7.06 (1H, s, NH), 7.60 (2H, d, J = 9 Hz, Ar-
H), 7.86 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3): δ 25.5, 25.6, 25.9, 
26.2, 29.4, 33.2, 37.3, 47.8, 68.8, 71.9, 113.4, 117.3, 127.4, 130.0, 139.9, 146.9, 
155.1, 155.3, 160.0,167.18; MS(ES+) m/z 398.5 [M + H]+; anal. calcd for 
C20H31NO5S: C, 60.43, H, 7.86, N, 3.52%; found: C, 59.69, H, 7.88, N, 3.58%. 
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3-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-
benzenesulfonyl]-propionic acid methyl ester (64) 
BocHN
S COOMe
O O
MeOOC S
N
H
N
N
N
H
N
OO O
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The compound was prepared according to General Procedure I from methyl 2-(4-
(tert-butoxycarbonylamino)phenylsulfonyl)-3-cyclohexylpropanoate (500 mg, 1.18 
mmol) and 6-cyclohexylmethoxy-2-fluoro-9H-purine (150 mg, 0.6 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc) and then by 
preparative HPLC (CH3CN/0.1% aqueous formic acid 1:1). The title compound was 
isolated as a white solid (51 mg, 32%). 
Rf  = 0.28 (EtOAc/MeOH 9:1); mp: decomposes >211 °C; IR (cm-1): 2924, 2850, 
2333, 2360, 1737, 1579, 1523, 1446; λmax (EtOH)/nm: 315; 1H NMR (300 MHz, 
CD3OD) δ 1.0-2.05 (25H, m, 2 x cyclohexyl + CyCH2CHSO2), 3.66 (3H, s, COOMe), 
4.15 (1H, dd, J = 11; 4 Hz, SO2CHCOOMe), 4.40 (2H, d, J = 6 Hz, OCH2Cy), 7.73 
(1H, d, J = 9 Hz, Ar-H), 8.06 (2H, d, J = 9 Hz, Ar-H), 8.10 (1H, s, H-8); 13C NMR (125 
MHz, CDCl3) δ 25.5, 25.6, 25.9, 26.2, 29.4, 33.2, 37.3, 47.8, 68.8, 71.9, 113.4, 
117.3, 127.4, 130.0, 139.9, 146.9, 155.1, 155.3, 160.0, 167.1; MS(ES+) m/z 556.5 
[M + H]+; HRMS calcd for C28H26NO3S [M + H]+ 556.2588, found 556.2589. 
 
3-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-
benzenesulfonyl]-propan-1-ol (63) 
BocHN
S
O O
S
N
H
N
N
N
H
N
OO O
OH HO
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The compound was prepared according to General Procedure I from [4-(1-
cyclohexyl-3-hydroxy-propane-2-sulfonyl)-phenyl]-carbamic acid tert-butyl ester (270 
mg, 0.68 mmol) and 6-cyclohexylmethoxy-2-fluoro-9H-purine (170 mg, 0.68 mmol). 
The crude product was purified by flash chromatography on silica (EtOAc) and then 
by preparative HPLC (CH3CN/0.1% aqueous formic acid 1:1). The title compound 
was isolated as a white solid (54 mg, 39%). 
Rf  = 0.28 (EtOAc/MeOH 9:1); mp: decomposes >236.1 °C; IR (cm-1): IR: 3329, 
3146, 2921, 2850, 1580, 1529, 1496, 1446; λmax (EtOH)/nm: 313.5; 1H NMR (300 
MHz, CD3OD) δ 1.0-1.96 (25H, m, 2 x cyclohexyl + CyCH2CHSO2), 3.21 (1H, m, 
SO2CHCH2OH), 3.83 (2H, dd, J = 12; 5 Hz, CH2OH), 3.87 (2H, dd, J = 12; 5 Hz, 
CH2OH), 4.39 (2H, d, J = 6 Hz, OCH2Cy), 7.78 (1H, d, J = 9 Hz, Ar-H), 8.08 (2H, d, J 
= 9 Hz, Ar-H), 8.10 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 15.0, 15.1, 15.9, 16.2, 
19.4, 23.2, 27.3, 37.1, 58.2, 61.0, 65.8, 103.0, 107.3, 117.5, 120.4, 129.5, 136.9, 
145.1, 155.1, 159.2; MS(ES+) m/z 528.5 [M + H]+; HRMS calcd for C27H37N5O4S [M 
+ H]+ 528.2639, found 528.2639. 
 
(4-Nitro-phenyl)-acetic acid methyl ester (73) 259 
 
O2N
COOH
O2N
COOMe
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To a stirred solution of (4-nitro-phenyl)-acetic acid (5 g, 27 mmol) in methanol (50 
mL) at 0 °C was added thionyl chloride (9.2 mL, 124  mmol). After 10 min at 0 °C, the 
reaction mixture was heated to reflux and stirred for 4 h. The mixture was 
concentrated under reduced pressure and the residue was taken up in saturated 
aqueous NaHCO3 (25 mL) and extracted with EtOAc (2 x 25 mL). The combined 
organic layers were dried over Na2SO4 and evaporated to yield the title compound as 
a yellow solid (5.2 g, 99%). 
Rf = 0.25 (EtOAc/MeOH 9:1); mp: 53-55 oC; 1H NMR (300 MHz, CDCl3) δ 3.70 (3H, 
s, COOMe), 3.74 (2H, s, CH2COOMe), 7.45 (2H, d, J = 9 Hz, Ar-H), 8.16 (2H, d, J = 
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9 Hz, Ar-H); 13C NMR (75 MHz, CDCl3) δ 45.1, 53.3, 128.8, 129.9, 134.1, 135.1, 
168.2; MS(ES+) m/z 197.2 [M + H]+. 
 
2-Cyclohexylacetaldehyde (79) 260 
 
OH
CHO
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To a stirred solution of 2-cyclohexylethanol (0.5 mL, 3.6 mmol) in CH2Cl2 (5 mL) was 
added PCC (1.5 g, 7.2 mmol). The mixture was stirred at room temperature for 3 h. 
The reaction mixture was diluted with ether (35 mL) and stirred vigorously for 30 min, 
then filtered over a pad of celite. The filtrate was washed with saturated aqueous 
NaHCO3 (2 x 20 mL) and dried over Na2SO4 before evaporating the solvent. The 
crude product was purified by taking up in EtOAc (50 mL), filtering through a pad of 
silica and then evaporating the filtrate, affording the title compound as a colourless 
oil (485 mg, 76%). 
Rf = 0.25 (EtOAc/Hexane 1:9); bp: 90-100 oC; 1H NMR (300 MHz, CDCl3) δ 0.9-1.65 
(11H, m, cyclohexyl), 2.01 (2H, d, J = 4.5 Hz, CH2CHO), 9.7 (1H, s, CHO); 13C NMR 
(75 MHz, CDCl3) δ 26.6, 36.7, 51.0, 201.5; MS(ES+) m/z 127.2 [M + H]+. 
 
4-Cyclohexyl-2-(4-nitro-phenyl)-but-2-enoic acid methyl ester (78) 
O2N
COOMe
O2N
COOMe
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In a microwave vial, to a stirred solution of (4-nitro-phenyl)-acetic acid methylester 
(900 mg, 4.6 mmol) in CH3CN (5 mL) at 0 °C was added cyclohexylacetaldehyde 
(3.5 g, 27 mmol) and tetramethylguanidine (0.02 mL, 0.01 mmol). The reaction 
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mixture was heated for 1 h at 120 °C under microwav e irradiation. 3 M HCl was 
added until pH < 4 and the mixture was diluted with water (20 mL) and extracted with 
CH2Cl2 (2 x 25 mL). The combined organic layers were dried over Na2SO4 and 
evaporated. The crude product was purified by medium pressure column 
chromatography (EtOAc/Hexane 2:3) and the title compound was obtained as a 
yellow solid (0.9 g, 54%). 
Rf  = 0.8 (EtOAc/Hexane 1:3); mp: 211 °C; IR (cm-1): 2924, 2851, 1589, 1531, 1497, 
1445; λmax (EtOH)/nm: 275; 1H NMR (300 MHz, CDCl3) δ 0.9-1.9 (11H, m, 
cyclohexyl), 2.23 (2H, d, J = 7.5 Hz, CHCH2Cy), 3.76 (3H, s, COOMe), 7.22 (1H, t, J 
= 7.5 Hz, CHCH2Cy), 7.34 (2H, d, J = 9 Hz, Ar-H), 8.23 (2H, d, J = 9 Hz, Ar-H); 13C 
NMR (125 MHz, CDCl3) δ 21.4, 27.3, 28.0, 31.2, 39.1, 42.7, 47.5, 53.0, 53.6, 54.1, 
54.6, 73.6, 119.2, 130.7, 131.4, 148.1, 157.1, 171.9; MS(ES+) m/z 307.0 [M + H]+; 
HRMS calcd for C17H21NO4 [M + H]+ 307.2544, found 307.2543. 
 
2-(4-Amino-phenyl)-4-cyclohexyl-butyric acid methyl ester (83) 
 
O2N
COOMe
H2N
COOMe
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The compound was prepared according to General Procedure IV from 4-cyclohexyl-
2-(4-nitro-phenyl)-but-2-enoic acid methyl ester (1.5 g, 5 mmol), and was obtained as 
a yellow oil (1.2 g, 99%). 
Rf  = 0.8 (EtOAc/Hexane 1:3); IR (cm-1): 2942, 2581, 1836, 1731, 1426; λmax 
(EtOH)/nm 210; 1H NMR (300 MHz, CDCl3) δ 2.03-0.90 (11H, m, cyclohexyl), 2.23 
(2H, d, J = 7.5 Hz, CHCH2Cy), 3.39 (1H, t, J = 8 Hz, CHCOOMe), 3.64 (3H, s, 
COOMe), 6.68  (2H, d, J = 9 Hz, Ar-H), 7.10  (2H, d, J = 9 Hz, Ar-H), 7.22 (2H, s, 
NH2); 13C NMR (125 MHz, CDCl3) δ 25.4, 28.6, 30.0, 31.9, 33.3, 36.1, 50.5, 52.2, 
116.6, 129.8, 145.3, 173.8; MS(ES+) m/z 276.7 [M + H]+; HRMS calcd for C17H25NO2 
[M + H]+ 276.7657, found 276.7651. 
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Methyl 4-cyclohexyl-2-(4-(6-(cyclohexylmethoxy)-9H-purin-2-
ylamino)phenyl)butanoate (66) 
 
MeOOC
N
H
N
N
N
H
N
O
H2N
COOMe
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The compound was prepared according to General Procedure I from 2-(4-amino-
phenyl)-4-cyclohexyl-butyric acid methyl ester (500 mg, 1.8 mmol) and 6-
(cyclohexylmethoxy)-2-fluoro-9H-purine (230 mg, 0.9 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc) and then by semi-preparative 
HPLC (CH3CN/water 1:1), yielding the title compound as a white solid (205 mg, 
43%). 
Rf  = 0.2 (EtOAc/Hexane 1:1); mp: 110.0-111.7 °C;  IR (cm-1): 3107, 2922, 2848, 
2212, 1730, 1583, 1526, 1446; λmax (EtOH)/nm  274.0; 1H NMR (300 MHz, CD3OD) δ 
1.79-1.05 (26H, m, 2 x cyclohexyl + 2 x CH2), 3.40 (1H, t, J = 7 Hz, CHCOOMe), 
3.59 (3H, s, COOMe), 4.23 (2H, d, J = 6 Hz, OCH2Cy), 7.19 (2H, d, J = 9 Hz, Ar-H) 
7.48 (2H, d, J = 9 Hz, Ar-H), 7.80 (1H, s, NH); 13C NMR (125 MHz, CDCl3) δ 27.2, 
27.7, 27.9, 28.1, 31.2, 32.3, 34.7, 34.8, 36.6, 39.1, 39.2, 52.6, 53.0, 73.4, 121.0, 
129.4, 134.2, 140.8, 141.6, 158.3, 161.9, 177.0; MS(ES+) m/z 506.5 [M + H]+; HRMS 
calcd for C29H39N5O3 [M + H]+ 506.3126, found 506.3128. 
 
2-(4-Amino-phenyl)-4-cyclohexyl-butan-1-ol (84)  
 
H2N
COOMe
H2N
OH
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To a stirred solution of 2-(4-amino-phenyl)-4-cyclohexyl-butyric acid methyl ester (1 
g, 3.6 mmol) in THF (10 mL) at -78 °C was added 1 M  DIBAH in THF (11 mL, 11 
mmol). The mixture was stirred at -78 °C for 3 h an d then at room temperature for 16 
h. Saturated aqueous sodium potassium tartrate (40 mL) was added to the mixture, 
which was extracted with CH2Cl2 (6 x 40 mL). The combined organic layers were 
dried over Na2SO4 and evaporated in vacuo, and the crude product was purified by 
medium pressure column chromatography (EtOAc/Hexane 1:1) yielding the title 
compound as a white solid (0.9 g, 89%). 
Rf  = 0.2 (EtOAc); IR (cm-1): 2942, 2924, 2851, 2581, 1836, 1731, 1426; λmax 
(EtOH)/nm 211.5; 1H NMR (300 MHz, CDCl3) δ 0.68-1.64 (15H, m, Cy + 2 x CH2), 
2.45 (1H, m, CHCH2OH), 2.00 (2H, s, NH2), 3.64 (2H, m, CH2OH), 6.67 (2H, d, J = 9 
Hz, Ar-H), 6.99 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 24.8, 28.1, 
29.3, 30.9, 32.1, 35.8, 50.0, 51.7, 65.9, 116.0, 129.1, 144.2; MS(ES+) m/z 248.3 [M 
+ H]+; HRMS calcd for C16H25NO [M + H]+ 248.3487, found 248.3480. 
 
4-Cyclohexyl-2-[4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-phenyl]-butan-1-
ol (65) 
 
N
H
N
N
N
H
N
O
H2N
OH OH
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The compound was prepared according to General Procedure I from 2-(4-amino-
phenyl)-4-cyclohexyl-butan-1-ol (200 mg, 0.8 mmol) and 6-(cyclohexylmethoxy)-2-
fluoro-9H-purine (101 mg, 0.4 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc) and then by preparative HPLC (CH3CN/water 1:1), 
yielding the title compound as a white solid (105 mg, 42%). 
Rf  = 0.2 (EtOAc/Hexane 1:1); mp: 129.4-129.8 °C;  IR (cm-1): 3439, 2918, 2846, 
2164, 1753, 1604, 1582, 1527,  1449; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, 
CD3OD) δ 0.72-1.83 (26H, m, 2 x cyclohexyl + CH2CH2Cy), 2.63 (1H, m, CHCH2OH), 
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3.64 (2H, ddd, J = 20; 10; 5 Hz, CH2OH), 4.24 (2H, d, J = 6 Hz, OCH2Cy), 6.93 (1H, 
s, H-8), 7.09 (2H, d, J = 9 Hz, Ar-H), 7.41 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 
MHz, CDCl3) δ 27.2, 27.8, 27.8, 27.9, 28.1, 31.0, 31.2, 34.7, 35.1, 36.6, 39.7, 39.5, 
68.8, 68.8, 73.4, 78.7, 79.5, 121.2, 129.5, 138.5, 140.6; MS(ES+) m/z 478.7  [M + 
H]+; HRMS calcd for C28H39N5O2 [M + H]+ 478.3177, found 478.3178. 
 
N-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-nitro-benzenesulfonamide (104) 
 
O2N
S
Cl
O O
O2N
S
N
H
O O
N
N
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To a stirred solution of p-nitro benzenesulfonyl chloride (2 g, 9 mmol) in CH2Cl2 (20 
mL) at 0 °C was added K 2CO3 (2.7 g, 19.8 mmol) and 3-(4-methyl-piperazin-1-yl)-
propylamine (1.7 mL, 9.9 mmol). The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered and the filtrates were combined, dried 
over Na2SO4 and evaporated in vacuo to yield the title compound as a yellow oil (2.8 
g, 92%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 1.60 (2H, t, J = 6 Hz, 
CH2CH2CH2), 2.25 (3H, s, NMe), 2.38 (8H, m, piperazine), 2.40 (2H, t, J = 6 Hz, 
CH2N), 3.05 (2H, t, J = 6 Hz, CH2NH), 7.96 (2H, d, J = 9 Hz, Ar-H), 8.29 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 28.4, 36.8, 53.7, 57.8, 66.5, 79.8, 117.4, 
128.2, 128.3, 142.5, 152.9, 166.0; MS(ES+) m/z 343.9 [M + H]+. 
 
N-[3-(4-Methyl-piperazin-1-yl)-propyl]-4-nitro-benzamide (105) 
 
O2N
Cl
O2N
N
H
N
N
O O
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To a stirred solution of p-nitro benzoyl chloride (2 g, 10.8 mmol) in CH2Cl2 (20 mL) at 
0 °C was added K 2CO3 (3.3 g, 23.8 mmol) and 3-(4-methyl-piperazin-1-yl)-
propylamine (2 mL, 11.8 mmol). The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered and the filtrates were combined, dried 
over Na2SO4 and evaporated in vacuo to yield the title compound as a yellow oil (2.9 
g, 94%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 1.91 (2H, t, J = 6 Hz, 
CH2CH2CH2), 2.34 (3H, s, NMe), 2.38 (8H, m, piperazine), 2.40 (2H, t, J = 6 Hz, 
CH2N), 2.65 (8H, m, piperazine), 2.74 (2H, t, J = 6 Hz, CH2N), 3.52 (2H, t, J = 6 Hz, 
CH2NH), 8.04 (2H, d, J = 9 Hz, Ar-H), 8.57 (1H, s, NH); 8.20 (2H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 28.4, 60.5, 69.3, 72.5, 79.8, 117.4, 128.1, 128.3, 
142.5, 152.9, 166.1; MS(ES+) m/z 307.9 [M + H]+. 
 
 
1-(2-Chloro-ethoxy)-4-nitro-benzene (112) 261 
 
O2N
O
Cl
O2N
OH
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To a stirred solution of p-nitro phenol (10 g, 72 mmol) in acetonitrile (100 mL) was 
added K2CO3 (25 g, 180 mmol) and dichloroethane (56 mL, 720 mmol). The mixture 
was heated to reflux and stirred for 48 h. The excess base was filtered and the 
filtrate was evaporated in vacuo to yield the title compound as a yellow solid (15 g, 
99%). 
Rf  = 0.7 (EtOAc); mp: 63-64 °C  1H NMR (300 MHz, CDCl3) δ 3.79 (2H, t, J = 6 Hz, 
CH2Cl), 4.26 (2H, t, J = 6 Hz, OCH2), 6.91 (2H, d, J = 9 Hz, Ar-H), 8.14 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 40.4, 45.0, 110.6, 125.5, 140.4, 172.7; 
MS(ES+) m/z 202.7 [M + H]+. 
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1-Methyl-4-[2-(4-nitro-phenoxy)-ethyl]-piperazine (113) 262 
 
O2N
O
Cl
O2N
O
N
N
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The compound was prepared according to General Procedure III from 1-(2-chloro-
ethoxy)-4-nitro-benzene (2 g, 10 mmol) and N-methyl piperazine (5.5 mL, 50 mmol), 
and was obtained as a yellow solid (2.8 g, 91%).  
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.22 (3H, s, NMe), 2.55-
2.40 (8H, m, piperazine), 2.78 (2H, t, J = 6 Hz, CH2N), 4.12 (2H, t, J = 6 Hz, OCH2), 
6.89 (2H, d, J = 9 Hz, Ar-H), 8.16 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) 
δ 45.6, 47.0, 58.6, 60.8, 70.9, 115.5, 130.2, 145.8, 165.7; MS(ES+) m/z 266.7 [M + 
H]+. 
 
 
4-Amino-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzenesulfonamide (108) 263 
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The compound was prepared according to General Procedure IV from N-[3-(4-
methyl-piperazin-1-yl)-propyl]-4-nitro-benzenesulfonamide (2.5 g, 7.3 mmol), and 
was obtained as an orange oil (2.3 g, 99%).  
Rf  = 0.4 (EtOAc); 1H NMR (300 MHz, CDCl3) δ 1.53 (2H, t, J = 6 Hz, CH2CH2CH2), 
2.22 (3H, s, NMe), 2.31 (2H, t, J = 6 Hz, CH2N), 2.40 (8H, m, piperazine), 2.92 (2H, t, 
J = 6 Hz, CH2NH), 4.20 (2H, s, NH2), 6.60 (2H, d, J = 9 Hz, Ar-H), 7.52 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 15.4, 28.5, 40.5, 44.3, 51.7, 59.1, 111.5, 
120.5, 128.7, 140.3, 141.5, 159.8; MS(ES+) m/z 313.2 [M + H]+. 
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4-Amino-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide (109) 264 
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The compound was prepared according to General Procedure IV from 4-[3-(4-
methyl-piperazin-1-yl)-propyl]-4-nitro-benzamide (2.5 g, 8.2 mmol), and was obtained 
as an orange oil (2.3 g, 98%).  
Rf  = 0.4 (EtOAc); 1H NMR (300 MHz, CDCl3) δ 1.83 (2H, t, J = 6 Hz, CH2CH2CH2), 
2.42 (3H, s, NMe), 2.61 (2H, t, J = 6 Hz, CH2N), 2.80 (8H, m, piperazine), 3.25 (2H, t, 
J = 6 Hz, CH2NH), 3.40 (2H, s, NH2), 6.60 (2H, d, J = 9 Hz, Ar-H), 7.58 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 16.5, 29.5, 41.6, 43.2, 50.6, 58.0, 112.6, 
121.6, 129.8, 139.2, 140.4, 158.7; MS(ES+) m/z 277.2 [M + H]+. 
 
4-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-phenylamine (114) 265 
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The compound was prepared according to General Procedure IV from 1-methyl-4-[2-
(4-nitro-phenoxy)-ethyl]-piperazine (2.5 g, 9.4 mmol), and was obtained as an 
orange oil (2.3 g, 99%).  
Rf  = 0.35 (EtOAc); 1H NMR (300 MHz, CDCl3) δ 2.23 (3H, s, NMe), 2.50 (8H, m, 
piperazine), 2.72 (2H, t, J = 6 Hz, CH2N), 3.36 (2H, s, NH2), 3.97 (2H, t, J = 6 Hz, 
OCH2), 6.52 (2H, d, J = 9 Hz, Ar-H), 6.69 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 
MHz, CDCl3) δ 44.5, 46.9, 57.5, 61.9, 71.0, 114.4, 131.3, 146.9, 167.8; MS(ES+) m/z 
236.7 [M + H]+. 
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4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)propyl)benzenesulfonamide (91) 
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The compound was prepared according to General Procedure I from 4-amino-N-[3-
(4-methyl-piperazin-1-yl)-propyl]-benzenesulfonamide (250 mg, 0.8 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (100 mg, 0.4 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (105 mg, 42%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 142.4-144.0 °C;  IR (cm-1): 2848, 1758, 1596, 
1529, 1460, 1425; λmax (EtOH)/nm  307.0; 1H NMR (300 MHz, CDCl3) δ 1.03-2.04 
(13H, m, cyclohexyl + CH2CH2CH2), 2.24 (3H, s, NMe), 2.34 (2H, t, J = 4 Hz, NCH2), 
2.31-2.50 (8H, m, piperazine), 2.98 (2H, t, J = 4 Hz, CH2NHSO2), 4.27 (2H, d, J = 6 
Hz, OCH2Cy), 7.38 (1H, s, NH), 7.74 (2H, d, J = 9 Hz, Ar-H), 7.70 (2H, d, J = 9 Hz, 
Ar-H), 7.78 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 25.6, 26.6, 26.7, 26.9, 30.3, 
37.4, 43.2, 46.5, 53.8, 55.4, 57.0, 72.6, 118.3, 128.7, 132.9, 144.1, 155.3; MS(ES+) 
m/z 543.6  [M + H]+; HRMS calcd for C26H38N8O3S [M + H]+ 543.2860, found 
543.2855. 
 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)propyl)benzamide (93) 
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The compound was prepared according to General Procedure I from 4-amino-N-[3-
(4-methyl-piperazin-1-yl)-propyl]-benzamide (250 mg, 0.9 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (113 mg, 0.45 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (102 mg, 42%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 145.5-146.9 °C;  IR (cm-1): 3095, 2924, 2849, 
2805, 2160, 1603, 1525, 1603, 1525, 1496, 1447; λmax (EtOH)/nm  314.0; 1H NMR 
(300 MHz, CDCl3) δ 1.00-2.06 (13H, m, cyclohexyl + CH2CH2CH2), 2.22 (3H, s, 
NMe), 2.48 (2H, t, J = 4 Hz, NCH2), 2.41-2.63 (8H, m, piperazine), 3.46 (2H, t, J = 4 
Hz, CH2NH), 4.24 (2H, d, J = 6 Hz, OCH2Cy), 7.37 (1H, s, NH), 7.67 (2H, d, J = 9 
Hz, Ar-H), 7.71 (2H, d, J = 9 Hz, Ar-H), 7.76 (1H, s, NH), 8.10 (1H, s, H-8); 13C NMR 
(125 MHz, CDCl3) δ 25.5, 26.0, 26.7, 30.1, 37.7, 40.5, 46.1, 53.4, 55.3, 57.9, 72.6, 
115.6, 118.2, 128.4, 139.2, 143.7, 155.7, 161.2, 167.7; MS(ES+) m/z 507.6  [M + 
H]+; HRMS calcd for C27H38N8O2 [M + H]+ 507.3190, found 507.3189. 
 
6-(Cyclohexylmethoxy)-N-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-9H-
purin-2-amine (94) 
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The compound was prepared according to General Procedure I from 4-(2-(4-
methylpiperazin-1-yl)ethoxy)benzenamine (250 mg, 1 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (133 mg, 0.5 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (106 mg, 44%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 156.0-156.9 °C;  IR (cm-1): 3626, 3416, 2916, 
2848, 2789, 2160, 1624, 1584, 1538, 1497, 1445, 1406; λmax (EtOH)/nm  272.0; 1H 
NMR (300 MHz, CDCl3) δ 1.07-1.81 (11H, m, cyclohexyl), 2.23 (3H, s, NMe), 2.43-
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2.57 (8H, m, piperazine), 2.74 (2H, t, J = 6 Hz, OCH2CH2N), 3.99 (2H, t, J = 6 Hz, 
OCH2CH2N) , 4.21 (2H, d, J = 6 Hz, OCH2Cy), 6.78 (2H, d, J = 9 Hz, Ar-H), 6.87 (1H, 
s, H-8), 7.05 (1H, s, NH), 7.34 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 
26.0, 26.7, 30.1, 37.7, 46.1, 53.7, 55.3, 57.5, 66.9, 72.4, 115.6, 122.6, 133.7, 138.2, 
155.3, 157.0, 161.5; MS(ES+) m/z 466.6  [M + H]+; HRMS calcd for C25H35N7O2 [M + 
H]+ 466.2925, found 466.2923. 
 
1-(3-(4-Methylpiperazin-1-yl)propyl)-3-(4-nitrophenyl)urea (97) 266  
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To a stirred solution of p-nitrophenyl isocyanate (2 g, 12.2 mmol) in THF (25 mL) 
was added 3-(4-methyl-piperazin-1-yl)-propylamine (2.7 mL, 16 mmol). The mixture 
was stirred at room temperature for 3 h. The solvent was evaporated in vacuo 
yielding the title compound as a yellow solid (3.5 g, 75%). 
 
Rf  = 0.35 (EtOAc/MeOH 9:1); mp: 97-100 °C 1H NMR (300 MHz, CDCl3) δ 1.64 (2H, 
t, J = 6.5 Hz, CH2CH2CH2), 2.19 (3H, s, NMe), 2.34 (8H, m, piperazine), 3.27 (2H, t, 
J = 6.5 Hz, CH2N), 3.69 (2H, t, J = 6.5 Hz, NHCH2), 6.15 (1H, s, NH), 7.46 (2H, d, J 
= 9 Hz, Ar-H), 8.06 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.5, 40.2, 
43.3, 50.0, 52.6, 55.5, 121.1, 122.9, 142.7, 144.8; MS(ES+) m/z 322.2 [M + H]+. 
 
1-(4-Aminophenyl)-3-(3-(4-methylpiperazin-1-yl)propyl)urea (99) 266 
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The compound was prepared according to General Procedure III from 1-(3-(4-
methylpiperazin-1-yl)propyl)-3-(4-nitrophenyl)urea (1 g, 3.1 mmol), to yield the title 
compound as an orange solid (0.87 g, quantitative). 
Rf (EtOAc/MeOH 9:1) = 0.5 mp: 132.9-133.9 °C 1H NMR (300 MHz, CDCl3) δ 1.55 
(2H, t, J = 6.5 Hz, CH2CH2CH2), 2.16 (3H, s, NMe), 2.20 (8H, m, piperazine), 2.27 
(2H, t, J = 6 Hz, CH2N), 3.15 (2H, t, J = 6 Hz, NHCH2), 6.53 (2H, d, J = 9 Hz, Ar-H), 
6.96 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 12.0, 24.8, 43.1, 117.5, 
124.0, 131.9, 145.0, 159.7; MS(ES+) m/z 292.2 [M + H]+. 
 
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)phenyl)-3-(3-(4-
methylpiperazin-1-yl)propyl)urea (89) 
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The compound was prepared according to General Procedure I from 1-(4-
aminophenyl)-3-(3-(4-methylpiperazin-1-yl)propyl)urea (500 mg, 1.7 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (215 mg, 0.85 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (208 mg, 43%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 146.0-147.2 °C;  IR (cm-1): 2922, 2843, 1587, 
1502, 1445; λmax (EtOH)/nm  277.0; 1H NMR (300 MHz, CDCl3) δ 1.04-2.01 (13H, m, 
cyclohexyl + CH2CH2CH2), 2.21 (3H, s, NMe), 2.37 (2H, t, J = 4 Hz, CH2), 2.25-2.45 
(8H, m, piperazine), 3.29 (2H, t, J = 4 Hz, CH2NH), 4.31 (2H, d, J = 6 Hz, OCH2Cy), 
6.96 (2H, d, J = 9 Hz, Ar-H), 7.37 (2H, d, J = 9 Hz, Ar-H), 7.76 (1H, s, NH), 8.10 (1H, 
s, H-8); 13C NMR (125 MHz, CDCl3) δ 26.0, 26.7, 27.1, 29.7, 30.1, 37.7, 39.1, 45.8, 
49.0, 49.2, 49.5, 49.8, 50.1, 53.0, 55.0, 55.1, 56.3, 72.4, 114.9, 120.8, 120.9, 122.4, 
122.5, 122.6, 133.7, 133.7, 136.5, 136.5, 138.6, 155.3, 156.5, 156.6, 157.3, 157.4, 
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161.2; MS(ES+) m/z 522.5   [M + H]+; HRMS calcd for C27H39N9O2 [M + H]+ 
522.3299, found 522.3301. 
 
 
N-[3-(4-Methyl-piperazin-1-yl)-ethyl]-4-nitro-benzenesulfonamide (106) 267 
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To a stirred solution of p-nitro benzenesulfonyl chloride (2 g, 9 mmol) in CH2Cl2 (20 
mL) at 0 °C was added K 2CO3 (2.7 g, 19.8 mmol) and 3-(4-methyl-piperazin-1-yl)-
ethylamine (1.42 mL, 9.9 mmol). The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered and the filtrates were combined, dried 
over Na2SO4 and evaporated in vacuo to yield the title compound as a yellow oil (2.7 
g, 94%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.25 (3H, s, NMe), 2.38 
(8H, m, piperazine), 2.40 (2H, t, J = 6 Hz, CH2N), 3.05 (2H, t, J = 6 Hz, CH2NH), 7.96 
(2H, d, J = 9 Hz, Ar-H), 8.29 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 
28.4, 36.8, 53.7, 57.8, 66.5, 79.8, 117.4, 128.2, 128.3, 142.5, 152.9, 166.0; MS(ES+) 
m/z 343.9 [M + H]+. 
 
N-[3-(4-Methyl-piperazin-1-yl)-ethyl]-4-nitro-benzamide (103) 268 
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To a stirred solution of p-nitro benzoyl chloride (2 g, 10.9 mmol) in CH2Cl2 (20 mL) at 
0 °C was added K 2CO3 (3.3 g, 24.0 mmol) and 3-(4-methyl-piperazin-1-yl)-
ethylamine (1.72 mL, 11.9 mmol). The reaction mixture was stirred at room 
temperature for 18 h. The mixture was filtered and the filtrates were combined, dried 
over Na2SO4 and evaporated in vacuo to yield the title compound as a yellow oil (2.7 
g, 92%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.34 (3H, s, NMe), 2.38 
(8H, m, piperazine), 2.40 (2H, t, J = 6 Hz, CH2N), 2.65 (8H, m, piperazine), 2.74 (2H, 
t, J = 6 Hz, CH2N), 3.52 (2H, t, J = 6 Hz, CH2NH), 8.04 (2H, d, J = 9 Hz, Ar-H), 8.57 
(1H, s, NH); 8.20 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 28.4, 60.5, 
69.3, 72.5, 79.8, 117.4, 128.1, 128.3, 142.5, 152.9, 166.1; MS(ES+) m/z 307.9 [M + 
H]+. 
 
4-Amino-N-[3-(4-methyl-piperazin-1-yl)-ethyl]-benzenesulfonamide (110) 267 
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The compound was prepared according to General Procedure IV from N-[3-(4-
methyl-piperazin-1-yl)-ethyl]-4-nitro-benzenesulfonamide (2 g, 6.1 mmol), and was 
obtained as an orange oil (1.85 g, 99%).  
Rf  = 0.4 (EtOAc); 1H NMR (300 MHz, CDCl3) δ 2.22 (3H, s, NMe), 2.31 (2H, t, J = 6 
Hz, CH2N), 2.40 (8H, m, piperazine), 2.92 (2H, t, J = 6 Hz, CH2NH), 4.20 (2H, s, 
NH2), 6.60 (2H, d, J = 9 Hz, Ar-H), 7.52 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, 
CDCl3) δ 15.4, 28.5, 40.5, 44.3, 51.7, 59.1, 111.5, 120.5, 128.7, 140.3, 141.5, 159.8; 
MS(ES+) m/z 313.2 [M + H]+. 
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4-Amino-N-[3-(4-methyl-piperazin-1-yl)-ethyl]-benzamide (107) 268 
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The compound was prepared according to General Procedure IV from 4-[3-(4-
methyl-piperazin-1-yl)-ethyl]-4-nitro-benzamide (2 g, 6.8 mmol), and was obtained as 
an orange oil (1.87 g, 99%).  
Rf  = 0.4 (EtOAc); 1H NMR (300 MHz, CDCl3) δ 2.42 (3H, s, NMe), 2.61 (2H, t, J = 6 
Hz, CH2N), 2.80 (8H, m, piperazine), 3.25 (2H, t, J = 6 Hz, CH2NH), 3.40 (2H, s, 
NH2), 6.60 (2H, d, J = 9 Hz, Ar-H), 7.58 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, 
CDCl3) δ 16.5, 29.5, 41.6, 43.2, 50.6, 58.0, 112.6, 121.6, 129.8, 139.2, 140.4, 158.7; 
MS(ES+) m/z 277.2 [M + H]+. 
 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)ethyl)benzenesulfonamide (90) 
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The compound was prepared according to General Procedure I from 4-amino-N-[3-
(4-methyl-piperazin-1-yl)-ethyl]-benzenesulfonamide (500 mg, 1.7 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (210 mg, 0.8 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (65 mg, 22%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 142.4-144.0 °C;  IR (cm-1): 2848, 1758, 1596, 
1529, 1460, 1425; λmax (EtOH)/nm  307.0; 1H NMR (300 MHz, CDCl3) δ 1.03-2.04 
(11H, m, cyclohexyl), 2.24 (3H, s, NMe), 2.34 (2H, t, J = 4 Hz, NCH2), 2.31-2.50 (8H, 
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m, piperazine), 2.98 (2H, t, J = 4 Hz, CH2NHSO2), 4.27 (2H, d, J = 6 Hz, OCH2Cy), 
7.38 (1H, s, NH), 7.74 (2H, d, J = 9 Hz, Ar-H), 7.70 (2H, d, J = 9 Hz, Ar-H), 7.78 (1H, 
s, H-8); 13C NMR (125 MHz, CDCl3) δ 25.6, 26.6, 26.7, 26.9, 30.3, 37.4, 43.2, 46.5, 
53.8, 55.4, 57.0, 72.6, 118.3, 128.7, 132.9, 144.1, 155.3; MS(ES+) m/z 543.6  [M + 
H]+; HRMS calcd for C26H38N8O3S [M + H]+ 543.2860, found 543.2855. 
 
4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)-N-(3-(4-methylpiperazin-1-
yl)ethyl)benzamide (92)  
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The compound was prepared according to General Procedure I from 4-amino-N-[3-
(4-methyl-piperazin-1-yl)-ethyl]-benzamide (500 mg, 1.9 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (240 mg, 0.95 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (152 mg, 45%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 145.5-146.9 °C;  IR (cm-1): 3095, 2924, 2849, 
2805, 2160, 1603, 1525, 1603, 1525, 1496, 1447; λmax (EtOH)/nm  314.0; 1H NMR 
(300 MHz, CDCl3) δ 1.00-2.06 (11H, m, cyclohexyl), 2.22 (3H, s, NMe), 2.48 (2H, t, J 
= 4 Hz, NCH2), 2.41-2.63 (8H, m, piperazine), 3.46 (2H, t, J = 4 Hz, CH2NH), 4.24 
(2H, d, J = 6 Hz, OCH2Cy), 7.37 (1H, s, NH), 7.67 (2H, d, J = 9 Hz, Ar-H), 7.71 (2H, 
d, J = 9 Hz, Ar-H), 7.76 (1H, s, NH), 8.10 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 
25.5, 26.0, 26.7, 30.1, 37.7, 40.5, 46.1, 53.4, 55.3, 57.9, 72.6, 115.6, 118.2, 128.4, 
139.2, 143.7, 155.7, 161.2, 167.7; MS(ES+) m/z 507.6  [M + H]+; HRMS calcd for 
C27H38N8O2 [M + H]+ 507.3190, found 507.3189. 
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1-(3-(4-Methylpiperazin-1-yl)ethyl)-3-(4-nitrophenyl)urea (98) 269 
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To a stirred solution of p-nitrophenyl isocyanate (2 g, 12.2 mmol) in THF (25 mL) 
was added 3-(4-methyl-piperazin-1-yl)-ethylamine (2.3 mL, 15.8 mmol). The mixture 
was stirred at room temperature for 3 h. The solvent was evaporated in vacuo 
yielding the title compound as a yellow solid (3.8 g, 82%). 
 
Rf  = 0.35 (EtOAc/MeOH 9:1); mp: 97-100 °C; 1H NMR (300 MHz, CDCl3) δ 1.91 (2H, 
quint, J = 6.5 Hz, CH2CH2CH2), 2.34 (3H, s, NMe), 2.74 (8H, m, piperazine), 2.80 
(2H, t, J = 6.5 Hz, CH2N), 3.54 (2H, t, J = 6.5 Hz, CH2NH), 7.46 (2H, d, J = 9 Hz, Ar-
H), 8.06 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.5, 40.2, 43.3, 50.0, 
52.6, 55.5, 121.1, 122.9, 142.7, 144.8; MS(ES+) m/z 308.2 [M + H]+. 
 
 
1-(4-Aminophenyl)-3-(3-(4-methylpiperazin-1-yl)ethyl)urea (100) 269 
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The compound was prepared according to General Procedure III from 1-(3-(4-
methylpiperazin-1-yl)ethyl)-3-(4-nitrophenyl)urea (2 g, 6.5 mmol), to yield the title 
compound as an orange solid (1.78 g, 99%). 
Rf (EtOAc/MeOH 9:1) = 0.5 mp: 132.9-133.9 °C 1H NMR (300 MHz, CDCl3) δ 2.16 
(3H, s, NMe), 2.20 (8H, m, piperazine), 2.27 (2H, t, J = 6 Hz, CH2N), 3.15 (2H, t, J = 
6 Hz, NHCH2), 6.53 (2H, d, J = 9 Hz, Ar-H), 6.96 (2H, d, J = 9 Hz, Ar-H); 13C NMR 
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(125 MHz, CDCl3) δ 12.0, 24.8, 43.1, 117.5, 124.0, 131.9, 145.0, 159.7; MS(ES+) 
m/z 278.2 [M + H]+. 
 
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)phenyl)-3-(3-(4-
methylpiperazin-1-yl)ethyl)urea (88) 
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The compound was prepared according to General Procedure I from 1-(4-
aminophenyl)-3-(3-(4-methylpiperazin-1-yl)ethyl)urea (500 mg, 1.8 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (225 mg, 0.9 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (132 mg, 44%). 
 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 146.0-147.2 °C;  IR (cm-1): 2922, 2843, 1587, 
1502, 1445; λmax (EtOH)/nm  277.0; 1H NMR (300 MHz, CDCl3) δ 1.04-2.01 (11H, m, 
cyclohexyl), 2.21 (3H, s, NMe), 2.37 (2H, t, J = 4 Hz, CH2), 2.25-2.45 (8H, m, 
piperazine), 3.29 (2H, t, J = 4 Hz, CH2NH), 4.31 (2H, d, J = 6 Hz, OCH2Cy), 6.96 
(2H, d, J = 9 Hz, Ar-H), 7.37 (2H, d, J = 9 Hz, Ar-H), 7.76 (1H, s, NH), 8.10 (1H, s, H-
8); 13C NMR (125 MHz, CDCl3) δ 26.0, 26.7, 27.1, 29.7, 30.1, 37.7, 39.1, 45.8, 49.0, 
49.2, 49.5, 49.8, 50.1, 53.0, 55.0, 55.1, 56.3, 72.4, 114.9, 120.8, 120.9, 122.4, 122.5, 
122.6, 133.7, 133.7, 136.5, 136.5, 138.6, 155.3, 156.5, 156.6, 157.3, 157.4, 161.2; 
MS(ES+) m/z 508.5   [M + H]+; HRMS calcd for C26H37N9O2 [M + H]+ 508.3299, 
found 508.3301. 
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1-(3-Bromopropoxy)-4-nitrobenzene (116) 270-271  
 
O2N
OH
O2N
O Br
 
                             115                                                 116 
To a stirred solution of p-nitro phenol (2 g, 14.3 mmol) in acetonitrile (25 mL) was 
added K2CO3 (5 g, 35.7 mmol) and dibromopropane (15 mL, 140 mmol). The mixture 
was heated to reflux and stirred for 48 h. The excess base was filtered and the 
filtrate was evaporated in vacuo to yield the title compound as a yellow solid (3.5 g, 
quantitative). 
Rf  = 0.7 (EtOAc); mp: 63-64 °C  1H NMR (300 MHz, CDCl3) δ 1.97 (2H, t, J = 6 Hz, 
CH2CH2CH2) 3.79 (2H, t, J = 6 Hz, CH2Br), 4.26 (2H, t, J = 6 Hz, OCH2), 6.91 (2H, d, 
J = 9 Hz, Ar-H), 8.14 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 40.4, 
45.0, 110.6, 125.5, 140.4, 172.7; MS(ES+) m/z 259.98 [M(79Br) + H], 261.98 [M(81Br) 
+ H]+. 
 
1-(3-(4-Nitrophenoxy)propyl)-4-methylpiperazine (117) 262, 272 
O2N
O Br
O2N
O N
N
 
                        116                                                   117 
 
The compound was prepared according to General Procedure III from 1-(3-
bromopropoxy)-4-nitrobenzene (2.5 g, 9.6 mmol) and N-methyl piperazine (5.5 mL, 
48 mmol), and was obtained as an orange solid (2.3 g, 85%).  
Rf  = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 1.97 (2H, quint, J = 6 Hz, 
CH2CH2CH2), 2.25 (3H, s, NMe), 2.55-2.40 (8H, m, piperazine), 2.52 (2H, t, J = 6 Hz, 
CH2N), 4.08 (2H, t, J = 6 Hz, OCH2), 6.90 (2H, d, J = 9 Hz, Ar-H), 8.12 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 45.6, 47.0, 58.6, 60.8, 70.9, 115.5, 130.2, 
145.8, 165.7; MS(ES+) m/z 280.7 [M + H]+. 
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4-(3-(4-Methylpiperazin-1-yl)propoxy)benzenamine (118) 262 
 
O2N
O N
N
H2N
O N
N
 
                   117                                                             118 
 
The compound was prepared according to General Procedure IV from 21-(3-(4-
nitrophenoxy)propyl)-4-methylpiperazine (2.5 g, 10.02 mmol) and obtained as a clear 
yellow oil (2.0 g, 96%). 
Rf = 0.5 (EtOAc/MeOH 9:1); bp 168-169 °C (lit.); 1H NMR (300 MHz, CDCl3): δ 1.97 
(2H, quint, J = 6 Hz, CH2CH2CH2), 2.30 (3H, s, NMe), 2.45-2.50 (8H, m, piperazine), 
2.52 (2H, t, J = 6 Hz, CH2N), 3.98 (2H, t, J = 6 Hz, OCH2), 6.61 (2H, d, J = 9 Hz, Ar-
H), 6.82 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, MeOD) δ 45.6, 61.0, 69.4, 
111.8, 114.9, 142.5, 148.4. MS(ES+) m/z 250.6 [M + H]+. 
 
N-(4-(3-(4-Methylpiperazin-1-yl)propoxy)phenyl)-6-(cyclohexylmethoxy)-9H-
purin-2-amine (95) 
O
N
H
N
N
N
H
N
O
H2N
O N
N
N
N
 
         118                                                                                           95 
 
The compound was prepared according to General Procedure I from 4-(3-(4-
methylpiperazin-1-yl)propoxy)benzenamine (500 mg, 2.27 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (285 mg, 1.14 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (307 mg, 43%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 116.0-116.9 °C;  IR (cm-1): 2924, 2849, 2776, 
1618, 1583, 1543, 1504, 1443; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 
1.1-1.9 (11H, m, cyclohexyl), 1.98 (2H, t, J = 6 Hz, CH2CH2CH2), 2.30 (3H, s, NMe), 
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2.45-2.50 (8H, m, piperazine), 2.72 (2H, t, J = 6 Hz, CH2N), 3.98 (2H, t, J = 6 Hz, 
OCH2), 4.3 (2H, d, J = 6 Hz, CH2Cy), 6.61 (2H, d, J = 9 Hz, Ar-H), 6.82 (2H, d, J = 9 
Hz, Ar-H), 6.89 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 26.0, 26.8, 30.1, 37.8, 
46.0, 58.7, 67.0, 72.4, 115.4, 115.5, 115.6, 116.7, 122.6, 122.7, 133.5, 137.8, 155.4, 
157.1, 161.6; MS(ES+) m/z 480.52  [M + H]+; HRMS calcd for C26H37N7O2 [M + H]+ 
480.2503, found 480.2498. 
 
(2-Cyclohexylethyl)(4-nitrophenyl)sulfane (189) 273 
 
O2N
SH
O2N
S
 
                                   137                                   189 
 
To a stirred solution of 4-nitrobenzenethiol (2 mL, 15.5 mmol) in acetonitrile (10 mL) 
was added K2CO3 (2.3 g, 14.7 mmol). The temperature was lowered to 0 °C and 
cyclohexylethyl bromide (2.2 mL, 14.7 mmol) was added dropwise. The mixture was 
heated to reflux and stirred for 48 h. The excess base was filtered and the filtrate 
was evaporated in vacuo to yield the title compound as a white solid (2.8 g, 
quantitative). 
Rf  = 0.7 (EtOAc); mp: 139 °C (lit. 138 °C);  1H NMR (300 MHz, CDCl3) δ 0.94-1.69 
(13H, m, cyclohexyl + CH2Cy), 2.95 (2H, t, J = 6 Hz, CH2S), 7.24 (2H, d, J = 9 Hz, 
Ar-H), 8.03 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 34.4, 38.5, 43.0, 
127.9, 128.0, 128.4, 137.1; MS(ES+) m/z 266.1 [M + H]+. 
 
1-(2-Cyclohexylethylsulfonyl)-4-nitrobenzene (190) 274 
 
O2N
S
O2N
S
O O
 
                         189                                                        190 
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To a stirred solution of (2-cyclohexylethyl)(4-nitrophenyl)sulfane (2 g, 7.5 mmol) in 
CH2Cl2 (10 mL) was added mCPBA (3 g, 16.6 mmol). The reaction mixture was 
stirred at room temperature for 48 h. The solvent was removed under reduced 
pressure and the residue was taken up in EtOAc (20 mL) and washed with saturated 
aqueous NaHCO3 (6 x 20 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure, yielding the title 
compound as a white solid (2.1 g, 76%). 
Rf  = 0.5 (EtOAc/Hexane 1:9); mp: 95-96 °C (lit. 96 ° C); 1H NMR (300 MHz, CDCl3) δ 
0.94-1.69 (13H, m, cyclohexyl + CH2Cy), 3.35 (2H, t, J = 6 Hz, CH2S), 8.04 (2H, d, J 
= 9 Hz, Ar-H), 8.44 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 35.4, 57.5, 
58.0, 124.6, 129.1, 130.6, 137.1; MS(ES+) m/z 298.2 [M + H]+. 
 
4-(2-Cyclohexylethylsulfonyl)benzenamine 274 
 
O2N
S
O O
H2N
S
O O
 
                          190 
 
The compound was prepared according to General Procedure IV from 1-(2-
cyclohexylethylsulfonyl)-4-nitrobenzene (3 g, 10 mmol) and obtained as a clear 
yellow oil (2.8 g, 95%). 
Rf 0.5 (EtOAc/MeOH 9:1); mp: 83-84 °C (lit. 85 °C);  1H NMR (300 MHz, CDCl3) δ 
0.91-1.70 (13H, m, cyclohexyl + CH2Cy), 3.05 (2H, t, J = 6 Hz, CH2S), 6.02 (2H, s, 
NH2), 6.64 (2H, d, J = 9 Hz, Ar-H), 7.41 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, 
MeOD) δ 50.0, 55.8, 79.8, 61.0, 65.6, 69.4, 115.8, 116.9, 129.9, 136.0, 139.5, 144.4, 
145.4, 149.3;  MS(ES+) m/z  268.2 [M+H]+. 
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N-(4-(2-Cyclohexylethylsulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (188) 
 
S
N
H
N
N
N
H
N
O
H2N
S
O O O O
 
                                                                                                188 
 
The compound was prepared according to General Procedure I from 4-(2-
cyclohexylethylsulfonyl)benzenamine (1 g, 3.74 mmol) and 6-cyclohexylmethoxy-2-
fluoro-9H-purine (500 mg, 1.87 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/Petrol 7:3) yielding the title compound as a white 
solid (511 mg, 41%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 116.0-116.9 °C;  IR (cm-1): 2924, 2849, 2776, 
1618, 1583, 1543, 1504, 1443; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 
0.91-1.70 (13H, m, cyclohexyl + CH2Cy), 3.05 (2H, t, J = 6 Hz, CH2S), 4.35 (2H, d, J 
= 6 Hz, CH2Cy), 6.81 (1H, s, H-8), 6.94 (2H, d, J = 9 Hz, Ar-H), 7.21 (1H, s, NH), 
7.45 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.0, 26.8, 30.1, 37.8, 
46.0, 58.7, 67.0, 72.4, 115.4, 115.5, 115.6, 116.7, 122.6, 122.7, 133.5, 137.8, 155.4, 
157.1, 161.6; MS(ES+) m/z 498.3  [M + H]+; HRMS calcd for C26H35N5O3S [M + H]+ 
498.2503, found 498.2498. 
 
N,N-dimethyl-2-(4-nitrophenoxy)ethanamine (119) 275  
 
O2N
O
Cl
O2N
O
N
 
                              112                                                  119 
 
The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (1 g, 4.96 mmol) and 2 M dimethylamine in methanol 
(10 mL). The compound was obtained as a yellow solid (1.12 g, 89%). 
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Rf = 0.5 (EtOAc/MeOH 9:1); mp: 79-80 °C (lit. 82 °C) 1H NMR (300 MHz, CDCl3) δ 
2.81 (6H, s, NMe2), 3.54 (2H, t, J = 6 Hz, CH2N), 4.64 (2H, t, J = 6 Hz, OCH2), 7.18 
(2H, d, J = 9 Hz, Ar-H), 8.16 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 
45.9, 59.5, 66.4, 115.5, 124.8, 139.0, 163.4. MS(ES+) m/z 211.1 [M+H]+. 
 
1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine (120) 275 
 
O2N
O
Cl
O2N
O
N
 
                           112                                                    120 
 
The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (1 g, 4.96 mmol) and 2 mL of pyrrolidine. The 
compound was obtained as a yellow solid (1.03 g, 84%). 
Rf = 0.5 (EtOAc/MeOH 9:1); mp: 71-72 °C (lit. 74 °C);  1H NMR (300 MHz, CDCl3) δ 
2.65 (2H, t, J = 6 Hz, NCH2), 3.24 (2H, t, J = 6 Hz, NCH2), 3.44 (2H, t, J = 6 Hz, 
CH2N), 4.82 (2H, t, J = 6 Hz, OCH2), 7.01 (2H, d, J = 9 Hz, Ar-H), 8.27 (2H, d, J = 9 
Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 25.6, 58.9, 59.0, 66.9, 115.5, 121.0, 140.4, 
161.5; MS(ES+) m/z  237.6 [M+H]+. 
 
1-(2-(4-Nitrophenoxy)ethyl)piperidine (121) 276 
 
O2N
O
Cl
O2N
O
N
 
                          112                                                     121 
 
The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (1 g, 4.96 mmol) and 2 mL of piperidine. The 
compound was obtained as a yellow solid (1.05 g, 81%). 
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Rf = 0.5 (EtOAc/MeOH 9:1); mp: 63-64 °C (lit. 65 °C);  1H NMR (300 MHz, CDCl3) δ 
1.3 (2H, m, CH2), 1.5 (4H, m, CH2), 2.4 (4H, m, NCH2), 2.6 (2H, t, J = 6 Hz, CH2N), 
3.9 (2H, t, J = 6 Hz, OCH2), 7.1 (2H, d, J = 9 Hz, Ar-H), 8.4 (2H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 25.6, 54.7, 60.0, 68.4, 110.8, 122.5, 138.4, 158.7; 
MS(ES+) m/z 251.3 [M+H]+. 
 
 
4-(2-(4-Nitrophenoxy)ethyl)morpholine (122) 275 
 
O2N
O
Cl
O2N
O
N
O
 
                           112                                                   122 
 
The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (1 g, 4.96 mmol) and 2 mL of morpholine. The 
compound was obtained as a yellow solid (1.09 g, 87%). 
Rf = 0.5 (EtOAc/MeOH 9:1); mp: 83-84 °C (lit. 82 °C);  1H NMR (300 MHz, CDCl3) δ 
2.6 (4H, m, NCH2), 2.9 (2H, t, J = 6 Hz, CH2N), 3.9 (2H, t, J = 6 Hz, CH2O), 4.2 (2H, 
t, J = 6 Hz, OCH2), 7.0 (2H, d, J = 9 Hz, Ar-H), 8.2 (2H, d, J = 9 Hz, Ar-H); 13C NMR 
(125 MHz, CDCl3) δ 22.6, 54.9, 57.0, 68.9, 117.5, 125.7, 143.1, 166.9. MS(ES+) m/z 
253.1 [M+H]+. 
 
 
2-(4-Nitrophenoxy)-N-benzylethanamine (123) 276 
 
O2N
O
Cl
O2N
O
N
H
 
                      112                                                    123 
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The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (1 g, 4.96 mmol), 2.5 mL of benzylamine and 0.56 g of 
NaI. The compound was obtained as a yellow solid (1.04 g, 88%). 
Rf = 0.5 (EtOAc/MeOH 9:1); mp: 63-64 °C (lit. 65 °C);  1H NMR (300 MHz, CDCl3) δ 
2.9 (2H, t, J = 6 Hz, CH2NH), 3.8 (2H, s, NHCH2), 4.0 (2H, t, J = 6 Hz, OCH2), 6.8 
(2H, d, J = 9 Hz, Ar-H), 7.2 (1H, m, NH), 7.2 (5H, s, Ar-H), 8.0 (2H, d, J = 9 Hz, Ar-
H); 13C NMR (125 MHz, CDCl3) δ 45.9, 49.5, 55.5, 70.4, 115.5, 124.8, 128.3, 129.6, 
133.3, 139.0, 163.4. MS(ES+) m/z  273.6 [M+H]+. 
 
4-(2-(Dimethylamino)ethoxy)benzenamine (124) 275 
 
O2N
O
N
H2N
O
N
 
                              119                                                  124 
 
The compound was prepared according to General Procedure IV from 2-(4-
nitrophenoxy)-N,N-dimethylethanamine (700 mg, 3.32 mmol) and obtained as a clear 
yellow oil (651 mg, quantitative). 
Rf = 0.5 (EtOAc/MeOH 9:1); bp 168-169 °C (lit.); 1H NMR (300 MHz, CDCl3): δ 2.2 
(6H, s, NMe2), 2.6 (2H, t, J = 6 Hz, CH2N), 3.9 (2H, t, J = 6 Hz, OCH2), 6.5 (2H, d, J 
= 9 Hz, Ar-H), 6.6 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, MeOD) δ 45.6, 61.0, 
69.4, 111.8, 114.9, 142.5, 148.4. MS(ES+) m/z 181.6 [M+H]+. 
 
4-(2-(Pyrrolidin-1-yl)ethoxy)benzenamine (125) 277 
 
O2N
O
N
H2N
O
N
 
                          120                                                     125 
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The compound was prepared according to General Procedure IV from 1-(2-(4-
nitrophenoxy)ethyl)pyrrolidine (1 g, 4.22 mmol) and obtained as a clear yellow oil 
(898 mg, 98%). 
Rf = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 1.9 (4H, m, 2 x CH2), 2.4 
(4H, m, NCH2), 6.4 (2H, d, J = 9 Hz, Ar-H), 6.7 (2H, d, J = 9 Hz, Ar-H). 13C NMR (125 
MHz, MeOD) δ 24.0, 55.6, 59.9, 67.0, 69.4, 111.8, 114.9, 142.5, 148.4; MS(ES+) m/z  
207.5 [M+H]+. 
 
4-(2-(Piperidin-1-yl)ethoxy)benzenamine (126) 278 
 
O2N
O
N
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                            121                                                   126 
 
The compound was prepared according to General Procedure IV from 1-(2-(4-
nitrophenoxy)ethyl)piperidine (800 mg, 3.19 mmol) and obtained as a clear yellow oil 
(710 mg, 98%). 
Rf = 0.5 (EtOAc/MeOH 9:1);1H NMR (300 MHz, CDCl3): δ 1.3 (2H, m, CH2), 1.5 (4H, 
m, CH2), 2.4 (4H, m, NCH2), 2.6 (2H, t, J = 6 Hz, CH2N), 3.9 (2H, t, J = 6 Hz, OCH2), 
6.5 (2H, d, J = 9 Hz, Ar-H), 6.6 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, MeOD) δ 
22.9, 51.6, 59.6, 111.8, 113.9, 143.5, 149.4. MS(ES+) m/z  221.9 [M+H]+. 
 
4-(2-Morpholinoethoxy)benzenamine (127) 275 
 
O2N
O
N
H2N
O
N
O O
 
                          122                                                     127 
The compound was prepared according to General Procedure IV from 4-(2-(4-
nitrophenoxy)ethyl)morpholine (1 g, 3.96 mmol) and obtained as a clear yellow oil 
(909 mg, 99%). 
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Rf = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.6 (4H, m, NCH2), 2.7 
(2H, t, J = 6 Hz, CH2N), 3.7 (4H, t, J = 6 Hz, CH2O), 4.0 (2H, t, J = 6 Hz, OCH2), 6.6 
(2H, d, J = 9 Hz, Ar-H), 6.7 (2H, d, J = 9 Hz, Ar-H). 13C NMR (125 MHz, MeOD) δ 
51.0, 55.6, 59.4, 61.0, 65.6, 69.4, 110.8, 115.9, 141.5, 149.4. MS(ES+) m/z 223.2 
[M+H]+. 
 
4-(2-(Benzylamino)ethoxy)benzenamine (128) 276 
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                 123                                                                 128 
 
The compound was prepared according to General Procedure IV from 2-(4-
nitrophenoxy)-N-benzylethanamine (800 mg, 2.83 mmol) and obtained as a clear 
yellow oil (712 mg, 98%). 
Rf 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.89 (2H, t, J = 6 Hz, 
CH2NH), 3.7 (2H, s, CH2Ph), 3.9 (2H, t, J = 6 Hz, OCH2), 6.5 (2H, d, J = 9 Hz, Ar-H), 
6.6 (2H, d, J = 9 Hz, Ar-H), 7.2 (5H, s, Ar-H); 13C NMR (125 MHz, MeOD) δ 50.0, 
55.8, 79.8, 61.0, 65.6, 69.4, 115.8, 116.9, 129.9, 136.0, 139.5, 144.4, 145.4, 149.3;  
MS(ES+) m/z  243.2 [M+H]+. 
 
N-(4-(2-(Dimethylamino)ethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (129) 
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             124                                                                                 129 
The compound was prepared according to General Procedure I from 4-(2-
(dimethylamino)ethoxy)benzenamine (500 mg, 2.77 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (312 mg, 1.25 mmol). The crude product was 
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purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (311 mg, 44%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 116.0-116.9 °C;  IR (cm-1): 2924, 2849, 2776, 
1618, 1583, 1543, 1504, 1443; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 
1.1-1.9 (11H, m, cyclohexyl), 2.3 (6H, s, NMe2), 2.7 (2H, t, J = 6 Hz, CH2N), 4.1 (2H, 
t, J = 6 Hz, OCH2), 4.3 (2H, d, J = 6 Hz, CH2Cy), 6.8 (1H, s, H-8), 6.9 (2H, d, J = 9 
Hz, Ar-H), 7.2 (1H, s, NH), 7.4 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 
26.0, 26.8, 30.1, 37.8, 46.0, 58.7, 67.0, 72.4, 115.4, 115.5, 115.6, 116.7, 122.6, 
122.7, 133.5, 137.8, 155.4, 157.1, 161.6; MS(ES+) m/z 411.3  [M + H]+; HRMS calcd 
for C25H35N7O2 [M + H]+ 411.2503, found 411.2498. 
 
N-(4-(2-(Pyrrolidin-1-yl)ethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (130) 
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The compound was prepared according to General Procedure I from 4-(2-(pyrrolidin-
1-yl)ethoxy)benzenamine (500 mg, 2.42 mmol) and 6-cyclohexylmethoxy-2-fluoro-
9H-purine (312 mg, 1.25 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (308 mg, 45%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 118.0-118.9 °C;  IR (cm-1): 2924, 2850, 1584, 
1531, 1502, 1446; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 0.9-1.6 (11H, 
m, cyclohexyl), 1.7 (4H, m, CH2CH2 pyrrolidine), 2.5 (4H, m, NCH2 pyrrolidine), 2.8 
(2H, t, J = 6 Hz, CH2N), 4.0 (2H, t, J = 6 Hz, OCH2), 4.2 (2H, d, J = 6 Hz, CH2Cy), 6.7 
(2H, d, J = 9 Hz, Ar-H), 6.9 (1H, s, H-8), 7.1 (1H, s, NH), 7.3 (1H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 14.4, 23.9, 26.0, 26.7, 29.9, 30.0, 30.1, 37.7, 48.2, 
54.8, 55.3, 60.5, 67.5, 72.4, 73.0, 115.5, 122.5, 133.9, 138.4, 140.9, 155.1, 155.2, 
232 
 
157.0, 161.5; MS(ES+) m/z 437.3  [M + H]+; HRMS calcd for C24H32N6O2 [M + H]+ 
437.2660, found 437.2659. 
 
N-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(131) 
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N
H
N
O
NN
 
              126                                                                                131 
 
The compound was prepared according to General Procedure I from 4-(2-(piperidin-
1-yl)ethoxy)benzenamine (500 mg, 2.26 mmol) and 6-cyclohexylmethoxy-2-fluoro-
9H-purine (312 mg, 1.25 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (298 mg, 43%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 128.3-129.1 °C;  IR (cm-1): 3266, 2922, 2850, 
2783, 1616, 1584, 1537, 1502, 1446; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, 
CDCl3) δ 1.2-1.9 (17H, m, cyclohexyl + piperidine), 2.5 (4H, m, piperidine), 2.7 (2H, t, 
J = 6 Hz, CH2N), 4.1 (2H, t, J = 6 Hz, OCH2), 4.3 (2H, d, J = 6 Hz, CH2Cy), 6.8 (2H, 
d, J = 9 Hz, Ar-H), 7.1 (1H, s, NH), 7.2 (1H, s, H-8), 7.4 (1H, d, J = 9 Hz, Ar-H); 13C 
NMR (125 MHz, CDCl3) δ 24.5, 26.0, 26.2, 26.8, 30.1, 37.7, 55.3, 58.3, 66.8, 72.4, 
115.6, 116.7, 122.7, 133.5, 138.2, 155.4, 157.5, 161.6; MS(ES+) m/z 451.5  [M + 
H]+; HRMS calcd for C25H34N6O2 [M + H]+ 451.2816, found 451.2819. 
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N-(4-(2-Morpholinoethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(132) 
H2N
O O
N
H
N
N
N
H
N
O
NN
O O
 
              127                                                                                132 
 
The compound was prepared according to General Procedure I from 4-(2-
morpholinoethoxy)benzenamine (500 mg, 2.24 mmol) and 6-cyclohexylmethoxy-2-
fluoro-9H-purine (312 mg, 1.25 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (315 mg, 46%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 125.8-126.5 °C;  IR (cm-1): 2923, 2850, 2157, 
2023, 1618, 1584, 1541, 1504, 1446; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, 
CDCl3) δ 1.1-1.9 (11H, m, cyclohexyl), 2.6 (4H, m, NCH2 morpholine), 2.8 (2H, t, J = 
6 Hz, CH2N), 3.7 (4H, t, J = 6 Hz, CH2O morpholine), 4.1 (2H, t, J = 6 Hz, OCH2), 4.3 
(2H, d, J = 6 Hz, CH2Cy), 6.8 (2H, d, J = 9 Hz, Ar-H), 7.0 (1H, s, NH), 7.2 (1H, s, H-
8), 7.4 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.0, 26.8, 30.2, 37.8, 
54.4, 58.1, 67.2, 72.5, 115.7, 116.7, 122.9, 133.5, 137.7, 137.8, 155.5, 157.1, 161.7; 
MS(ES+) m/z 453.4   [M + H]+; HRMS calcd for C24H32N6O3 [M + H]+ 453.2609, 
found 453.2610. 
 
N-(4-(2-(Benzylamino)ethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(133) 
H2N
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H
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N
H
 
          128                                                                                        133 
The compound was prepared according to General Procedure I from 4-(2-
(benzylamino)ethoxy)benzenamine (500 mg, 2.06 mmol) and 6-cyclohexylmethoxy-
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2-fluoro-9H-purine (312 mg, 1.25 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (355 mg, 51%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 115.9-116.0 °C;  IR (cm-1): 3265, 2922, 2849, 
2154, 1730, 1584, 1532, 1499, 1448; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, 
CDCl3) δ 11.0-1.9 (11H, m, cyclohexyl), 3.0 (2H, t, J = 6 Hz, CH2N) , 3.9 (2H, s, 
PhCH2), 4.0 (2H, t, J = 6 Hz, OCH2), 4.3 (2H, d, J = 6 Hz, CH2Cy), 6.8 (2H, d, J = 9 
Hz, Ar-H), 7.1 (1H, s, NH), 7.3 (1H, s, H-8), 7.3 (5H, m, Ar-H), 7.4 (1H, d, J = 9 Hz, 
Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.0 ; 26.8, 30.1, 37.8, 48.6, 54.0, 68.6, 72.5, 
115.4, 115.7, 116.7, 122.8, 127.3, 128.4, 128.7, 133.6, 137.8, 140.5, 154.9, 155.6, 
157.1, 161.6; MS(ES+) m/z 473.1   [M + H]+; HRMS calcd for C27H32N6O2 [M + H]+ 
473.2660, found 473.2659. 
 
(2-Chloroethyl)(4-nitrophenyl)sulfane (138) 279 
 
O2N
S
Cl
O2N
SH
 
                                       137                                    138 
 
To a stirred solution of p-nitro benzenethiol (2 g, 13 mmol) in acetonitrile (50 mL) 
was added K2CO3 (4.5 g, 32 mmol) and dichloroethane (10 mL, 130 mmol). The 
mixture was heated to reflux and stirred for 24 h. The excess base was filtered and 
the filtrate was evaporated in vacuo to yield the title compound as a yellow oil (2.8 g, 
quantitative). 
 
Rf = 0.7 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 3.3 (2H, t, J = 6 Hz, 
CH2Cl), 3.6 (2H, t, J = 6 Hz, SCH2), 7.3 (2H, d, J = 9 Hz, Ar-H), 8.0 (2H, d, J = 9 Hz, 
Ar-H); 13C NMR (125 MHz, MeOD) δ 34.4, 43.0, 122.8, 130.0, 142.2, 142.6;  
MS(ES+) m/z  218.5 [M(35Cl) + H]+; 220.5 [M(37Cl) + H]+. 
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1-(2-(4-Nitrophenylthio)ethyl)-4-methylpiperazine (139) 280 
 
O2N
S
Cl
O2N
S
N
N
 
                        138                                                     139 
 
The compound was prepared according to General Procedure III from (2-
chloroethyl)(4-nitrophenyl)sulfane (2.94 g, 13 mmol) and N-methyl piperazine (7.5 
mL, 67.5 mmol). The compound was obtained as a yellow solid (2.85 g, 91%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 83-84 °C (lit. 86 °C) ; 1H NMR (300 MHz, CDCl3) δ 
2.2 (3H, s, NMe), 2.4 (8H, m, NCH2), 2.6 (2H, t, J = 6 Hz, CH2N), 3.0 (2H, t, J = 6 Hz, 
SCH2), 7.2 (2H, d, J = 9 Hz, Ar-H), 8.5 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, 
CDCl3) δ 34.4, 43.0, 44.4, 47.9, 53.7, 53.9, 57.6, 121.8, 133.4, 141.8, 142.7; 
MS(ES+) m/z 282.5 [M + H]+. 
 
4-(2-(4-Methylpiperazin-1-yl)ethylthio)benzenamine (140) 265 
 
O2N
S
N
N
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S
N
N
 
                  139                                                                  140 
 
The compound was prepared according to General Procedure IV from 1-methyl-4-(2-
(4-nitrophenylthio)ethyl)piperazine (800 mg, 2.84 mmol) and obtained as a clear 
yellow oil (0.42 g, 48%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 88.9-89.9 °C 1H NMR (300 MHz, CDCl3) δ 2.2 (3H, 
s, NMe), 2.4 (8H, m, CH2), 2.5 (2H, t, J = 6 Hz, CH2N), 2.8 (2H, t, J = 6 Hz, SCH2), 
3.7 (2H, s, NH2), 6.6 (2H, d, J = 9 Hz, Ar-H), 7.2 (2H, d, J = 9 Hz, Ar-H); 13C NMR 
(125 MHz, CDCl3) δ 32.6, 42.9, 46.4, 48.1, 54.7, 56.7, 58.6, 123.4, 134.0, 143.8, 
148.2; MS(ES+) m/z 252.3 [M + H]+. 
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N-(4-(2-(4-Methylpiperazin-1-yl)ethylthio)phenyl)-6-(cyclohexylmethoxy)-9H-
purin-2-amine (134) 
N
H
N
N
N
H
N
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S
N
N
S
N
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             140                                                                                   134 
 
The compound was prepared according to General Procedure I from 4-(2-(4-
methylpiperazin-1-yl)ethylthio)benzenamine (250 mg, 1 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (125 mg, 0.55 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (108 mg, 47%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 146.0-146.9 °C;  IR (cm-1): 3096, 2924, 2848, 
2798, 2191, 1731, 1596, 1575, 1530, 1492, 1444; λmax (EtOH)/nm  288.5; 1H NMR 
(300 MHz, CDCl3) δ 1.2-1.9 (11H, m, cyclohexyl), 2.3 (3H, s, NMe), 2.5 (8H, m, 
piperazine), 2.6 (2H, t, J = 6 Hz, CH2N), 3.0 (2H, t, J = 6 Hz, SCH2), 4.3 (2H, d, J = 6 
Hz, OCH2), 7.0 (1H, s, H-8), 7.3 (2H, d, J = 9 Hz, Ar-H), 7.5 (1H, d, J = 9 Hz, Ar-H), 
7.6 (1H, s, NH); 13C NMR (125 MHz, CDCl3) δ 25.7, 26.4, 29.8, 37.3, 45.7, 52.7, 
54.7, 57.7, 66.9, 72.2, 115.6, 119.6, 131.7, 138.2, 155.3, 157.0, 161.5; MS(ES+) m/z 
482.5  [M + H]+; HRMS calcd for C25H35N7OS [M + H]+ 482.2697, found 482.26982. 
 
 
1-(3-Chloropropyl)-4-nitrobenzene (145) 281-282 
 
Cl Cl
O2N
 
                       144                                                         145 
 
To stirred nitric acid (1.6 mL, 260 mmol) at 0 °C w as added sulfuric acid (1.05 mL, 
193.5 mmol) dropwise. 3-chloropropyl benzene (2 mL, 12.9 mmol) was then added 
dropwise. The mixture was stirred at 0 °C for 10 mi n, then allowed to warm up to 
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room temperature and stirred for further 3 h. Ice water (10 mL) was added to the 
mixture, which was then extracted with CH2Cl2 (3 x 10 mL). The crude product was 
purified by column chromatography on silica (Et2O/Hexane 5:95) and the title 
compound was isolated as a colourless oil (1.4 g, 62%). 
 
Rf  = 0.5 (EtOAc); bp: 168-169 °C 1H NMR (300 MHz, CDCl3) δ 22.1 (2H, quint, J = 6 
Hz, CH2CH2CH2), 2.9 (2H, t, J = 6 Hz, PhCH2), 3.5 (2H, t, J = 6 Hz, CH2Cl), 7.3 (2H, 
d, J = 9 Hz, Ar-H), 8.1 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.9, 
37.5, 44.4, 121.3, 129.4, 140.0, 145.23; MS(ES+) m/z 200.3 [M(35Cl) + H]+; 202.3 
[M(37Cl) + H+]. 
 
1-Methyl-4-(3-(4-nitrophenyl)propyl)piperazine (146) 280, 283 
 
Cl
O2N
N
O2N
N
 
                       145                                                       146 
 
The compound was prepared according to General Procedure III from 1-(3-
chloropropyl)-4-nitrobenzene (700 mg, 3.5 mmol) and N-methyl piperazine (2 mL, 
17.5 mmol). The compound was obtained as a yellow solid (697 mg, 85%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 76-77 °C (lit. 79 °C) ; 1H NMR (300 MHz, CDCl3) δ 
1.9 (2H, quint, J = 6 Hz, CH2CH2CH2), 2.2 (3H, s, NMe), 2.3 (2H, t, J = 6 Hz, PhCH2), 
2.4 (8H, m, CH2 piperazine), 2.6 (2H, t, J = 6 Hz, CH2N), 7.2 (2H, d, J = 9 Hz, Ar-H), 
8.0 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 27.6, 33.4, 40.8, 50.7, 
54.7, 56.7, 56.9, 57.0, 120.3, 128.4, 141.0, 147.7; MS(ES+) m/z 264.6 [M + H]+. 
 
1-Methyl-4-(3-(4-nitrophenyl)propyl)piperazine (147) 284 
 
N
O2N
N
N
H2N
N
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The compound was prepared according to General Procedure IV from 1-methyl-4-(3-
(4-nitrophenyl)propyl)piperazine (700 mg, 2.66 mmol) and obtained as a clear yellow 
oil (0.65 g, 98%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 83.0-84.1 °C (lit. 89  °C); 1H NMR (300 MHz, 
CDCl3) δ 1.9 (2H, quint, J = 6 Hz, CH2CH2CH2), 2.0 (3H, s, NMe), 2.1 (2H, t, J = 6 
Hz, PhCH2), 2.2 (8H, m, CH2 piperazine), 2.4 (2H, t, J = 6 Hz, CH2N), 6.4 (2H, d, J = 
9 Hz, Ar-H), 7.0 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 30.5, 31.8, 
39.6, 51.3, 53.6, 53.7, 58.9, 59.0, 121.3, 127.9, 142.6, 148.5; MS(ES+) m/z 234.1 [M 
+ H]+. 
 
6-(Cyclohexylmethoxy)-N-(4-(3-(4-methylpiperazin-1-yl)propyl)phenyl)-9H-
purin-2-amine (136) 
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                  147                                                                        136 
 
The compound was prepared according to General Procedure I from 4-(3-(4-
methylpiperazin-1-yl)propyl)benzenamine (250 mg, 1 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (125 mg , 0.55 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (102 mg, 52%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 102.2-103.6 °C;  IR (cm-1): 2920, 2803, 1615, 
1581, 1535, 1506, 1444; λmax (EtOH)/nm  272.5; 1H NMR (300 MHz, CDCl3) δ 1.0-1.9 
(13H, m, cyclohexyl + CH2CH2CH2), 2.3 (3H, s, NMe), 2.3 (2H, t, J = 8 Hz, CH2Ph), 
2.5 (8H, m, CH2 piperazine), 2.6 (2H, t, J = 9 Hz, CH2N), 4.3 (2H, d, J = 6 Hz, OCH2), 
7.0 (1H, s, NH), 7.1 (2H, d, J = 9 Hz, Ar-H), 7.4 (2H, d, J = 9 Hz, Ar-H), 8.0 (1H, s, H-
8); 13C NMR (125 MHz, CDCl3) δ 26.9, 27.5, 29.4, 30.8, 34.0, 38.7, 45.9, 48.5, 48.7, 
48.8, 49.0, 49.2, 49.4, 49.5, 53.6, 55.5, 58.9, 72.9, 120.3, 129.4, 136.3, 140.0, 140.2, 
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157.4, 161.4; MS(ES+) m/z 464.7 [M + H]+; HRMS calcd for C26H37N7O [M + H]+ 
464.3132, found 464.3134. 
 
N-(2-(4-Methylpiperazin-1-yl)ethyl)-4-nitrobenzenamine (142) 285 
 
O2N
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                                141                                       142 
 
To a stirred solution of p-nitro fluorobenzene (1.63 mL, 15.4 mmol) in acetonitrile (10 
mL) was added 2-(4-methylpiperazin-1-yl)ethanamine (2 mL, 14 mmol). The mixture 
was heated to reflux and stirred for 48 h. The solvent was removed under reduced 
pressure and the residue was taken up in water (20 mL) and extracted with CH2Cl2 
(3 x 20 mL). The combined organic layers were dried over Na2SO4 and evaporated 
in vacuo, yielding the title compound as a yellow solid (2.2 g, 84%). 
 
Rf  = 0.7 (EtOAc); mp: 200-201 °C (lit. 201 °C); 1H NMR (300 MHz, CDCl3) δ 2.3 (3H, 
s, NMe), 2.5 (8H, m, CH2 piperazine), 2.6 (2H, t, J = 6 Hz, CH2N), 3.2 (2H, t, J = 6 
Hz, NHCH2), 5.3 (1H, s, PhNH), 6.5 (2H, d, J = 9 Hz, Ar-H), 8.0 (2H, d, J = 9 Hz, Ar-
H); 13C NMR (125 MHz, CDCl3) δ 43.8, 47.7, 53.5, 55.9, 58.1, 72.8, 114.6, 123.0, 
132.6, 158.7; MS(ES+) m/z 265.1 [M + H]+. 
 
N1-(2-(4-Methylpiperazin-1-yl)ethyl)benzene-1,4-diamine (143) 285 
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                      142                                                            143 
 
The compound was prepared according to General Procedure IV from N-(2-(4-
methylpiperazin-1-yl)ethyl)-4-nitrobenzenamine (2 g, 7.56 mmol) and obtained as an 
orange solid (1.85 g, 98%). 
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Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 200-201 °C (lit. 201 °C); 1H NMR (300 MHz, 
CDCl3) δ 2.2 (3H, s, NMe), 2.4 (8H, m, CH2 piperazine), 2.5 (2H, t, J = 6 Hz, CH2N), 
3.0 (2H, t, J = 6 Hz, NHCH2), 3.5 (2H, s, NH2), 6.4 (2H, d, J = 9 Hz, Ar-H), 6.5 (2H, d, 
J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 43.8, 47.7, 53.5, 56.0, 58.1, 72.8, 
112.4, 117.8, 132.6, 158.7; MS(ES+) m/z 235.6 [M + H]+. 
 
N1-(6-(cyclohexylmethoxy)-9H-purin-2-yl)-N4-(2-(4-methylpiperazin-1-
yl)ethyl)benzene-1,4-diamine (135)  
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                  143                                                                         135 
 
The compound was prepared according to General Procedure I from N1-(2-(4-
methylpiperazin-1-yl)ethyl)benzene-1,4-diamine (250 mg, 1 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (0.55 mmol, 125 mg). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (98 mg, 49%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 143.1-144.0 °C;  IR (cm-1): 2922, 2846, 2803, 
1732, 1618, 1582, 1500, 1446; λmax (EtOH)/nm  279.0; 1H NMR (300 MHz, CDCl3) δ 
1.0 -1.9  (11H, m, cyclohexyl), 2.3 (3H, s, NMe), 2.4 (8H, m, CH2 piperazine), 2.6 
(2H, t, J = 8 Hz, NCH2), 3.1 (2H, t, J = 8 Hz, CH2N), 4.2 (2H, d, J = 6 Hz, OCH2), 6.6 
(2H, d, J = 9 Hz, Ar-H), 6.7 (1H, s, NH), 7.2 (2H, d, J = 9 Hz, Ar-H), 7.3 (1H, s, H-8); 
13C NMR (125 MHz, CDCl3) δ 26.9, 27.6, 30.8, 38.7, 42.5, 45.9, 48.5, 48.6, 48.8, 
49.0, 49.2, 49.3, 49.5, 53.7, 55.6, 58.1, 72.8, 114.6, 123.0, 132.3, 158.7; MS(ES+) 
m/z 465.5 [M + H]+; HRMS calcd for C25H36N8O [M + H]+ 465.3085, found 465.3058. 
 
 
 
241 
 
Benzyl(2-chloroethyl)sulfane (176) 286-287 
 
SH S
Cl
 
                                175                                    176 
 
To a stirred solution of phenylmethanethiol (2 mL, 15.5 mmol) in acetonitrile (10 mL) 
was added K2CO3 (5.3 g, 38.7 mmol) and dichloroethane (12.2 mL, 155 mmol). The 
mixture was heated to reflux and stirred for 48 h. The excess base was filtered and 
the filtrate was evaporated in vacuo to yield the title compound (2.8 g, quantitative). 
Rf  = 0.7 (EtOAc); mp: 139 °C (lit. 138 °C); 1H NMR (300 MHz, CDCl3) δ 2.7 (2H, t, J 
= 6 Hz, CH2Cl), 3.5 (2H, t, J = 6 Hz, SCH2), 3.7 (2H, s, PhCH2), 7.3 (5H, br s, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 34.4, 38.5, 43.0, 127.9, 128.0, 128.4, 137.1; MS(ES+) 
m/z 187.3 [M(35Cl) + H]+; 189.3 [M(37Cl) + H]+. 
 
1-((2-Chloroethylsulfonyl)methyl)benzene (177) 288-289  
 
S
Cl
S
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O O
 
                          176                                                177 
 
To a stirred solution of N-( benzyl(2-chloroethyl)sulfane (3 g, 16.07 mmol) in CH2Cl2 
(50 mL) was added mCPBA (15 g, 80.34 mmol). The reaction mixture was stirred at 
room temperature for 48 h. The solvent was removed under reduced pressure and 
the residue was taken up in EtOAc (50 mL) and washed with saturated aqueous 
NaHCO3 (6 x 30 mL). The combined organic layers were dried over Na2SO4 and the 
solvent was removed under reduced pressure, yielding the title compound as a white 
solid (2.7 g, 79%). 
Rf  = 0.5 (EtOAc/Hexane 1:9); mp: 95-96 °C (lit. 96 ° C); 1H NMR (300 MHz, CDCl3) δ 
3.3 (2H, t, J = 6 Hz, CH2Cl), 3.8 (2H, t, J = 6 Hz, SO2CH2), 4.3 (2H, s, PhCH2), 7.4 
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(5H, s, Ar-H); 13C NMR (125 MHz, CDCl3) δ 35.4, 57.5, 58.0, 124.6, 129.1, 130.6, 
137.1; MS(ES+) m/z 219.2 [M(35Cl) + H]+; 221.3 [M(37Cl) + H]+. 
 
 
1-((2-Chloroethylsulfonyl)methyl)-4-nitrobenzene (178) 289 
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                   177                                                              178 
 
To stirred nitric acid (2 mL, 22.86 mmol) at 0 °C w as added sulfuric acid (1 mL, 17.15 
mmol) dropwise. ((2-chloroethylsulfonyl)methyl)benzene (2.5 g, 11.4 mmol) was then 
added in small portions. The mixture was stirred at 0 °C for 10 min, then allowed to 
warm up to room temperature and stirred for further 3 h. Ice water (10 mL) was 
added to the mixture, which was then extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over Na2SO4 and evaporated under reduced 
pressure, and the crude product was purified by column chromatography on silica 
using a gradient solvent system (EtOAc/Hex 1:9  1:1). The title compound was 
isolated as a white solid (1.20 g, 51%). 
 
Rf  = 0.3 (EtOAc/Hexane 1:9); mp: 87 °C (lit. 89 °C);  1H NMR (300 MHz, CDCl3) δ 3.3 
(2H, t, J = 6 Hz, CH2Cl), 3.9 (2H, t, J = 6 Hz, SO2CH2), 4.4 (2H, s, PhCH2), 7.6 (2H, 
d, J = 9 Hz, Ar-H), 8.2 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 35.4, 
57.5, 58.0, 121.6, 121.9, 131.0, 149.5; MS(ES+) m/z 264.1 [M(35Cl) + H]+; 266.1 
[M(37Cl) + H]+. 
 
1-(2-(4-Nitrobenzylsulfonyl)ethyl)-4-methylpiperazine (179) 
S
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The compound was prepared according to General Procedure III from 1-((2-
chloroethylsulfonyl)methyl)-4-nitrobenzene (800 mg, 3.0 mmol) and N-methyl 
piperazine (1.7 mL, 15 mmol). The compound was obtained as a yellow solid (784 
mg, 86%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 93-94 °C; IR (cm -1): 3315, 3000, 2900, 2837, 1608, 
1510, 1450; λmax (EtOH)/nm  275.0; 1H NMR (300 MHz, CDCl3) δ 2.2 (3H, s, NMe), 
2.2-2.8 (8H, m, CH2 piperazine), 3.0 (2H, t, J = 6 Hz, CH2N), 4.5 (2H, t, J = 6 Hz, 
SO2CH2), 5.2 (2H, s, PhCH2), 7.5 (2H, d, J = 9 Hz, Ar-H), 8.2 (2H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 43.7, 49.4, 50.0, 52.3, 55.2, 57.5, 58.0, 122.4, 123.0, 
133.1, 150.6; MS(ES+) m/z 328.13 [M + H]+; HRMS calcd for C14H21N3O4S [M + H]+ 
328.1489, found 328.1488. 
 
4-((2-(4-methylpiperazin-1-yl)ethylsulfonyl)methyl)benzenamine (180) 
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The compound was prepared according to General Procedure IV from 1-methyl-4-(2-
(4-nitrobenzylsulfonyl)ethyl)piperazine (800 mg, 3.0 mmol) and obtained as a clear 
yellow oil (702 mg, 98%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 98-99 °C; IR (cm -1): 3407, 3332, 3224, 3094, 2959, 
1683, 1597, 1514; λmax (EtOH)/nm  290.6; 1H NMR (300 MHz, CDCl3) δ 2.3 (3H, s, 
NMe), 2.3-2.5 (8H, m, CH2 piperazine), 2.5 (2H, t, J = 6 Hz, CH2N), 3.5 (2H, t, J = 6 
Hz, SO2CH2), 4.4 (2H, s, PhCH2), 6.7 (2H, d, J = 9 Hz, Ar-H); 7.2 (2H, d, J = 9 Hz, 
Ar-H); 13C NMR (125 MHz, CDCl3) δ 43.7, 49.4, 50.0, 52.3, 55.2, 57.5, 58.0, 114.8, 
116.3, 132.4, 149.0, 150.1; MS(ES+) m/z 298.15 [M + H]+; HRMS calcd for 
C14H23N3O2S [M + H]+ 298.8712, found 298.5623. 
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N-(4-((2-(4-Methylpiperazin-1-yl)ethylsulfonyl)methyl)phenyl)-6-
(cyclohexylmethoxy)-9H-purin-2-amine (174) 
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The compound was prepared according to General Procedure I from 4-((2-(4-
methylpiperazin-1-yl)ethylsulfonyl)methyl)benzenamine (250 mg, 0.84 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (75 mg, 0.42 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (116 mg, 47%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 158-160 °C; IR (cm -1): 3431, 2920, 2849, 2806, 
1730, 1585, 1533, 1496, 1439; λmax (EtOH)/nm  247.5; 1H NMR (300 MHz, CDCl3) δ 
1.2-1.8 (11H, m, cyclohexyl), 2.2 (3H, s, NMe), 2.5 (8H, m, CH2 piperazine), 2.9 (2H, 
t, J = 8 Hz, CH2N), 3.0 (2H, t, J = 8 Hz, CH2CH2SO2), 4.2 (2H, d, J = 6 Hz, OCH2), 
4.3 (2H, d, J = 6 Hz, SO2CH2Ph), 7.0 (1H, s, NH), 7.30 (2H, d, J = 9 Hz, Ar-H), 7.51 
(2H, d, J = 9 Hz, Ar-H), 7.8 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 26.9, 27.5, 
30.8, 38.7, 45.9, 48.5, 48.7, 48.8, 49.0, 49.2, 49.3, 49.5, 49.9, 50.0, 51.8, 51.9, 53.4, 
55.6, 55.7, 60.6, 73.0, 73.1, 119.8, 120.3, 132.4; MS(ES+) m/z 528.4 [M + H]+; 
HRMS calcd for C26H37N7O3S [M + H]+ 528.2751, found 528.27183. 
 
6-Chloro-2-fluoro-9H-purine (184) 290 
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A 50% (w/w) aqueous solution of HBF4 (40 mL) was brought to the temperature of -5 
°C. 2-amino-6-chloro purine (6 g, 27.8 mmol) was th en added in one portion. NaNO2 
245 
 
(4.2 g, 0.76 mol) was dissolved in water (50 mL) and added dropwise, ensuring that 
the temperature remained below 0 °C. The temperatur e was raised to 20 °C and the 
mixture was stirred for 2 h. The solution was neutralised with Na2CO3 and the 
mixture was concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/MeOH 9:1) yielding the title compound as a white solid (4.3 
g, 64%). 
Rf  = 0.5 (EtOAc/Hexane 1:9); mp: 169-173 °C (lit. 17 3 °C); 1H NMR (300 MHz, 
DMSO) δ 8.3 (1H, s, H-8); 13C NMR (125 MHz, DMSO) δ 131.5, 144.1, 151.5, 153.7, 
158.9; MS(ES+) m/z 172.3 [M + H]+. 
 
2-Fluoro-9H-purine (185) 290 
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To a stirred solution of 6-chloro-2-fluoro purine (1 g, 5.8 mmol) in methanol (10 mL) 
was added ammonium formate (1.82 g, 30 mmol) followed by palladium hydroxide 
(20% on activated carbon, 1 g). The mixture was heated to reflux and stirred for 1 h. 
The reaction mixture was filtered through a pad of celite and the filtrate was 
evaporated in vacuo to yield the title compound as a white crystalline solid (702 mg, 
92%). 
Rf  = 0.5 (EtOAc/Hexane 1:9); mp: 225-228 °C (lit. 22 8 °C); 1H NMR (300 MHz, 
DMSO) δ 8.3 (1H, s, H-8), 9.3 (1H, s, H-6); 13C NMR (125 MHz, DMSO) δ 133.6, 
145.0, 151.9, 152.2, 159.9; MS(ES+) m/z 138.66 [M + H]+. 
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N-(4-(2-(4-Methylpiperazin-1-yl)ethylsulfonyl)phenyl)-9H-purin-2-amine (183) 
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The compound was prepared according to General Procedure I from tert-butyl 4-(2-
(4-methylpiperazin-1-yl)ethylsulfonyl)phenylcarbamate (250 mg, 0.65 mmol) and 2-
fluoro-9H-purine (70 mg, 0.32 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (116 mg, 45%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 118.7-120.0 °C; IR ( cm-1): 3277, 3180, 3101, 
2920, 2849, 2808, 1596, 1541, 1506, 1458, 1408; λmax (EtOH)/nm  247.5; 1H NMR 
(300 MHz, CDCl3) δ 2.0 (3H, s, NMe), 2.2 (8H, m, CH2 piperazine), 2.6 (2H, t, J = 8 
Hz, CH2N), 3.3 (2H, t, J = 8 Hz, CH2SO2), 7.7 (2H, d, J = 9 Hz, Ar-H), 7.9 (2H, d, J = 
9 Hz, Ar-H), 8.1 (1H, s, H-6), 8.7 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 45.9, 
48.5, 48.7, 48.8, 49.0, 49.2, 49.4, 49.5, 49.9, 52.5, 53.1, 54.3, 55.5, 79.0, 118.8, 
130.3, 144.9, 147.9, 157.6; MS(ES+) m/z 402.3  [M + H]+; HRMS calcd for 
C18H23N7O2S [M + H]+ 402.17345, found 402.17345. 
 
1-(Benzyloxy)-3-methylbutan-2-ol (211) 291 
 
O BnO
OH
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To stirred benzyl alcohol (25 mL, 0.23 mol) was added diced sodium (1.6 g, 69 
mmol). The reaction mixture was heated to 150 °C an d stirred until all the sodium 
had dissolved. The reaction mixture was cooled down to room temperature, then 2-
isopropyloxirane (2 mL, 23 mmol) was added dropwise. The reaction mixture was 
heated to 180 °C and stirred for 48 h. Water (15 mL ) was added to the mixture, then 
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acetic acid until pH neutral. The reaction mixture was then extracted with CH2Cl2 (3 x 
30 mL). The combined organic layers were dried over Na2SO4 and evaporated in 
vacuo. The crude product was purified by fractioned distillation, affording the title 
compound as a colourless oil (2.1 g, 74%). 
Rf  = 0.25 (EtOAc/Hexane 1:9); bp: 291 °C (lit.); 1H NMR (300 MHz, CDCl3) δ 0.7 
(3H, d, J = 6 Hz, (CH3)2), 1.1 (3H, d, J = 6 Hz, (CH3)2), 1.6 (1H, m, CH(CH3)2), 2.4 
(1H, s, OH), 3.3 (1H, q, J = 6 Hz, CHOH), 3.5 (2H, t, J = 6 Hz, OCH2), 4.4 (2H, s, 
PhCH2). 7.3 (5H, br s, Ar-H); 13C NMR (125 MHz, MeOD) δ 17.4, 30.5, 75.0, 78.9, 
127.9, 128.0, 128.4, 128.9, 129.0, 137.1; MS(ES+) m/z 194.6 [M + H]+. 
 
 
6-(1-(Benzyloxy)-3-methylbutan-2-yloxy)-9H-purin-2-amine (212) 
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1-(Benzyloxy)-3-methylbutan-2-ol (2 g, 10.3 mmol) was added dropwise to a 
suspension of NaH (200 mg, 7.7 mmol) in DMSO (10 mL), and the mixture was 
stirred at room temperature for 1 hour. 1-(2-Amino-9H-purin-6-yl)-4-aza-1-azonia-
bicyclo[2.2.2]octane chloride (750 mg, 2.5 mmol) was then added in portions and the 
mixture was stirred at room temperature for 24 h. The mixture was concentrated in 
vacuo and the residue was taken up in water (10 mL) and acetic acid was added 
until pH neutral. The mixture was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by column chromatography (EtOAc/Petrol 
1:1) to yield the title compound as a white solid (645 mg, 78%). 
Rf  = 0.25 (EtOAc); mp: decomposes > 258 °C; IR (cm -1): 3471, 3323, 3186, 2962, 
2870, 2791, 2560, 1616, 1575, 1497, 1452; λmax (EtOH)/nm  282.0; 1H NMR (300 
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MHz, CDCl3) δ 0.9 (6H, d, J = 6 Hz, (CH3)2), 2.1 (1H, m, CH(CH3)2), 3.7 (2H, d, J = 6 
Hz, CH2O); 4.5 (1H, q, J = 6 Hz, CHO-Ar), 5.0 (2H, s, OCH2Ph), 5.5 (1H, s, NH), 7.2 
(5H, s, Ar-H), 7.7 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 17.2, 30.7, 75.6, 79.0, 
116.4, 127.9, 128.0, 128.4, 128.9, 129.0, 137.1, 144.8, 153.2, 159.9, 160.1; 
MS(ES+) m/z 328.0  [M + H]+; HRMS calcd for C17H21N5O2 [M + H]+ 328.1768, found 
328.17586. 
 
6-(1-(Benzyloxy)-3-methylbutan-2-yloxy)-2-fluoro-9H-purine (213) 
 
N
N
N
H
N
H2N
O
OBn
N
N
N
H
N
F
O
OBn
 
                                     212                                             213 
 
6-(1-(benzyloxy)-3-methylbutan-2-yloxy)-9H-purin-2-amine (400 mg, 1.22 mmol) was 
dissolved in TFE (2.5 mL) and water (5 mL), then brought to 5 °C. A 50% ( w/w) 
aqueous solution of HBF4 (0.25 mL, 2.44 mmol) was added dropwise, then LiBF4 
(2.3 g, 24.4 mmol) was added in one portion. NaNO2 (170 mg, 2.5 mmol) was 
dissolved in water (3 mL) and added dropwise to the mixture, which was stirred at 5 
°C for 1 h. The reaction was allowed to warm up to room temperature and stirred for 
further 3 h. Aqueous saturated NaHCO3 was added to the mixture until pH neutral. 
The mixture was extracted with CH2Cl2 (3 x 15 mL) and the combined organic layers 
were dried over Na2SO4 and evaporated under reduced pressure. The crude product 
was purified by column chromatography (EtOAc/Petrol 1:1) yielding the title 
compound as a white solid (222 mg, 58%). 
Rf  = 0.5 (EtOAc); mp: 145-146 °C; IR (cm -1): 3742, 3232, 3168, 2926, 2880, 2719, 
2590, 1661, 1557, 1487, 1492; λmax (EtOH)/nm  282.0; 1H NMR (300 MHz, CDCl3) δ 
0.9 (6H, d, J = 6 Hz, (CH3)2), 2.2 (1H, m, CH(CH3)2), 3.4 (2H, s, CH2Ph), 3.7 (1H, q, 
J = 6 Hz, CHO-Ar), 4.5 (2H, d, J = 6 Hz, CH2O), 5.5 (1H, s, NH), 7.2 (5H, s, Ar-H), 
8.1 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) δ 12.7, 37.0, 76.5, 79.6, 114.6, 129.7, 
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128.5, 128.9, 129.1, 130.0, 131.7, 148.4, 152.3, 159.8, 161.0; MS(ES+) m/z 331.2  
[M + H]+; HRMS calcd for C17H19FN4O2 [M + H]+ 331.1565, found 331.1566. 
 
6-(1-(Benzyloxy)-3-methylbutan-2-yloxy)-N-(4-(2-(4-methylpiperazin-1-
yl)ethylsulfonyl)phenyl)-9H-purin-2-amine (214) 
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The compound was prepared according to General Procedure I from tert-butyl 4-(2-
(4-methylpiperazin-1-yl)ethylsulfonyl)phenylcarbamate (370 mg, 0.97 mmol) and 6-
(1-(benzyloxy)-3-methylbutan-2-yloxy)-2-fluoro-9H-purine (160 mg, 0.48 mmol). The 
crude product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) 
yielding the title compound as a white solid (155 mg, 46%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 187.3-187.7 °C; IR ( cm-1): 2924, 2850, 1584, 
1531, 1502, 1446; λmax (EtOH)/nm  274.5; 1H NMR (300 MHz, CDCl3) δ 0.99 (6H, m, 
CH(CH3)2), 2.25 (1H, ept, J = 4 Hz, CH(CH3)2), 2.30 (3H, s, NMe), 2.41 (8H, m, 
piperazine), 2.72 (2H, t, J = 4 Hz, CH2N), 3.21 (2H, t, J = 4 Hz, CH2SO2), 3.72 (2H, 
dd, J = 6; 2 Hz, CH2OBn), 4.04 (2H, s, OCH2Ph), 5.60 (1H, m, OCH), 6.62 (2H, d, J 
= 9 Hz, Ar-H), 7.19 (5H, m, Ar-H) ; 7.58 (2H, d, J = 9 Hz, Ar-H), 7.80 (1H, s, H-8); 13C 
NMR (125 MHz, CDCl3) δ 45.9, 48.5, 48.7, 48.8, 49.0, 49.2, 49.4, 49.5, 49.9, 52.5, 
53.1, 54.3, 55.5, 79.0, 118.8, 130.3, 144.9, 147.9, 157.6; MS(ES+) m/z 593.36 [M + 
H]+; HRMS calcd for C30H39N7O4S [M + H]+ 594.2852, found 594. 28346. 
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6-(Cyclohexylmethoxy)pyrimidine-2,4-diamine (194) 197 
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Sodium (0.84 g, 36 mmol) was added to cyclohexylmethanol (30 mL, 244 mmol) and 
the mixture was heated to 150 °C and stirred for 2 h. 4-Chloro-2,6-diaminopyrimidine 
(4.32 g, 30.0 mmol) was added, the temperature was increased to 180 °C and 
stirring was continued for 2 h. After cooling, the reaction mixture was neutralised with 
1 M HCl. The excess of cyclohexylmethanol was removed by distillation under 
reduced pressure to yield a white viscous residue, which was taken up in methanol 
and filtered. The crude product was purified by chromatography on silica 
(EtOAc/MeOH 9:1). The title compound was obtained as a white solid (6.6 g, 95%). 
Rf  = 0.4 (EtOAc/MeOH 9:1); mp: 137-139 °C (lit. 142 °C); 1H NMR (300 MHz, 
DMSO) δ 0.9-1.2 (5H, m, C6H11), 1.6-1.7 (6H, m, C6H11), 3.8 (2H, d, J = 6.0, OCH2), 
5.0 (1H, s, H-5), 5.8 (2H, s, NH2), 5.9 (2H, s, NH2); 13C NMR (125 MHz, DMSO) δ 
25.2, 26.0, 29.3, 36.9, 69.7, 75.9, 162.9, 165.9, 170.2; MS(ES+) m/z 223.01 [M + 
H]+. 
 
6-(Cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine (195) 164 
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To a stirred solution of 6-(cyclohexylmethoxy)pyrimidine-2,4-diamine (1 g, 4.5 mmol) 
in 30% (v/v) aqueous acetic acid (10 mL) at 80 °C was added so dium nitrite (350 mg, 
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5 mmol). The reaction mixture was stirred at 80 °C for 40 min. The purple precipitate 
was collected by filtration resulting in 504 mg of the title compound (56%). 
Rf  = 0.7 (EtOAc/MeOH 9:1); mp: 242-246 °C (lit. 254 °C); 1H NMR (300 MHz, 
DMSO) δ 1.0-1.2 (5H, m, C6H11), 1.6-1.8 (6H, m, C6H11), 4.2 (2H, d, J = 6 Hz, OCH2), 
7.7 (2H, s, NH2), 8.0 (1H, s, NH), 10.1 (1H, s, NH); 13C NMR (125 MHz, DMSO) δ 
25.1, 25.9, 29.1, 36.7, 71.5, 139.5, 150.1, 163.5, 170.8; MS(ES+) m/z 252.26 [M + 
H]+. 
 
N-(2-Amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-4-yl)acetamide (196) 197  
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6-(Cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine (500 mg, 2 mmol) was 
suspended in acetic anhydride (3 mL) and stirred at 80 °C for 30 min. The mixture 
was poured into water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were dried over Na2SO4 and evaporated under reduced pressure. The 
crude product was purified by column chromatography on silica (EtOAc/Hexane 7:3) 
yielding the title compound as a blue solid (170 mg, 53%). 
Rf  = 0.8 (EtOAc); mp: 278-279 °C (lit. 274 °C); 1H NMR (300 MHz, MeOD) δ 1.1-1.9 
(11H, m, cyclohexyl), 2.4 (3H, s, CH3CO), 4.4 (2H, d, J = 6 Hz, CH2O), 5.9 (2H, s, 
NH2), 6.5 (1H, s, NH); 13C NMR (125 MHz, MeOD) δ 22.2, 25.8, 28.3, 29.9, 29.4, 
38.4, 74.9, 84.9, 126.0, 131.2, 163.3, 165.7, 168.4; MS(ES+) m/z 294.8 [M + H]+. 
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6-(Cyclohexylmethoxy)-8-methyl-9H-purin-2-amine (197) 
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N-(2-Amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-4-yl)acetamide (100 mg, 0.34 
mmol) was suspended in o-xylene (25 mL) and stirred at 100 °C for 30 min. 
Triphenylphosphine (250 mg, 0.85 mmol) was then added, and the mixture was 
heated to 200 °C and refluxed for 24 h. The mixture  was concentrated in vacuo and 
the crude product was purified by column chromatography (EtOAc) yielding the title 
compound as a white solid (90 mg, 83%). 
Rf  = 0.2 (EtOAc); mp: 232-236 °C; IR (cm -1): 3480, 3311, 3163, 2916, 1582; λmax 
(EtOH)/nm  290.0; 1H NMR (300 MHz, CDCl3) δ 1.1-1.9 (11H, m, cyclohexyl), 2.4 
(3H, s, Ar-CH3), 4.4 (2H, d, J = 6 Hz, CH2O), 6.2 (2H, s, NH2); 13C NMR (125 MHz, 
CDCl3) δ 25.6, 26.4, 29.6, 37.2, 70.8, 160.1; MS(ES+) m/z 262.8  [M + H]+; HRMS 
calcd for C13H20ON5 [M + H]+ 262.1662, found 262.16507. 
 
6-(Cyclohexylmethoxy)-2-fluoro-8-methyl-9H-purine (198) 
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A 50% (w/w) aqueous solution of HBF4 (5 mL, 19.8 mmol) was brought to the 
temperature of -5 °C. 6-(Cyclohexylmethoxy)-8-methy l-9H-purin-2-amine (235 mg, 
0.9 mmol) was then added in one portion. NaNO2 (124 mg, 1.8 mmol) was dissolved 
in water (50 mL) and added dropwise, ensuring that the temperature remained below 
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0 °C. The temperature was raised to 20 °C and the m ixture was stirred for 18 h. The 
solution was neutralised with Na2CO3 and the mixture was extracted with CH2Cl2 (3 x 
15 mL) and the combined organic layers were dried over Na2SO4 and evaporated 
under reduced pressure. The crude product was purified by column chromatography 
(EtOAc/Petrol 1:1) yielding the title compound as a white solid (41 mg, 41%). 
Rf  = 0.5 (EtOAc); mp: 171-173 °C; IR (cm -1): 2916, 2777, 2538, 1597; λmax 
(EtOH)/nm  291.0; 1H NMR (300 MHz, DMSO) δ 1.2 (6H, m, cyclohexyl), 1.7 (5H, m, 
cyclohexyl), 2.4 (3H, s, Ar-CH3), 4.3 (2H, d, J = 6 Hz, OCH2); 13C NMR (125 MHz, 
CDCl3) δ 18.0, 25.8, 28.3, 29.9, 29.4, 38.4, 74.9, 116.2, 147.6 153.0, 158.9, 160.1; 
MS(ES+) m/z 264.1   [M + H]+; HRMS calcd for C13H17FN4O [M + H]+ 264.5622, 
found 264.56235. 
 
6-(Cyclohexylmethoxy)-8-methyl-N-(4-(2-(4-methylpiperazin-1-
yl)ethylsulfonyl)phenyl)-9H-purin-2-amine (192) 
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The compound was prepared according to General Procedure I from tert-butyl 4-(2-
(4-methylpiperazin-1-yl)ethylsulfonyl)phenylcarbamate (250 mg, 0.65 mmol) and 6-
(cyclohexylmethoxy)-2-fluoro-8-methyl-9H-purine (70 mg, 0.32 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding 
the title compound as a white solid (121 mg, 48%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 112.2-113.6 °C; IR ( cm-1): 3455, 2923, 2848, 
1674, 1620, 1591, 1531, 1452; λmax (EtOH)/nm  313.0; 1H NMR (300 MHz, CDCl3) δ 
1.1-1.8 (11H, m, cyclohexyl), 2.3 (3H, s, NMe), 2.4 (8H, m, CH2 piperazine), 2.5 (3H, 
s, Ar-CH3), 2.7 (2H, t, J = 6 Hz, CH2N), 3.2 (2H, t, J = 6 Hz, CH2SO2), 4.2 (2H, d, J = 
6 Hz, OCH2), 7.3 (1H, s, NH), 7.6 (2H, d, J = 9 Hz, Ar-H), 7.7 (2H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 15.2, 25.6, 26.4, 29.8, 37.2, 45.1, 50.8, 51.6, 53.7, 
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54.3, 54.4, 72.3, 114.0,117.6, 129.3, 130.1; MS(ES+) m/z 528.3 [M + H]+; HRMS 
calcd for C26H37N7O3S [M + H]+ 528.2751, found 528.27153. 
 
2-(2-(4-Nitrophenoxy)ethyl)-1,2,3,4-tetrahydroisoquinoline (152) 292 
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The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (500 mg, 2.5 mmol), NaI (560 mg, 3.73 mmol) and 
1,2,3,4-tetrahydroisoquinoline (0.62 mL, 5 mmol). The compound was obtained as a 
yellow solid (521 mg, 81%). 
Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 186-187 °C (lit. 189 °C); 1H NMR (300 MHz, 
CDCl3) δ 2.85 (2H, t, J = 4.5 Hz, CH2N), 2.88 (2H, t, J = 4.5 Hz, CH2CH2N), 3.74 (2H, 
s, PhCH2N), 4.23 (2H, t, J = 5.5 Hz, OCH2), 6.91 (2H, d, J = 9 Hz, Ar-H), 7.03 (4H, br 
s, Ar-H), 8.15 (2H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 27.1, 52.5, 54.3, 
60.7, 66.9, 115.3, 121.7, 125.7, 127.2, 127.5, 128.8, 133.3, 137.1, 140.0, 163.6; 
MS(ES+) m/z 299.34 [M + H]+. 
 
2-(2-(4-Nitrophenoxy)ethyl)isoindoline (151) 293 
 
O2N
O
Cl
O2N
O
N
 
                           112                                               151 
 
The compound was prepared according to General Procedure III from 1-(2-
chloroethoxy)-4-nitrobenzene (500 mg, 2.5 mmol), NaI (560 mg, 3.73 mmol) and 
isoindoline (0.56 mL, 5 mmol). The compound was obtained as a yellow solid (598 
mg, 91%). 
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Rf  = 0.5 (EtOAc/MeOH 9:1); mp: 165-166 °C (lit. 169 °C); 1H NMR (300 MHz, 
CDCl3) δ  3.16 (2H, t, J = 5.5 Hz, CH2N), 4.01 (4H, s, PhCH2N), 4.21 (2H, t, J = 5.5 
Hz, OCH2), 6.93 (2H, d, J = 9 Hz, Ar-H), 7.14 (4H, br s, Ar-H), 8.15 (2H, d, J = 9 Hz, 
Ar-H); 13C NMR (125 MHz, CDCl3) δ 56.5, 60.3, 66.6, 115.3, 121.7, 125.7, 127.0, 
127.5, 128.8, 133.3, 137.1, 140.0, 163.6; MS(ES+) m/z 285.31 [M + H]+. 
 
4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethoxy)benzenamine (154) 292 
 
H2N
O
O2N
O
N N
 
                   152                                                              154 
 
The compound was prepared according to General Procedure IV from 2-(2-(4-
nitrophenoxy)ethyl)-1,2,3,4-tetrahydroisoquinoline (600 mg, 2.01 mmol) and obtained 
as a clear yellow oil (584 mg, 99%). 
Rf = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 2.81 (2H, t, J = 4.5 Hz, 
CH2N), 2.89 (2H, t, J = 4.5 Hz, CH2CH2N), 3.39 (2H, s, PhCH2N), 3.69 (2H, s, NH2), 
4.07 (2H, t, J = 5.5 Hz, OCH2), 6.56 (2H, d, J = 9 Hz, Ar-H), 6.71 (2H, d, J = 9 Hz, Ar-
H), 7.03 (4H, m, Ar-H); 13C NMR (125 MHz, CDCl3) δ 27.1, 52.5, 54.3, 60.7, 66.9, 
115.3, 121.7, 125.7, 127.2, 127.5, 128.8, 133.3, 137.1, 140.0; MS(ES+) m/z 269.35 
[M + H]+. 
 
4-(2-(Isoindolin-2-yl)ethoxy)benzenamine (153) 294 
 
H2N
O
N
O2N
O
N
 
                    151                                                             153 
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The compound was prepared according to General Procedure IV from 2-(2-(4-
nitrophenoxy)ethyl)isoindoline (700 mg, 2.46 mmol) and obtained as a clear yellow 
oil (674 mf, 98%). 
Rf = 0.5 (EtOAc/MeOH 9:1); 1H NMR (300 MHz, CDCl3) δ 3.07 (2H, t, J = 5.5 Hz, 
CH2N), 3.98 (4H, s, PhCH2N), 4.05 (2H, t, J = 5.5 Hz, OCH2), 6.57 (2H, d, J = 9 Hz, 
Ar-H), 6.72 (2H, d, J = 9 Hz, Ar-H), 7.12 (4H, br s, Ar-H); 13C NMR (125 MHz, CDCl3) 
δ 56.5, 60.3, 66.6, 115.3, 116.9, 121.7, 125.7, 127.0, 127.5, 128.8, 133.3, 137.1, 
140.0; MS(ES+) m/z 255.33 [M + H]+. 
 
N-(4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethoxy)phenyl)-6-(cyclohexylmethoxy)-
9H-purin-2-amine (148) 
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N
         154                                                                                          148 
 
The compound was prepared according to General Procedure I from 4-(2-(3,4-
dihydroisoquinolin-2(1H)-yl)ethoxy)benzenamine (450 mg, 1.77 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (221 mg, 0.88 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (311 mg, 57%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 170.2-170.6 °C;  IR (cm-1): 2921, 2848, 1732, 
1584, 1531, 1498, 1448; λmax (EtOH)/nm  207.0; 1H NMR (300 MHz, CDCl3) δ 1.10-
2.07 (11H, m, cyclohexyl), 2.94 (2H, t, J = 6 Hz, CH2N), 3.03 (2H, t, J = 6 Hz, 
PhCH2), 3.82 (2H, s, PhCH2N), 4.17 (2H, t, J = 6 Hz, CH2O), 4.33 (2H, d, J = 6 Hz, 
CH2Cy), 6.87 (2H, d, J = 9 Hz, Ar-H), 6.87 (1H, s, H-8), 6.92 (2H, d, J = 9 Hz, Ar-H), 
7.06 (4H, m, Ar-H), 6.89 (1H, s, NH), 7.49 (2H, d, J = 9 Hz, Ar); 13C NMR (125 MHz, 
CDCl3) δ 14.2, 21.0, 25.7, 26.4, 28.7, 29.8, 37.3, 51.3, 56.7, 56.8, 60.4, 66.4, 72.1, 
76.7, 77.0, 115.1, 122.9, 125.7, 126.2, 126.6, 128.7, 133.8, 156.5; MS(ES+) m/z 
499.36 [M + H]+; HRMS calcd for C29H34N6O2 [M + H]+ 499.2816, found 499.27919. 
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N-(4-(2-(Isoindolin-2-yl)ethoxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (149) 
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The compound was prepared according to General Procedure I from 4-(2-(isoindolin-
2-yl)ethoxy)benzenamine (450 mg, 1.77 mmol) and 6-cyclohexylmethoxy-2-fluoro-
9H-purine (221 mg, 0.88 mmol). The crude product was purified by flash 
chromatography on silica (EtOAc/MeOH 9:1) yielding the title compound as a white 
solid (308 mg, 56%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 177.2-177.6 °C;  IR (cm-1): 2359, 2035, 1734, 
1676, 1584, 1495, 1447; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 1.14-
1.97 (11H, m, cyclohexyl), 3.13 (2H, t, J = 4 Hz, CH2N), 4.03 (4H, s, PhCH2N), 4.11 
(2H, t, J = 6 Hz, CH2O); 4.24 (2H, d, J = 6 Hz, CH2Cy), 6.74 (1H, s, H-8), 6.86  (2H, 
d, J = 9 Hz, Ar-H), 7.13 (1H, s, NH), 7.14 (4H, m, Ar-H), 7.41 (2H, d, J = 9 Hz, Ar-H); 
13C NMR (125 MHz, CDCl3) δ 25.7, 26.4, 29.8, 37.3, 54.7, 59.5, 60.4, 72.1, 76.7, 
77.0, 115.1, 122.3, 126.8; MS(ES+) m/z 485.38  [M + H]+; HRMS calcd for 
C28H32N6O2 [M + H]+ 485.2660, found 485.26181. 
 
3-Aminopiperidin-2-one (167) 183 
 
H2N
COOH
NH2
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                                                 166                                      167 
 
L-Ornithine hydrochloride (1 g, 5.9 mmol) was added to a stirred solution of sodium 
hydroxide pellets (0.23 g, 5.9 mmol) in water (5 mL). After 15 min, this solution was 
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added to a stirred mixture of alumina (3 g) and toluene (100 mL) and heated under 
reflux for 1.5 h. The water produced during the reaction was collected in a Dean–
Stark trap. The reaction mixture was allowed to cool and the alumina was filtered off 
and washed with 10% MeOH/CH2Cl2 (30 mL). The filtrate and washings were 
combined and the solvent removed in vacuo to yield the title compound as a white 
solid (611 mg, 90%). 
Mp 35–37°C; 1H NMR (CDCl3, 500 MHz) δ 1.5–2.1 (4H, m, CH2CH2), 1.75 (2H, bs, 
NH2), 3.2 (2H, m, CH2N), 3.2 (1H, dd, J = 3.8; 3.9 Hz, CHNH2), 7.0 (1H, bs, NH); 13C 
NMR (125 MHz, CDCl3) δ 20.6, 21.8, 29.6, 37.1, 51.0, 168.8; MS(ES+) m/z 115.15 
[M + H]+. 
 
3-Diazo-piperidin-2-one (168) 183 
 
NH
O
H2N NH
O
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                                              167                                     168 
 
3-Amino-piperidin-2-one (1.6 g, 14 mmol) was dissolved in chloroform (30 mL). iso-
Amyl nitrite (2.31 g, 18 mmol) and glacial acetic acid (0.126 g, 2.1 mmol) were added 
with stirring. The resulting solution was heated to reflux and stirred for 15 min, cooled 
in ice and washed with an ice-cold saturated solution of NaHCO3 (10 mL). The 
organic layer was separated, dried over Na2SO4 and the solvent removed in vacuo. 
The solid was purified by column chromatography on silica (20% MeOH/CH2Cl2) to 
give the title compound as bright orange needles (1.07 g, 60%). 
Mp 117–120°C; 1H NMR (CDC13, 500 MHz) δ 1.9 (2H, m, CH2), 2.7 (2H, t, J = 6.3 
Hz, CH2), 3.25 (2H, m, CH2N), 6.5 (1H, bs, NH); 13C NMR (CDCl3, 500 MHz) δ 20 
(CH2), 21 (CH2), 41 (CH2N), 53 (C=N2),167 (C=O); MS(ES+) m/z 126.13 [M + H]+. 
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tert-Butyl 4-(2-oxopiperidin-3-yloxy)phenylcarbamate (169) 183 
 
NH
O
N2
NH
O
BocHN
O
 
                                 168                                           169 
 
3-Diazo-piperidin-2-one (1.5 g, 12 mmol) was dissolved in THF (25 mL). tert-Butyl 4-
hydroxyphenylcarbamate (5 g, 72 mmol) was added in portions, then 
Rhodium(II)acetate (35 mg). The solution was stirred for 10 h. The solution was 
concentrated under reduced pressure and the residue taken up in CH2Cl2 (20 mL) 
and washed with saturated aqueous NaHCO3. The organic layer was separated, 
dried over Na2SO4 and the solvent removed in vacuo. The solid was purified by 
column chromatography on silica (EtOAc/Petrol 1:1) to give the title compound as a 
white solid (502 mg, 41%). 
Mp 156–158°C; 1H NMR (CDC13, 500 MHz) δ 1.43 (4H, s, (CH3)3), 1.52 (5H, s, 
(CH3)3), 1.62-2.05 (4H, m, CH2CH2), 3.25 (2H, dd, J = 7.5; 5.5 Hz, CH2NH), 4.51 
(1H, dd, J = 7.5; 5.5 Hz, CHOAr), 5.75 (1H, s, NH), 6.25 (1H, s, NH), 6.93 (2H, d, J = 
9 Hz, Ar-H), 7.19 (2H, d, J = 9 Hz, Ar-H); 13C NMR (CDCl3, 500 MHz) δ 20 (CH2), 21 
(CH2), 41 (CH2N), 53 (C=N2),167 (C=O); MS(ES+) m/z 307.36 [M + H]+. 
 
tert-Butyl 4-(2-oxopiperidin-3-yloxy)phenylcarbamate (170) 295 
 
NH
O
BocHN
O
NH
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                          169                                                               170 
 
tert-Butyl 4-(2-oxopiperidin-3-yloxy)phenylcarbamate (129 mg, 0.49 mmol) was 
dissolved in anhydrous THF (10 mL) and cooled to 0 °C. LiAlH 4 (1M in THF, 1.4 mL, 
1.2 mmol) was added dropwise and the reaction was allowed to warm up to room 
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temperature and stirred for 3 h. The reaction was quenched adding dropwise: water 
(0.2 mL), 15% (w/v) aqueous NaOH (0.2 mL) and then water again (0.6 mL). The 
resulting grey suspension was stirred for 30 min. The resulting white precipitate was 
filtered through a pad of celite and the filtrate was evaporated to give an oil which 
was taken up in CH2Cl2 (20 mL) and washed with water (2 x 20 mL). It was then 
dried over Na2SO4, evaporated and the resulting solid was purified by flash 
chromatography (EtOAc/MeOH 95:5), yielding the title compound as an off-white 
solid (44 mg, 38%). 
 
Rf = 0.25 (EtOAc/MeOH 9:1); mp: 125-126 oC 1H NMR (300 MHz, CDCl3) δ 1.43 
(9H, s, (CH3)3), 1.73 (4H, m, CH2CH2), 2.73 (2H, dd, J = 7.5; 5.5 Hz, NHCH2), 2.85 
(2H, dd, J = 7.5; 5.5 Hz, CH2NH), 4.04 (1H, dd, J = 7.5; 5.5 Hz, CHOAr), 6.48 (1H, s, 
NH), 6.50 (2H, d, J = 9 Hz, Ar-H), 6.77 (2H, d, J = 9 Hz, Ar-H); 13C NMR (75 MHz, 
CDCl3) δ 24.4, 25.5, 25.9, 26.4, 29.6, 32.2, 37.3, 54.2, 58.5, 71.5, 119.5, 126.9, 
131.0, 140.3; MS(ES+) m/z 293.37 [M + H]+. 
 
tert-Butyl (4-((1-benzylpiperidin-3-yl)oxy)phenyl)carbamate (157)  
 
 
BocHN
O
NH
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N
                170                                                                     157 
 
In a microwave vial, to a stirred solution of tert-butyl 4-(2-oxopiperidin-3-
yloxy)phenylcarbamate (50 mg, 0.18 mmol) in THF (3 mL) were added 
benzaldehyde (12.6 µl, 0.12 mmol), phenylsilane (13.1 µl, 0.12 mmol) and 
dibutyldichlorostannane (3 mg, catalytic). The reaction mixture was heated for 15 
min at 100 °C under microwave irradiation. The mixt ure was filtered through a thiol-
based resin to eliminate excess tin, then concentrated under reduced pressure. The 
crude product was purified by flash chromatography (EtOAc), yielding the title 
compound as a white solid (21 mg, 74%). 
Rf = 0.35 (EtOAc); mp: 101-102 oC; 1H NMR (300 MHz, CDCl3) δ 1.43 (9H, s, 
(CH3)3), 1.78 (4H, m, CH2CH2), 2.43 (2H, dd, J = 7.5; 5.5 Hz, NCH2), 3.05 (2H, dd, J 
261 
 
= 7.5; 5.5 Hz, CH2N), 3.5 (2H, 2 x d, J = 6.5, NCH2Ph), 4.25 (1H, dd, J = 7.5; 5.5 Hz, 
CHOAr), 6.28 (1H, s, NH), 6.75 (2H, d, J = 9 Hz, Ar-H), 7.10 (5H, m, Ar-H), 7.27 (2H, 
d, J = 9 Hz, Ar-H); 13C NMR (75 MHz, CDCl3) δ 24.3, 25.8, 25.9, 27.1, 30.2, 33.7, 
38.0, 54.2, 58.5, 79.5, 114.8, 119.5, 126.9, 131.0, 140.3, 152.8; MS(ES+) m/z 
383.57 [M + H]+. 
 
 
N-(4-((1-Benzylpiperidin-3-yl)oxy)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (150) 
 
 
            157                                                           150 
 
The compound was prepared according to General Procedure I from tert-butyl (4-((1-
benzylpiperidin-3-yl)oxy)phenyl)carbamate (10 mg, 0.026 mmol) and 6-
cyclohexylmethoxy-2-fluoro-9H-purine (32 mg, 0.013 mmol). The crude product was 
purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding the title 
compound as a white solid (38 mg, 46%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 177.2-177.6 °C;  IR (cm-1): 2539, 2053, 1743, 
1667, 1548, 1459, 1474; λmax (EtOH)/nm  272.0; 1H NMR (300 MHz, CDCl3) δ 0.84-
1.90 (11H, m, cyclohexyl), 2.45 (2H, dd, J = 7.5; 5.5 Hz, NCH2), 3.15 (2H, dd, J = 
7.5; 5.5 Hz, CH2N), 3.50 (2H, 2 x d, J = 6.5, NCH2Ph), 4.27 (1H, dd, J = 7.5; 5.5 Hz, 
CHOAr), 6.78 (1H, s, NH), 7.15 (2H, d, J = 9 Hz, Ar-H), 7.20 (5H, m, Ar-H), 7.57 (2H, 
d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 26.0 ; 26.8, 30.1, 37.8, 48.6, 54.0, 
68.6, 72.5, 115.4, 115.7, 116.7, 122.8, 127.3, 128.4, 128.7, 133.6, 137.8, 140.5, 
154.9, 155.6, 157.1, 161.6; MS(ES+) m/z 513.28  [M + H]+; HRMS calcd for 
C28H32N6O2 [M + H]+ 513.65600, found 513.66530. 
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Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione (232) 296 
 
 
            230                                231                                                         232 
 
To 150 mL of stirred EtOH were added 2.3 g of sodium (0.1 mol) and the suspension 
was stirred until all the sodium had dissolved. 1H-Pyrazol-5-amine (4.2 g, 50 mmol) 
was added, followed by diethylmalonate (8.25 mL, 55 mmol). The solution was 
heated to reflux and stirred for 4 h. The white precipitate was collected and stirred in 
1.2 M HCl for 2 h, then filtered and dried (3.8 g, 68%). Due to complete insolubility of 
the compound, only the measurement of melting point was possible (decomposed at 
350 oC), therefore the compound was carried forward to the next step without 
characterisation. 
 
 
5,7-Dichloropyrazolo[1,5-a]pyrimidine (233) 296 
 
 
          232                                                            233 
 
In a microwave vial, to pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione (200 mg, 6.61 
mmol) was added POCl3 (5 mL). The reaction mixture was heated for 30 min at 150 
°C under microwave irradiation. The reaction mixtur e was poured onto ice, then 2.5 
M NaOH was added until pH neutral. NaCl was added until saturation, and the 
resulting solution was extracted with THF (3 x 30 mL). The organic layers were 
collected, combined and dried over Na2SO4, and the solvent was removed in vacuo. 
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The crude product was purified by flash chromatography (EtOAc/Hexane 1:1) 
yielding the title compound as an off white solid (176 mg, 74%). 
Rf = 0.35 (EtOAc); mp: 68-71 oC; 1H NMR (300 MHz, CDCl3) δ 6.68 (1H, s, H3), 6.93 
(1H, s, H4), 8.16 (1H, s, H8); 13C NMR (75 MHz, CDCl3) δ 96.3, 122.8, 144.9, 148.1, 
164.2, 171.7; MS(ES+) m/z 187.57 [M + H]+. 
 
 
5-Chloro-N-(4-((2-(4-methylpiperazin-1-yl)ethyl)sulfonyl)phenyl)pyrazolo[1,5-
a]pyrimidin-7-amine (234) 
 
 
        233                                                                                  234 
 
The compound was prepared according to General Procedure I from 5,7-
dichloropyrazolo[1,5-a]pyrimidine (50 mg, 0.26 mmol) and tert-butyl 4-(2-(4-
methylpiperazin-1-yl)ethylsulfonyl)phenylcarbamate (150 mg, 0.52 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding 
the title compound as a white solid (98 mg, 49%). 
Rf  = 0.28 (EtOAc/MeOH 9:1); mp: 135-137 °C; IR (cm-1) 2926, 2844, 1590, 1535, 
1499, 1444; λmax (EtOH)/nm: 312; 1H NMR (300 MHz, CDCl3) δ 2.35 (3H, s, NMe), 
2.67 (8H, m, piperazine ring), 2.69 (2H, t, J = 7 Hz, CH2N), 3.19 (2H, t, J = 7 Hz, 
CH2SO2), 6.52 (2H, d, J = 18 Hz, H3 het.), 6.90 (1H, s, H4 het), 7.76 (2H, d, J = 9 Hz, 
Ar-H), 7.49 (2H, d, J = 9 Hz, Ar-H), 8.16 (1H, s, H8 het); 13C NMR (75 MHz, CDCl3) δ 
26.0, 26.7, 30.1, 37.6, 46.0, 51.6, 52.8, 54.1, 55.0, 72.9, 115.6, 118.0, 129.6, 130.8, 
139.6, 145.8, 155.1, 161.1; MS(ES+) m/z 435.3 [M(35Cl) + H]+; 437.3 [M(37Cl) + H]+; 
anal. calcd for C19H23ClN6O2S: C, 52.46, H, 5.87, N, 19.09%; found: C, 52.65, H, 
5.49, N, 19.11%. 
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5-(Cyclohexylmethoxy)-N-(4-((2-(4-methylpiperazin-1-
yl)ethyl)sulfonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-amine (229) 
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In a microwave vial, to 5-chloro-N-(4-((2-(4-methylpiperazin-1-
yl)ethyl)sulfonyl)phenyl)pyrazolo[1,5-a]pyrimidin-7-amine (50 mg, 0.11 mmol) was 
added THF (5 mL) and cyclohexylmethanol (800 µl, 1.14 mmol). In a second 
microwave vial, a catalytic amount of Pd(OAc)2 (1.5 mg), ligand A (see Chapter 5, 
1.3 mg) and cesium carbonate (60 mg, 0.171 mmol) were flushed with nitrogen for 1 
h. The mixture from the first vial was added into the second vial, and the reaction 
mixture was heated for 30 min at 120 °C under micro wave irradiation. The reaction 
mixture was filtered through a celite pad and the solvent was removed in vacuo. The 
crude product was purified by flash chromatography (EtOAc) yielding the title 
compound as an off white solid (46 mg, 44%). 
Rf  = 0.28 (EtOAc/MeOH 9:1); mp: 146-148 °C; IR (cm-1) 2999, 2996, 1690, 1630, 
1598, 1567, 1834; λmax (EtOH)/nm: 312; 1H NMR (300 MHz, CDCl3) δ 0.78-1.18 (5H, 
m, cyclohexyl), 1.65-1.84 (6H, m, cyclohexyl), 2.35 (3H, s, NMe), 2.67 (8H, m, 
piperazine ring), 2.69 (2H, t, J = 7 Hz, CH2N), 3.19 (2H, t, J = 7 Hz, CH2SO2), 6.67 
(2H, d, J = 18 Hz, H3 het.), 6.91 (1H, s, H4 het), 7.76 (2H, d, J = 9 Hz, Ar-H), 7.50 
(2H, d, J = 9 Hz, Ar-H), 7.66 (1H, s, H8 het); 13C NMR (75 MHz, CDCl3) δ 26.0, 26.7, 
30.1, 37.6, 46.0, 51.6, 52.8, 54.1, 55.0, 72.9, 115.6, 118.0, 129.6, 130.8, 139.6, 
145.8, 155.1, 161.1; MS(ES+) m/z 513.3 [M + H]+; anal. calcd for C26H36N6O3S: C, 
60.96, H, 7.07, N, 16.39%; found: C, 60.95, H, 7.09, N, 16.41%. 
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6-(Cyclohexylmethoxy)-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (202) 
 
                   55                                                                  202 
To 500 mg of 6-cyclohexylmethoxy-2-fluoropurine in 15 mL of EtOAc were added 
313 µL of 3,4-dihydro-2H-pyran and 30 mg of camphosulfonic acid (catalytic). The 
reaction mixture was heated at 60 °C for 18 h, then  washed twice with 20 mL of 
saturated aqueous sodium bicarbonate. The combined organic layers were 
concentrated in vacuo and the crude product was purified by flash column 
chromatography (EtOAc/Hexane 1:1), yielding the title compound as a white solid 
(350 mg, 65%). 
Rf  = 0.51 (EtOAc/Hexane 3:1); mp: 146-148 °C; IR (cm-1) 2999, 2996, 1690, 1630, 
1598, 1567; λmax (EtOH)/nm: 312; 1H NMR (300 MHz, CDCl3) δ 1.08-1.23 (5H, m, 
cyclohexyl), 1.54-2.02 (11H, m, cyclohexyl + THP), 3.71 (1H, t, J = 11 Hz, H3 ax 
THP), 4.08 (1H, d, J = 11 Hz, H3 eq THP), 4.31 (2H, d, J = 6 Hz, CH2Cy), 5.58 (1H, 
d, J = 10.5 Hz, H1 THP), 8.00 (1H, s, H8 purine); 13C NMR (75 MHz, CDCl3) δ 22.7, 
24.8, 25.6, 26.3, 29.6, 31.8, 37.1, 68.8, 73.3, 82.1, 140.0, 158.9, 162.9; MS(ES+) 
m/z 331.3 [M + H]+; anal. calcd for C17H25N5O2: C, 61.96, H, 7.07, N, 21.39%; found: 
C, 61.95, H, 7.09, N, 21.41%. 
 
6-(Cyclohexylmethoxy)-2-fluoro-8-methyl-9-(tetrahydro-2H-pyran-2-yl)-9H-
purine (203) 
 
               202                                                             203 
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The compound was prepared according to General Procedure V using 300 mg (0.89 
mmol) of 202, 189 µL (1.34 mmol) of diisopropylamine, 536 µL of nBuLi solution and 
167 µL (2.69 mmol) of MeI. The crude product was purified by flash chromatography 
on silica (EtOAc/Hexane 1:1) yielding the title compound as a white solid (154 mg, 
51%). 
Rf  = 0.51 (EtOAc/Hexane 1:1); mp: 146-148 °C; IR (cm-1) 2925, 2852, 2324, 1610, 
1584, 1446; λmax (EtOH)/nm: 257; 1H NMR (300 MHz, CDCl3) δ 1.17-1.20 (5H, m, 
cyclohexyl), 1.64-1.97 (11H, m, cyclohexyl + THP), 2.64 (3H, s, C8-Me), 3.71 (1H, t, 
J = 11 Hz, H3 ax THP), 4.11 (1H, d, J = 11 Hz, H3 eq THP), 4.30 (2H, d, J = 6 Hz, 
CH2Cy), 5.48 (1H, d, J = 10.5 Hz, H1 THP); 13C NMR (75 MHz, CDCl3) δ 14.2, 16.1, 
21.0, 23.1, 24.8, 25.6, 26.3, 29.6, 30.1, 37.1, 60.4, 69.1, 73.1, 82.9, 118.1, 151.6, 
153.8, 154.0, 156.5, 158.2, 161.6, 161.7; MS(ES+) m/z 265.2 [M + H]+. 
 
6-(Cyclohexylmethoxy)-2-fluoro-8-ethyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
(204) 
 
                202                                                            204 
The compound was prepared according to General Procedure V using 300 mg (0.89 
mmol) of 202, 379 µL (2.69 mmol) of diisopropylamine, 1.07 mL of nBuLi solution 
and 334 µL (5.29 mmol) of MeI. The crude product was purified by flash 
chromatography on silica (EtOAc/Hexane 1:1) yielding the title compound as a white 
solid (210 mg, 80%). 
Rf  = 0.51 (EtOAc/Hexane 1:1); mp: 146-148 °C; IR (cm-1) 2927, 2854, 1614, 1581, 
1442; λmax (EtOH)/nm: 258; 1H NMR (300 MHz, CDCl3) δ 1.13-1.21 (5H, m, 
cyclohexyl), 1.36 (3H, dd, J = 13; 2.5 Hz, C8-CH2CH3), 1.64-1.81 (11H, m, cyclohexyl 
+ THP), 2.97 (2H, dq, J = 13; 2.5 Hz, C8-CH2CH3), 3.61 (1H, t, J = 11 Hz, H3 ax 
THP), 4.09 (1H, d, J = 11 Hz, H3 eq THP), 4.30 (2H, d, J = 6 Hz, CH2Cy), 5.56 (1H, 
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d, J = 10.5 Hz, H1 THP); 13C NMR (75 MHz, CDCl3) δ 12.1, 22.6, 23.2, 24.8, 25.6, 
26.3, 29.6, 30.1, 37.0, 60.4, 69.1, 73.1, 83.1, 118.4, 153.8, 154.0, 156.3, 156.4, 
158.1, 161.7, 161.8; MS(ES+) m/z 363.4 [M + H]+. 
 
6-(Cyclohexylmethoxy)-2-fluoro-8-isopropyl-9-(tetrahydro-2H-pyran-2-yl)-9H-
purine (205) 
 
 
               202                                                             205 
 
The compound was prepared according to General Procedure V using 100 mg (0.27 
mmol) of 202, 45 µL (0.38 mmol) of diisopropylamine, 160 µL of nBuLi solution and 
60 µL (0.76 mmol) of MeI. The crude product was purified by flash chromatography 
on silica (EtOAc/Hexane 1:1) yielding the title compound as a white solid (115 mg, 
82%). 
Rf  = 0.51 (EtOAc/Hexane 1:1); mp: 146-148 °C; IR (cm-1) 2358, 2304, 2212, 2126, 
1946, 1617; λmax (EtOH)/nm: 258; 1H NMR (300 MHz, CDCl3) δ 0.93-1.18 (5H, m, 
cyclohexyl), 1.37 (6H, d, J = 13 Hz, C8-CH(CH3)2), 1.66-1.71 (11H, m, cyclohexyl + 
THP), 2.57 (2H, dq, J = 13; 2.5 Hz, C8-CH(CH3)2), 3.38 (1H, t, J = 11 Hz, H3 ax 
THP), 3.69 (1H, d, J = 11 Hz, H3 eq THP), 4.30 (2H, d, J = 6 Hz, CH2Cy), 5.56 (1H, 
d, J = 10.5 Hz, H1 THP); 13C NMR (75 MHz, CDCl3) δ 21.5, 22.0. 22.6, 23.2, 23.3, 
24.8, 25.6, 26.4, 28.0, 29.6, 30.1, 37.1, 69.2, 73.1, 83.1, 160.1, 161.9; MS(ES+) m/z 
293.4 [M + H]+. 
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6-(Cyclohexylmethoxy)-2-fluoro-8-methyl-9H-purine (206) 
 
                203                                                            206 
The compound was prepared according to General Procedure VI  from 150 mg (0.43 
mmol) of 203, yielding the title compound as a white solid (125 mg, 100%). 
Rf  = 0.21 (EtOAc/Hexane 1:1); mp: 169-170 °C; IR (cm-1) 2925, 2852, 2324, 1610, 
1584, 1446; λmax (EtOH)/nm: 258; 1H NMR (300 MHz, CDCl3) δ 1.07-1.90 (11H, m, 
cyclohexyl), 2.62 (3H, s, C8-Me), 4.30 (2H, d, J = 6 Hz, CH2Cy); 13C NMR (75 MHz, 
CDCl3) δ 15.3, 25.6, 26.3, 29.6, 37.1, 73.4; MS(ES+) m/z 265.2 [M + H]+. 
 
6-(Cyclohexylmethoxy)-2-fluoro-8-ethyl-9H-purine (207) 
 
                 204                                                            207 
The compound was prepared according to General Procedure VI  from 150 mg (0.43 
mmol) of 204, yielding the title compound as a white solid (131 mg, 100%). 
Rf  = 0.21 (EtOAc/Hexane 1:1); mp: 169-170 °C; IR (cm-1) 2534, 2159, 2025, 1976, 
1609, 1530, 1416; λmax (EtOH)/nm: 258; 1H NMR (300 MHz, CDCl3) δ 0.98-1.21 (5H, 
m, cyclohexyl), 1.40 (3H, t, J = 10 Hz, C8-CH2CH3), 1.66-1.83 (6H, m, cyclohexyl),  
2.95 (2H, q, J = 10 Hz, C8-CH2CH3), 4.30 (2H, d, J = 6 Hz, CH2Cy); 13C NMR (75 
MHz, CDCl3) δ 12.1, 23.0, 25.6, 26.3, 29.6, 37.1, 73.3; MS(ES+) m/z 279.3 [M + H]+. 
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6-(Cyclohexylmethoxy)-2-fluoro-8-isopropyl-9H-purine (208) 
 
                205                                                            208 
The compound was prepared according to General Procedure VI  from 100 mg (0.33 
mmol) of 205, yielding the title compound as a white solid (71 mg, 85%). 
Rf  = 0.21 (EtOAc/Hexane 1:1); mp: 169-170 °C; IR (cm-1) 2923, 2854, 1604, 1524, 
1442; λmax (EtOH)/nm: 258; 1H NMR (300 MHz, CDCl3) δ 0.98-1.21 (5H, m, 
cyclohexyl), 1.41 (6H, d, J = 10 Hz, C8-CH(CH3)2), 1.66-1.83 (6H, m, cyclohexyl),  
3.25 (2H, ept, J = 10 Hz, C8-CH(CH3)2), 4.32 (2H, d, J = 6 Hz, CH2Cy); 13C NMR (75 
MHz, CDCl3) δ 21.1, 25.6, 26.3, 29.5, 29.6, 37.1, 73.3; MS(ES+) m/z 291.3 [M + H]+. 
 
6-(Cyclohexylmethoxy)-8-methyl-N-(4-(2-(4-methylpiperazin-1-
yl)ethoxy)phenyl)-9H-purin-2-amine (199) 
 
 
               206                                                                    199 
The compound was prepared according to General Procedure I from 4-(2-(4-
methylpiperazin-1-yl)ethoxy)benzenamine (215 mg, 0.88 mmol) and 6-
cyclohexylmethoxy-2-fluoro-8-methyl-9H-purine (120 mg, 0.43 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding 
the title compound as a white solid (106 mg, 44%). 
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Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 156.0-156.9 °C;  IR (cm-1): 2977, 1805, 1753, 
1737, 1672, 1624, 1586, 1529, 1505, 1452, 1401; λmax (EtOH)/nm  273.0; 1H NMR 
(300 MHz, CDCl3) δ 1.17-1.83 (11H, m, cyclohexyl), 2.23 (3H, s, NMe), 2.29 (3H, s, 
C8-Me), 2.43-2.57 (8H, m, piperazine), 2.74 (2H, t, J = 6 Hz, OCH2CH2N), 3.99 (2H, 
t, J = 6 Hz, OCH2CH2N) , 4.21 (2H, d, J = 6 Hz, OCH2Cy), 6.78 (2H, d, J = 9 Hz, Ar-
H), 7.05 (1H, s, NH), 7.34 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 
25.7, 26.4, 29.8, 37.2, 46.0, 53.5, 55.0, 57.2, 66.1, 71.9, 114.9, 121.1; MS(ES+) m/z 
480.4  [M + H]+; HRMS calcd for C26H37N7O2 [M + H]+ 480.3081, found 480.3076. 
 
6-(Cyclohexylmethoxy)-8-ethyl-N-(4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-
9H-purin-2-amine (200) 
 
               207                                                                     200 
The compound was prepared according to General Procedure I from 4-(2-(4-
methylpiperazin-1-yl)ethoxy)benzenamine (202 mg, 0.86 mmol) and 6-
cyclohexylmethoxy-2-fluoro-8-ethyl-9H-purine (120 mg, 0.43 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding 
the title compound as a white solid (109 mg, 45%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 156.0-156.9 °C;  IR (cm-1): 2924, 2847, 2800, 
1810, 1745, 1740, 1682, 1665, 1587, 1535, 1507, 1450, 1400; λmax (EtOH)/nm  
272.0; 1H NMR (300 MHz, CDCl3) δ 0.90-1.15 (5H, m, cyclohexyl), 1.16 (3H, t, J = 11 
Hz, C8-CH2CH3), 1.65-1.97 (6H, m, cyclohexyl), 2.28 (3H, s, NMe), 2.65 (8H, m, 
piperazine), 2.66 (2H, q, J = 11 Hz, C8-CH2CH3), 2.74 (2H, t, J = 6 Hz, OCH2CH2N), 
4.02 (2H, t, J = 6 Hz, OCH2CH2N) , 4.22 (2H, d, J = 6 Hz, OCH2Cy), 6.77 (2H, d, J = 
9 Hz, Ar-H), 7.41 (1H, s, NH), 7.34 (1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, 
CDCl3) δ 12.2, 22.6, 25.7, 26.4, 29.8, 37.2, 46.0, 53.5, 55.0, 57.2, 66.2, 71.99, 114.9, 
121.1, 133.3, 152.2, 154.3; MS(ES+) m/z 494.4  [M + H]+; HRMS calcd for 
C27H39N7O2 [M + H]+ 494.3238, found 494.3232. 
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6-(Cyclohexylmethoxy)-8-isopropyl-N-(4-(2-(4-methylpiperazin-1-
yl)ethoxy)phenyl)-9H-purin-2-amine (201) 
 
               208                                                                      201 
The compound was prepared according to General Procedure I from 4-(2-(4-
methylpiperazin-1-yl)ethoxy)benzenamine (112 mg, 0.48 mmol) and 6-
cyclohexylmethoxy-2-fluoro-8-isoprophyl-9H-purine (70 mg, 0.24 mmol). The crude 
product was purified by flash chromatography on silica (EtOAc/MeOH 9:1) yielding 
the title compound as a white solid (79 mg, 55%). 
Rf  = 0.25 (EtOAc/MeOH 9:1); mp: 156.0-156.9 °C;  IR (cm-1): 2337, 2254, 2126, 
1749, 1738, 1727, 1710; λmax (EtOH)/nm  274.0; 1H NMR (300 MHz, CDCl3) δ 0.90-
1.15 (5H, m, cyclohexyl), 1.30 (6H, d, J = 11 Hz, C8-CH(CH3)2), 1.65-1.97 (6H, m, 
cyclohexyl), 2.24 (3H, s, NMe), 2.71 (8H, m, piperazine), 2.75 (1H, ept, J = 11 Hz, 
C8-CH(CH3)2), 2.76 (2H, t, J = 6 Hz, OCH2CH2N), 4.00 (2H, t, J = 6 Hz, OCH2CH2N) , 
4.24 (2H, d, J = 6 Hz, OCH2Cy), 6.77 (2H, d, J = 9 Hz, Ar-H), 7.41 (1H, s, NH), 7.34 
(1H, d, J = 9 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δ 21.3, 25.7, 26.5, 29.1, 29.9, 
37.1, 46.0, 53.6, 55.0, 57.2, 57.3, 66.3, 66.6, 114.9, 115.8, 116.3, 121.2, 140.1, 
155.5, 155.8; MS(ES+) m/z 508.5  [M + H]+; HRMS calcd for C28H41N7O2 [M + H]+ 
508.3395, found 508.3388. 
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7.7 Protein expression, kinase assays, MS and SPR 
 
Protein expression and purification (performed by colleagues at the 
Department of Biochemistry, University of Oxford) 
 
CDK2 phosphorylated at T160 (produced in Escherichia coli by coexpression of 
human GST–CDK2 and S. cerevisiae GST–Cak1), human cyclin A3 (residues 174-
432), GST–3C-protease and GST–pRb (residues 792–928) were expressed and 
purified as previously described. 297 S. cerevisiae GST–Cak1 (also called Civ1) was 
expressed and purified as previously described. 298 
 
GST-tagged K88E K89V mutant CDK2 (GST-CDK2*) was generated using a pGEX 
6P-I expression plasmid. E. coli competent cells (strain BL21 (DE3) pLysS) were 
transformed with the plasmid (as per standard transformation protocol provided by 
supplier) and then grown in LB medium supplemented with 0.1 mg/ml ampicillin to an 
optical density of 0.9 at 37 °C and then at 20 °C f or 2 h, before induction with 20 mM 
isopropyl-β-D-thiogalactoside (IPTG) and further incubation for 20–24 h at 20 °C. 
Centrifuged cells were resuspended in HEPES-buffered saline (HBS) containing 
protease inhibitors (10 mM HEPES, pH 7.4, 135 mM NaCl, 3 mM EDTA, 0.01% (v/v) 
monothioglycerol, and 0.01 % (w/v) sodium azide containing 0.1 mM 
phenylmethylsulphonyl fluoride (PMSF), 0.7 mg ml–1 pepstatin A and 0.5 mg ml–1 
leupeptin) and stored at –20 °C. 
 
Cells expressing GST–CDK2* were thawed and sonicated on ice. The clarified lysate 
was applied to a glutathione–Sepharose column (Amersham) equilibrated in HBS 
and washed with the same buffer. GST-CDK2* was eluted with freshly prepared 20 
mM glutathione in HBS and phosphorylated on Thr160 in the presence of 1/10 w/w 
GST-Civ1, 50 mM Tris-HCl pH 7.5, 10 mM magnesium chloride, 1 mM ATP for 18 h 
at 4 °C. Phospho-T160-GST-CDK2* was purified from G ST–Civ1 by gel filtration 
(Superdex SD-200). The pooled fractions from the gel filtration were applied to a 
second glutathione-Sepharose column, followed by a clarified lysate from thawed 
and sonicated cyclin-A3-expressing cells. The GST-pCDK2*/cyclin A complex was 
eluted with freshly prepared 20 mM glutathione in HBS and subjected to GST–3C-
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protease digestion (1/50 w/w, 18 h, 4 °C). pCDK2*/cyclin A was further purified  from 
GST dimer by gel filtration (Superdex SD-200) and a third glutathione–Sepharose 
column. 
 
Band shift assays 
 
Activity of both mutant and wild type CDK2/A was checked by gel shift on SDS-
PAGE using 15% acrylamide. Enzyme concentration (except for negative controls) 
was at 8 µg/ml, against 50 µg/ml pRb as substrate. Kinase reactions were performed 
in 10 µl of buffer containing 50 mM Tris-HCl pH 7.5, 10 mM magnesium chloride, 1.0 
mM ATP for 15 min at RT, monitoring at the following time intervals: 0’, 1’, 5’, 10’, 
15’. 
 
Radioactive kinase assays (kindly performed by Lan-Zhen Wang at the 
Northern Institute for Cancer Research, and by Elizabeth Anscombe at the 
department of Biochemistry, University of Oxford) 
 
The assay conditions used for evaluating the time-dependent inhibitory activity of 
NU6300 and NU6310 against CDK2 were as previously described. 199  
The purified enzyme was reacted with radiolabelled [32P] ATP and the protein 
substrate. The assay involved detecting the transfer of the radiolabelled γ-phosphate 
group from ATP to the protein substrate. 
IC50 determinations were carried out at five different concentrations of inhibitor to be 
tested. The IC50 is the concentration required to inhibit enzyme activity by 50% under 
the assay conditions employed. 
Compounds were dissolved in DMSO to give an initial 50 mM stock solution. 
Inhibitors were tested in the assay at a final DMSO concentration of 1%, and hence 
were diluted with the buffer solution 1/50 from the original stock solution. It was 
assumed that employing a higher concentration of DMSO in the assays would 
denaturate the enzyme.  
 
Radiolabelled [32P] ATP was added to the buffered inhibitor, which was incubated for 
ten minutes at 30 °C. After incubation, the assay m ixture was spotted onto 
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phosphocellulose filter paper to bind the protein, allowing a 20 second time interval 
for drying. The labelled filter paper was transferred to a stirred solution of 1% 
aqueous phosphoric acid to dilute the phosphate substrate, thereby terminating the 
reaction. The filters were washed a further 5-6 times for five minutes each and dried 
over paper towels, before being placed in a scintillation counter.  
The amount of [32P] incorporated into the histone was measured by counting the 
number of disintegrations per minute, giving an experimental measurement of 
enzyme activity.  
Control assays (without inhibitor) were also carried out in 1% DMSO solution, with 
the control defined as having 100% enzyme activity. The percentage of remaining 
activity was derived from the ratio of inhibitor activity to the activity of the control 
assay (pure enzyme). The percentage inhibition was equal to 100 minus the 
percentage of the remaining activity. 
 
% Remaining Activity = Inhibitor Activity / Control Activity 
% Inhibition = 100 - % Remaining Activity 
 
IC50 values for the inhibitors were determined by plotting the percentage of inhibition 
against inhibitor concentration. 
 
ESI Mass Spectrometry (kindly performed by David Staunton at the 
Department of Biochemistry, University of Oxford) 
 
Protein samples (at 3 mg/ml in HBS buffer) were desalted using C4 ZipTips 
(Millipore) as per manufacturer's instructions. The samples in 1:1 (v/v) acetonitrile 
and water + 0.1% formic acid were introduced at a flow rate of 10ul/min by 
electrospray ionisation (ESI) into a Micromass LCT orthogonal acceleration reflecting 
TOF mass spectrometer in positive ion mode. The mass spectrometer had been 
calibrated using myoglobin. 
The resultant m/z spectra were converted to mass spectra by using the maximum 
entropy analysis MaxEnt in the MassLynx suite of programmes. 
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Tryptic digest and MALDI-TOF TOF MS/MS (kindly performed by Ben Thomas 
at the Sir William Dunn School of Pathology, University of Oxford) 
 
Coomassie stained gel bands were excised and diced into 1 mm cubes before being 
destained with three washes of 25 mM ammonium bicarbonate (Fluka) in 50:50 (v/v) 
acetonitrile (Sigma) and water. Gel pieces were dehydrated with a wash of 
acetonitrile and reduced in 10 mM DTT (Fluka) for 30 minutes. Gel pieces were then 
washed twice with 25 mM ammonium bicarbonate and dehydrated with one wash of 
acetonitrile prior to being alkylated with 55 mM iodoacetamide (Fluka) for one hour. 
Gel pieces were washed twice with 25 mM ammonium carbonate and dehydrated 
with an acetonitrile wash. The gel pieces were dried in a SpeedVac (Thermo 
Savant). 3 µg of trypsin (Promega) in 25 mM ammonium bicarbonate were added to 
the gel pieces and the gel pieces were incubated at 37 °C overnight. The gel pieces 
were acidified to 1% formic acid. The supernatant was then collected in a fresh tube. 
The gel pieces were then incubated once with 0.1% formic acid (Sigma) in 5% 
aqueous acetonitrile for 30 min and once in 0.1% formic acid in 60% aqueous  
acetonitrile. The supernatants were pooled and dried to near dryness in a SpeedVac. 
The supernatant was then desalted using an in-house manufactured C18 reverse-
phase tip consisting of a C18 plug (3M, Empore) packed into a pipette tip. The tip 
was wetted with several washes of acetonitrile containing 0.1% formic acid and then 
conditioned with several washes aqueous of 5% acetonitrile containing 0.1% formic 
acid. The sample was then bound by passing it twice over the tip. The salt was then 
washed off the tip with a wash of aqueous 5% acetonitrile containing 0.1% formic 
acid. The sample was then eluted in a small volume of aqueous 60% acetonitrile 
containing 0.1% formic acid and concentrated in a SpeedVac. 
Mass spectrometry data were acquired on an Orbitrap mass spectrometer (Thermo) 
fitted with a nanospray source (Proxeon) coupled to a U3000 nano HPLC system 
(Dionex). The sample was loaded onto a 15 cm long, 100 µm ID, home-packed 
column manufactured by packing a Picotip emitter (New Objective) with ProntoSIL 
C18 phase (120 Å pore, 3 µm bead C18) (Bischoff Chromatography). The HPLC was 
run in a direct injection configuration. Buffer A consisted of 5% aqueous acetonitrile 
containing 0.1% formic acid and buffer B consisted of 95% aqueous acetonitrile 
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containing 0.1% formic acid. Samples were loaded onto the column at a flow rate of 
700 nl/min, and resolved using a 180 minute gradient at a flow rate of 300 nl/min. 
The Orbitrap was run in a data dependent acquisition mode in which the Orbitrap 
resolution was set at 60,000 and the top 5 multiply charged species were selected 
for MS/MS. The automatic gain control for the Orbitrap was set to 500,000 ions and 
the automatic gain control for the MS/MS in the ion trap was set at 10,000 ions. 
Maximum injection time into the ion trap in MS/MS was 200 ms and maximum 
accumulation time in the Orbitrap was 500 ms. Three MS/MS microscans were 
accumulated for each precursor. Dynamic exclusion was switched on and selected 
ions excluded for 180 s before they could be selected for another round of MS/MS. 
Samples were typically injected in triplicate in order to increase the number of 
identifications. 
Raw instrument data were converted into mzXML format using an in-house 
developed script. mzXML files were then submitted to an in-house developed 
proteomics data analysis  pipeline based on Seattle Proteome Center’s Trans 
Proteomic Pipeline (TPP). The data analysis pipeline incorporated three database 
search engines (Mascot, OMSSA and X!Tandem) in order to maximise the number 
of identifications and used various statistical tools (PeptideProphet, ProteinProphet 
and iProphet) in order to determine false discovery rates (FDR). Data were searched 
with the fixed modification carbamindomethyl cysteine and the variable modifications 
protein N-terminal acetylation, oxidised methionine and deamidated (NQ). Precursor 
mass tolerance was set at ±10 ppm and MS/MS fragment tolerance at ± 0.5 Da. 
Strict Trypsin specificity was used and 2 missed cleavages were allowed. Data were 
then exported from the pipeline into Proteincenter (Proxeon) for filtering, annotation, 
classification and interpretation. 
 
SPR experiments and data analysis (performed by colleagues at Beactica, 
Sweden) 
 
The interaction experiments were performed using Biacore S51 and T100 
instruments and CM5 biosensor chips (GE Healthcare/Biacore, Uppsala, Sweden). 
CDK2 was immobilised to activated carboxylated dextran surfaces by amine 
coupling to give surface densities of 6000-25000 RU. All interaction experiments 
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were performed at 25 °C in 10 mM phosphate pH 7.4, 137 mM NaCl, 3 mM KCl, with 
addition of 0.05 % Tween 20 (BDH/Prolabo), 5 % (v/v) DMSO (Riedel de Haën), and 
at a flow rate of 90 µl/min. For kinetic analysis the test compounds were diluted in 
the running buffer and injected for 30-240 s over the immobilised CDK2 at increasing 
concentrations. For analysis of the time dependence of the interaction, immobilised 
CDK2 was exposed to 10 µM NU6300 for 0 h, 4 h, and 4+16 h. A CDK2 surface 
incubated with buffer without NU6300 in parallel on the same chip was used as a 
reference. The binding capacity of the two surfaces was assayed by injections of 10 
µM NU6310. Sensorgrams or extracted report points from reference surfaces and 
blank injections were subtracted from the raw data prior to data analysis, using 
Biacore T100 evaluation software 2.0. A 1:1 interaction model was fitted globally to 
sets of sensorgrams recorded with different contact times and at different inhibitor 
concentrations in multi-cycle experiments. Kinetic parameters were determined from 
sensorgrams with 30 s and 60 s contact time. Standard deviations were based on at 
least 4 measurement series. 
 
Molecular modeling 
 
All calculations were performed in Schrödinger Suite 2009 Update 2. Default settings 
were used throughout unless specified otherwise. Pictures were generated with 
PyMol 0.99. The structure of CDK2/cyclin A in complex with the purine-based 
inhibitor NU6102 (1H1S.pdb) was considered. The structure was prepared for 
docking using the Protein Preparation Wizard. Chains B, C, D and all waters beyond 
5 Å of heterocyclic groups were removed. This left 10 water molecules surrounding 
NU6102. Docking grids were then calculated, using bound NU6102 to define the 
center of the grid box. Optional H-bond constraints were defined for the backbone 
carbonyl O's of Glu81 and Leu83, and the backbone NH of Leu83. NU6300 and 
NU6310 were built manually from the crystal conformation of NU6102 and then 
prepared with ligprep. The structures with the lowest Epik ionization state penalties 
were retained. The ligands were then docked with Glide XP. The Epik state penalties 
were added to the docking scores. 5 Poses were requested for each ligand.  
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